 Effect of Plant Protein on Blood Lipids: A Systematic Review and
Meta-Analysis of Randomized Controlled Trials
Siying S. Li, HBSc; Sonia Blanco Mejia, MD, MSc; Lyubov Lytvyn, MSc; Sarah E. Stewart, MSc, Effie Viguiliouk, MSc; Vanessa Ha, MSc; Russell J.
de Souza, ScD, RD; Lawrence A. Leiter, MD; Cyril W. C. Kendall, PhD; David J. A. Jenkins, MD, PhD, DSc; John L. Sievenpiper, MD, PhD
Background-—There is a heightened interest in plant-based diets for cardiovascular disease prevention. Although plant protein is
thought to mediate such prevention through modifying blood lipids, the effect of plant protein in specific substitution for animal
protein on blood lipids remains unclear. To assess the effect of this substitution on established lipid targets for cardiovascular risk
reduction, we conducted a systematic review and meta-analysis of randomized controlled trials using the Grading of
Recommendations Assessment, Development, and Evaluation system.
Methods and Results-—MEDLINE, EMBASE, and the Cochrane Registry were searched through September 9, 2017. We included
randomized controlled trials of ≥3 weeks comparing the effect of plant protein in substitution for animal protein on low-density
lipoprotein cholesterol, non–high-density lipoprotein cholesterol, and apolipoprotein B. Two independent reviewers extracted
relevant data and assessed risk of bias. Data were pooled by the generic inverse variance method and expressed as mean
differences with 95% confidence intervals. Heterogeneity was assessed (Cochran Q statistic) and quantified (I2 statistic). The
overall quality (certainty) of the evidence was assessed using the Grading of Recommendations Assessment, Development, and
Evaluation system. One-hundred twelve randomized controlled trials met the eligibility criteria. Plant protein in substitution for
animal protein decreased low-density lipoprotein cholesterol by 0.16 mmol/L (95% confidence interval, �0.20 to �0.12 mmol/L;
P<0.00001; I2=55%; moderate-quality evidence), non–high-density lipoprotein cholesterol by 0.18 mmol/L (95% confidence
interval, �0.22 to �0.14 mmol/L; P<0.00001; I2=52%; moderate-quality evidence), and apolipoprotein B by 0.05 g/L (95%
confidence interval, �0.06 to �0.03 g/L; P<0.00001; I2=30%; moderate-quality evidence).
Conclusions-—Substitution of plant protein for animal protein decreases the established lipid targets low-density lipoprotein
cholesterol, non–high-density lipoprotein cholesterol, and apolipoprotein B. More high-quality randomized trials are needed to
improve our estimates.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identifier: NCT02037321. (J Am Heart Assoc. 2017;6:
e006659. DOI: 10.1161/JAHA.117.006659.)
Key Words: animal protein • cholesterol • dyslipidemia • lipids • meta-analysis • protein • soy • systematic review • vegetable
protein
C
ardiovascular disease (CVD) accounts for �48% of
deaths attributable to noncommunicable disease world-
wide and remains the number one cause of mortality.1,2
Modification by diet and lifestyle of risk factors, particularly
dyslipidemia, remains the cornerstone of therapy, according
to major cardiovascular guidelines.3,4
From the Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre (S.S.L., S.B.M., L.L., S.E.S., E.V., V.H., R.J.d.S.,
L.A.L., C.W.C.K., D.J.A.J., J.L.S.), Division of Endocrinology and Metabolism (L.A.L., D.J.A.J., J.L.S.), and Li Ka Shing Knowledge Institute (L.A.L., D.J.A.J., J.L.S.), St.
Michael’s Hospital, Toronto, Ontario, Canada; School of Medicine, Faculty of Health Sciences, Queen’s University, Kingston, Ontario, Canada (S.S.L.); Departments of
Nutritional Sciences (S.B.M., S.E.S., E.V., L.A.L., C.W.C.K., D.J.A.J., J.L.S.) and Medicine (L.A.L., D.J.A.J.), Faculty of Medicine, University of Toronto, Ontario, Canada;
Departments of Health Research Methods, Evidence, and Impact (L.L., V.H., R.J.d.S.), Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada; and
College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan, Canada (C.W.C.K.).
Accompanying Tables S1 through S5 and Figures S1 through S13 are available at http://jaha.ahajournals.org/content/6/12/e006659/DC1/embed/inline-supple
mentary-material-1.pdf
Correspondence to: John L. Sievenpiper, MD, PhD, FRCPC Toronto 3D Knowledge Synthesis and Clinical Trials Unit, St. Michael’s Hospital, 6137-61 Queen St E,
Toronto, ON, Canada M5C 2T2. E-mail: john.sievenpiper@utoronto.ca
Received May 18, 2017; accepted November 6, 2017.
ª 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for
commercial purposes.
DOI: 10.1161/JAHA.117.006659
Journal of the American Heart Association
1
SYSTEMATIC REVIEW AND META-ANALYSIS
Downloaded from http://ahajournals.org by on June 4, 2019
 There has been increasing recent interest in plant-based
diets. Vegetarian and vegan dietary patterns and other plant-
based dietary patterns, such as the Mediterranean diet, have
been established as dietary patterns that improve lipid
profiles and reduce risks of CVD.5–7 Both the Scientific
Report of the 2015 Dietary Guidelines Advisory Committee
and
2016
Canadian
Cardiovascular
Society
guidelines
recently recommended a vegetarian dietary pattern and a
Mediterranean dietary pattern for cardiovascular protec-
tion.3,8 The mechanisms by which these dietary patterns
improve cardiovascular risk likely include intrinsic and extrin-
sic pathways. Plant protein sources, such as soy, dietary
pulses, and nuts, have all individually shown lipid-lowering
advantages through their specific components (specific
protein fractions [7s-globulin], viscous fibers, polyunsaturated
fatty acids, and plant sterols). Replacement of animal protein
with plant protein has also shown advantages through the
displacement of saturated fatty acids.9 The combination
allows for meaningful reductions in lipids in systematic
reviews and meta-analyses of randomized controlled trials
(RCTs).9–12
Despite the strong biological plausibility supporting their
benefit and endorsement of plant-based diets from recent
guidelines, there is still uncertainty as to whether the benefit
is attributable to the exchange of plant protein for animal
protein or to other aspects of a plant-based dietary pattern. It
remains difficult to isolate specific mechanisms,13–15 and the
strength of the evidence supporting the lipid-lowering effects
of plant protein remains disputed.16–19 As a result, many
authoritative guidelines do not specifically recommend sub-
stituting plant protein for animal protein for lipid-lowering and
cardiovascular protection.20–23 To summarize and evaluate
the available evidence, we conducted a systematic review and
meta-analysis using the Grading of Recommendations Assess-
ment, Development, and Evaluation (GRADE) system of the
effect of substituting plant protein for animal protein on the
established lipid targets for CVD prevention, low-density
lipoprotein cholesterol (LDL-C), non– high-density lipoprotein
cholesterol (non–HDL-C), and apolipoprotein B (Apo-B), in
RCTs.4,24
Methods
This study was planned and conducted following the Cochrane
Handbook for Systematic Review of Interventions.25 Data were
reported in accordance with Preferred Reporting Items for
Systematic Reviews and Meta-Analyses guidelines.26 The
authors declare that all supporting data are available within
the article (and its supplementary files).
Literature Search
We searched MEDLINE, EMBASE, and the Cochrane Register
through September 9, 2017, for eligible trials. Table S1 shows
our detailed search strategy.
Study Selection
We included randomized, long-term, dietary intervention trials
in human subjects comparing LDL-C, non–HDL-C, and/or
Apo-B parameters between plant and animal protein inter-
vention arms. To be included, studies had to be at least
3 weeks in duration and performed in accordance with the
minimum trial follow-up requirement of the US Food and Drug
Administration for lipid-lowering health claims.27 Studies
deliberately introducing confounding factors (eg, plant sterols
or combined therapeutic interventions) to the plant protein
arm were also excluded, including studies applying a broad
vegetarian or vegan dietary pattern as opposed to a direct
substitution of protein sources. No restrictions were placed
on language.
Clinical Perspective
What Is New?
• Although the cholesterol-lowering benefit of plant protein
sources, such as soy, pulses, and nuts, is well documented,
the overall cholesterol-lowering benefit of plant protein in
substitution for animal protein (as meat, dairy, and/or egg
alternatives) has not been synthesized.
• The available evidence from randomized controlled trials
suggests that 1 to 2 servings of plant protein in substitution
for animal protein decreases low-density lipoprotein choles-
terol,
non–high-density
lipoprotein
cholesterol,
and
apolipoprotein B by �4% in adults with and without
hyperlipidemia.
• Because of inconsistency or imprecision in the estimates,
the overall quality (certainty) of the evidence is moderate by
the Grading of Recommendations Assessment, Develop-
ment,
and
Evaluation
system,
suggesting
that
more
research will refine our estimates.
What Are the Clinical Implications?
• Because the intake of plant protein from soy, nuts, and
pulses remains low, there is an opportunity for people to
realize the lipid-lowering benefits of sustainable plant-based
dietary strategies that substitute plant protein for animal
protein.
• Plant
protein,
especially
in
combination
with
other
cholesterol-lowering foods (eg, viscous fiber and plant
sterols) and/or as an adjunct to lipid-lowering pharma-
cotherapy, may have a clinically meaningful benefit in
helping
people
to
achieve
lipid
targets
and
reduce
cardiovascular risk.
DOI: 10.1161/JAHA.117.006659
Journal of the American Heart Association
2
Plant Protein and Blood Lipids
Li et al
SYSTEMATIC REVIEW AND META-ANALYSIS
Downloaded from http://ahajournals.org by on June 4, 2019
 Data Extraction
Study characteristics and results of eligible trials were each
extracted by S.S.L. and a coextractor (L.L., S.B.M., S.E.S., E.V.,
or V.H.). Extracted characteristics include study setting,
design, duration, blinding, sample size, participant character-
istics, and plant and animal protein diet descriptions. Risk of
bias of eligible trials was also assessed by S.S.L. and the
same coextractor using the Cochrane risk of bias tool, which
categorizes studies as high, low, or unclear risk of bias on the
basis of criteria pertaining to selection bias, blinding, incom-
plete outcome data, and reporting bias.25 PlotDigitizer version
2.5.1 (Free Software Foundation, Boston, MA) was used to
extract data from graphs, where applicable. Any discrepancies
in data extraction or risk of bias assessment were reconciled
by consensus.
Grading of the Evidence
The overall quality (certainty) of evidence was assessed using
the GRADE system,28–40 which grades evidence as high,
moderate, low, or very low quality. RCTs are graded as high-
quality evidence by default. Scores can then be downgraded
on the basis of the following prespecified criteria: risk of bias
(weight of studies shows important risk of bias), inconsistency
(substantial unexplained interstudy heterogeneity of I2 >50%,
P<0.10), indirectness (presence of factors that limit the
generalizability of the results), imprecision (95% confidence
interval [CI] for risk estimates are wide or overlap a minimally
important difference of 0.1 mmol/L for LDL-C and non-HDL-C
and 0.04 g/L for Apo-B), and publication bias (evidence of
small-study effects).
Statistical Analysis
We used Review Manager version 5.3 (The Nordic Cochrane
Centre, The Cochrane Collaboration, Copenhagen, Denmark)
for primary analyses and Stata version 13 (StataCorp, College
Station, TX) for meta-regression and publication bias tests.
Data were pooled using the generic inverse variance method
with random-effects models and are expressed as mean
differences (MDs) with 95% CIs. All analyses were repeated
using fixed-effects models and parametric bootstrapping as
sensitivity analyses. Where there were multiple plant or
animal protein arms in a single trial, we pooled intervention
arms to obtain a single pairwise comparison, to mitigate unit-
of-analysis error25; where relevant, these arms were assessed
separately for subgroup analyses.
Change-from-baseline values were favored, and differences
in change-from-baseline values were used, where given;
otherwise, we used end-difference values, if reported, or
calculated the differences from available data. Non–HDL-C
values were calculated by subtracting HDL-C from total
cholesterol values, where non–HDL-C values were not directly
reported, and the variance sum law was used to derive SDs for
non–HDL-C from total cholesterol and HDL-C variance data.41
In crossover trials, missing variance data were calculated from t
test P values using standard formulas; where P values were
unavailable, a correlation coefficient of 0.5 was assumed as a
conservative estimate and used to impute SE data.25,42 Where
no variance data were available, the average SD of the MDs
across all other included trials was used to derive the SEM
difference on the basis of the respective trial’s sample size.
Interstudy heterogeneity was evaluated by the Cochran Q
statistic and quantified using the I2 statistic. P<0.10 was
considered significant; an I2 value of 50% or higher was
considered substantial.25 Potential sources of heterogeneity
were investigated by additional sensitivity analyses, in which
we recalculated the pooled effect estimate after removing
each individual trial, after removing all imputed data, and after
imputing alternative correlation coefficients of 0.25 and 0.75.
We additionally investigated potential sources of heterogene-
ity by subgroup analyses. Our a priori subgroups included
study design, protein dose, plant and animal protein type,
duration of follow-up, and baseline lipid values. A post hoc
analysis was also conducted for protein form (ie, whole food
or protein isolate product). Between-subgroup differences
were assessed using meta-regression with dummy variables.
A post hoc dose-response analysis was conducted using a
piecewise linear meta-regression via the mkspline function, to
assess potential dose thresholds for the continuous subgroup
addressing grams of protein substitution.
Publication bias was assessed by inspection of funnel plots
and by the use of Egger and Begg tests. Where publication
bias was suspected, Duval and Tweedie nonparametric “trim-
and-fill” analyses were also applied to assess the effect of the
imputed “missing” studies.43
Results
Search Results
Figure 1 shows the trial selection process. Our search
identified 3917 reports, of which 3689 were excluded on
the basis of review of titles and abstracts. The remaining 228
articles were reviewed in full, of which 104 provided data for
112 trial comparisons for inclusion in our analyses.44–147
Trial Characteristics
The Table summarizes characteristics of the included trials.
Detailed characteristics are shown in Table S2. In total, 5774
participants (median age, 54 years) were included in this
analysis. There were more women versus men overall (�5:3
DOI: 10.1161/JAHA.117.006659
Journal of the American Heart Association
3
Plant Protein and Blood Lipids
Li et al
SYSTEMATIC REVIEW AND META-ANALYSIS
Downloaded from http://ahajournals.org by on June 4, 2019
 ratio), but this difference is largely attributable to a few large
female-only trials, and the median sex ratio in trials was
relatively balanced (44% men). Sixty-one trials were crossover,
and all but 4 were in outpatient settings. Half of the trials
were conducted in the United States and Canada (60 of 112),
but trials were also distributed across European (24 trials),
Asian (10 trials), Middle-Eastern (9 trials), and South American
(3 trials) countries, as well as Australia (6 trials). Of 112 trials,
34
recruited
healthy
subjects
(including
healthy
post-
menopausal women); 51 trials recruited subjects with hyper-
lipidemia, 4 of which also selected for additional conditions.
The remaining 28 trials included participants with various
conditions, including renal disease, overweight, obesity, type
2 diabetes mellitus, and hypertension. Average baseline LDL-
C, non–HDL-C, and Apo-B measures were 3.81 mmol/L,
4.42 mmol/L, and 1.16 g/L, respectively.
Of 112 trials, 94 used soy as the sole plant protein
intervention, and 74 used dairy as the sole animal protein
intervention. Other plant protein sources included various
pulses, nuts, barley, and seeds; other animal protein sources
included meat, fatty fish, and eggs. Seventy-one trials used
protein isolate products, 37 used whole foods, and 4 used a
combination of the two. The median protein substitution was
�30 g/d. Trial follow-up ranged from 3 weeks to 4 years,
with a median follow-up of 6 weeks. Twenty-five trials
obtained funding from publicly funded agencies alone, 22
were supported by industry funding alone, and 55 used a
combination of the two.
Figure 1. Search summary.
DOI: 10.1161/JAHA.117.006659
Journal of the American Heart Association
4
Plant Protein and Blood Lipids
Li et al
SYSTEMATIC REVIEW AND META-ANALYSIS
Downloaded from http://ahajournals.org by on June 4, 2019
 Most of our included trials were deemed to be “low risk of
bias” or “unclear risk of bias” across most domains by the
Cochrane Risk of Bias tool. Of the trials rated has high risk of
bias, 3 were for allocation concealment, 3 were for blinding,
14 were for incomplete outcome data, and 5 were for
selective outcome reporting; 1 trial was considered to have an
alternative high-risk source of bias (substantial macronutrient
imbalance in protein interventions for tofu compared with
cheese, in the trial by Meredith et al107). Detailed risk of bias
assessment data can be found in Figure S1.
Effect on LDL-C
Figure 2 and Figures S2 and S3 show the effect of plant
protein in substitution for animal protein intake on LDL-C
across 108 trials. We found a significant reduction in LDL-C
(MD, �0.16 mmol/L [95% CI, �0.20 to �0.12 mmol/L];
P<0.00001), with evidence of substantial interstudy hetero-
geneity (I2=55%; P<0.00001). Fixed-effects model analysis,
bootstrap analysis (Table S3), and sensitivity analyses did not
alter the direction or significance of the effect estimates.
Subgroup analyses were nonsignificant and failed to explain
heterogeneity (Figure S4). Post hoc subgroup analyses
(Figure S5) failed to identify significant effect modification
by protein form on LDL-C, and post hoc dose-response
analyses (Table S4) did not find a dose threshold for LDL-C in
continuous subgroup analyses.
Effect on Non–HDL-C
Figure 2 and Figures S6 and S7 show the effect of plant
protein in substitution for animal protein intake on non–HDL-C
across 102 trials. We found a significant reduction in non–
HDL-C (MD, �0.18 mmol/L [95% CI, �0.22 to �0.14 mmol/
L]; P<0.00001), with evidence of substantial interstudy
heterogeneity (I2=52%; P<0.00001). Fixed-effects model anal-
ysis, bootstrap analysis (Table S3), and sensitivity analyses did
not alter the direction or significance of the effect estimates.
Subgroup analyses, however, did reveal a greater reduction in
non-HDL-C in trials with higher baseline non-HDL-C levels
(between-subgroup difference, �0.09 mmol/L [95% CI, �0.17
to
�0.01 mmol/L];
P=0.03),
with
a
residual
I2=43%
Table. Summary Table of Characteristics
Trial Characteristics
LDL-C
Non–HDL-C
Apo-B
Trial number, N
108
102
37
Total participants
5582
5401
1506
Trial size (participants)*
32 (4–352)
32 (4–352)
32 (4–130)
Male:female ratio†‡
37:63
39:61
51:49
Age, y‡§
54 (44–59)
54 (44–59)
54 (43–60)
Inpatient:outpatient setting†
4:96
3:97
3:97
Baseline serum level§||
3.7 (3.0–4.2) mmol/L
4.4 (3.8–5.0) mmol/L
1.2 (1–1.4) g/L
Crossover:parallel study
design†
54:46
54:46
57:43
Amount of substitution, g§
29 (23–49)
30 (22–50)
30 (25–50)
Follow-up duration, wks*
6 (3–208)
6 (3–208)
6 (3–52)
Funding sources (agency:
industry:agency-industry:
NR)†
23:19:48:9
23:19:49:10
19:32:43:5
Plant protein source, N
Soy, 91; lupin, 3; legumes, 3; pinto beans, 2;
pulses, 2; barley, 1; pea, 1; walnut, 1; various, 4
Soy, 84; legumes, 3; lupin, 3; pinto beans, 2;
pulses, 2; barley, 1; pea, 1; walnut, 1; various, 5
Soy, 34; legumes, 1;
walnut, 1; various,
1
Animal protein source, N
Dairy, 70; meat, 10; chicken noodle soup, 2; egg,
1; various, 25
Dairy, 64; meat, 10; chicken noodle soup, 2; egg,
1; various, 25
Dairy, 25; meat, 3;
egg, 1; various, 8
Protein form, N
Whole food, 38; protein isolate, 72
Whole food, 40; protein isolate, 63
Whole food, 10;
protein isolate, 28
Apo-B indicates apolipoprotein B; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; and NR, not reported.
*Values are reported as medians (ranges).
†Values are reported as percentage ratios.
‡Includes baseline data before dropouts, where final data were not available.
§Values are reported as medians (interquartile ranges).
||Baseline serum-level data correspond to the respective lipid marker for each end point.
DOI: 10.1161/JAHA.117.006659
Journal of the American Heart Association
5
Plant Protein and Blood Lipids
Li et al
SYSTEMATIC REVIEW AND META-ANALYSIS
Downloaded from http://ahajournals.org by on June 4, 2019
 (Figure S8). Post hoc subgroup analyses (Figure S5) failed to
identify significant effect modification by protein form on non–
HDL-C, and post hoc dose-response analyses (Table S4) did
not find a dose threshold in continuous subgroup analyses.
Effect on Apo-B
Figure 2 and Figures S9 and S10 show the effect of plant
protein in substitution for animal protein intake on Apo-B
across 37 trials. We found a significant reduction in Apo-B by
plant protein (MD, �0.05 g/L [95% CI, �0.06 to �0.03 g/L];
P<0.00001), with evidence of moderate interstudy hetero-
geneity (I2=30%; P=0.05). Fixed-effects model analysis, boot-
strap analysis (Table S3), and sensitivity analyses did not alter
the direction or significance of the effect estimates. Subgroup
analyses also did not explain the heterogeneity (Figure S11).
However, removal of the 2007 study by Azadbakht et al51
modified heterogeneity from significant to nonsignificant
(I2=21%; P=0.14). Post hoc subgroup analyses (Figure S5)
failed to identify significant effect modification by protein form
on
non–HDL-C,
and
post
hoc
dose-response
analyses
(Table S4) did not find a dose threshold in continuous
subgroup analyses.
Publication Bias
Figure S12 shows the funnel plots used to evaluate publica-
tion bias; on visual inspection, there was no evidence of
asymmetry or small-study effects for any outcome. The Egger
test identified significant publication bias for LDL-C (P=0.03),
but the Begg test was nonsignificant. The Egger and Begg
tests were nonsignificant across all other end points. Trim-
and-fill analyses were conducted for LDL-C, with data for 8
additional studies imputed to adjust for funnel plot asymmetry
(Figure S13). There was no evidence of meaningful small-
study effects. The direction, significance, and size of the
pooled effect estimate after inclusion of the imputed studies
were not significantly altered (MD, �0.18 mmol/L [95% CI,
�0.21 to �0.14 mmol/L]; P<0.001).
GRADE Assessment
Table S5 shows a summary of the GRADE assessments for
each end point. The evidence for both LDL-C and non–HDL-C
was rated moderate quality, on the basis of a downgrade for
inconsistency in both analyses. The evidence for Apo-B was
rated moderate quality, on the basis of a downgrade for
imprecision.
Discussion
We conducted a systematic review and meta-analysis of 112
RCTs assessing the effect of plant protein versus animal
protein on established lipid targets for CVD prevention in
5774 adult participants with and without hyperlipidemia. Plant
protein substitution for animal protein led to modest reduc-
tions in LDL-C (�0.16 mmol/L or �4%; 95% CI, �3%–5%),
non–HDL-C (�0.18 mmol/L or �4%; 95% CI, �3%–5%), and
Apo-B (�0.05 g/L or �3%; 95% CI, 2%–5%). On the basis of
Figure 2. Primary analyses. Pooled effect estimates for each end point (squares) shown. Paired
analyses were applied to all crossover trials. Data are expressed as mean differences (95% confidence
intervals [CIs]), using generic inverse-variance random-effects models. Interstudy heterogeneity was
tested using the Cochran Q statistic (v2) at a significance level of P<0.10 and quantified by I2; levels of
≥50% represented substantial heterogeneity. All outcomes had significant pooled effect estimates.
Heterogeneity was significant and substantial for low-density lipoprotein cholesterol (LDL-C) and
non–high-density lipoprotein cholesterol (HDL-C), and significant but not substantial for apolipoprotein B
(Apo-B).
DOI: 10.1161/JAHA.117.006659
Journal of the American Heart Association
6
Plant Protein and Blood Lipids
Li et al
SYSTEMATIC REVIEW AND META-ANALYSIS
Downloaded from http://ahajournals.org by on June 4, 2019
 studies finding a one-to-one relationship between LDL-C and
cardiovascular risk reductions, these findings would translate
to a 4% risk in major cardiovascular events.148,149
Findings in Relation to the Literature
Our findings are supported by other systematic reviews and
meta-analyses of the effect of individual sources of plant
protein in substitution for different macronutrients (not just
animal protein) on blood lipids. We showed, in an updated
analysis of an American Heart Association analysis, that soy
protein produced similar decreases in LDL-C (�4%) in RCTs
involving participants with and without hyperlipidemia.9 An
individual patient-level pooled analysis of RCTs showed that
tree nuts decrease LDL-C by �7%, along with other lipid end
points.10 A systematic review and meta-analysis of the effect
of dietary pulses on established lipid targets showed an LDL-
C–lowering effect of �5% and a tendency for a non–HDL-C–
lowering effect.12
Our findings are also aligned with previous evidence related
to plant protein as part of plant-based dietary patterns. A
systematic review of 13 observational studies and 14 RCTs
trials demonstrated the lipid-lowering benefits of plant-based
diets,6 and a recent systematic review and meta-analysis of 11
RCTs found significant reductions in LDL-C and non–HDL-C
following a vegetarian diet.150 We have shown that the Portfolio
diet, which combines cholesterol-lowering foods (including
plant protein from soy, pulses, and nuts) along with viscous
fibers and plant sterols, produces LDL-C reductions compara-
ble to lovastatin (�28.6% versus �30.9%) over 4 weeks when
all foods were provided.
151 There were more modest
reductions of 10% to 15% (with greater reductions seen with
greater adherence) when the diet was administered as dietary
advice under free living conditions over 6 months.152 Our Eco-
Atkins trial also found greater reductions in LDL-C with a vegan
low-carbohydrate (“Eco-Atkins”) diet that emphasizes plant
proteins, compared with a high-carbohydrate, low-fat, lacto-ovo
vegetarian diet (treatment difference, �0.49 mmol/L).153
Furthermore, studies have found an association between
plant-based diets and cardiovascular disease. The PREDIMED
(Prevenci�
on con Dieta Mediterr�
anea) trial showed that a
predominantly plant-based Mediterranean diet supplemented
with nuts as a source of plant protein decreases major
cardiovascular events.154 Prospective cohort studies offer
further support showing that dietary patterns high in plant
proteins, such as Mediterranean and vegetarian dietary
patterns,
are
associated
with
reduced
cardiovascular
events.155–158 An analysis of the Harvard cohorts found that
low-carbohydrate and high-protein diets were associated with
increased mortality, but inversely correlated with mortality and
particularly CVD mortality when based on plant protein.159
Other prospective cohort studies have also shown that plant-
based diets are associated with a mortality benefit.160 On the
other hand, increased intake of animal protein sources has
been associated with negative health outcomes. A pooled
analysis of the Harvard cohorts found that red meat consump-
tion was associated with increased risks of total, cardiovascu-
lar, and cancer mortality.161 Other large, prospective, cohort
studies have found an association between animal protein
sources and disease or mortality.162–164
There are several mechanisms by which plant protein may
exert a lipid-lowering effect. One explanation is that the plant
protein source acts as a vehicle for other established
antiatherogenic agents, such as plant sterols or soluble fiber;
similarly, the displaced animal protein source could also act
as a vehicle for hypercholesterolemic agents, such as
saturated fat and cholesterol.13–15,24 Interestingly, our post
hoc subgroup analyses did not find a significant difference
between protein isolate products and whole food sources for
any given end point, suggesting that the cholesterol-lowering
effects are at least, in part, attributable to the plant protein
itself rather than just the associated nutrients.
An alternative explanation relates to the amino acid
breakdown encountered in plant proteins versus animal
proteins; in particular, lysine, which is more prevalent in animal
proteins, has been shown to increase cholesterol levels in
animal models, whereas arginine, which is found more in plant
proteins, has been found to have the opposite effect.165–167 The
cholesterol-lowering effect of arginine has also been demon-
strated in a 5-week arginine feeding trial in humans,168 but
otherwise there are limited human studies investigating this
subject. Proposed mechanisms for these effects involve bile
acid production and binding of hepatic LDL receptors.166,169
A Priori Subgroup Analyses
Our results appear to be robust to different trial conditions.
Similar to a previous meta-analysis by Anderson et al,170 we
did find that increased baseline values amplified the effects
seen in non–HDL-C reduction. However, our overall analyses
indicate that the lipid-lowering effects of plant protein apply to
both hypercholesterolemic and normal subjects, because the
normocholesterolemic subgroup also showed a significant
improvement in non–HDL-C, and similar subgroup analyses in
LDL-C and Apo-B were nonsignificant. The beneficial effects
otherwise held across a range of ages and health statuses,
and all other subgroup analyses were nonsignificant.
Strengths and Limitations
Our
systematic
review
and
meta-analysis
has
several
strengths and limitations. The strengths include the identifi-
cation of all available evidence through a systematic search
strategy, the inclusion of RCTs that provide the greatest
DOI: 10.1161/JAHA.117.006659
Journal of the American Heart Association
7
Plant Protein and Blood Lipids
Li et al
SYSTEMATIC REVIEW AND META-ANALYSIS
Downloaded from http://ahajournals.org by on June 4, 2019
 protection against bias, quantitative syntheses of the data,
and assessment of the overall quality of the evidence using
the GRADE system.
The limitations of our systematic review and meta-analysis
relate toinconsistencyin thetreatmenteffects andimprecision.
Evidence of unexplained inconsistency in treatment effects was
seen for 2 of the established therapeutic lipid end points. There
was substantial interstudy heterogeneity in our LDL-C and non–
HDL-C analyses, which was not fully explained by sensitivity or
subgroup analyses. Evidence of imprecision was seen in Apo-B,
because the 95% CI for effect estimates for Apo-B overlapped
the prespecified minimally important difference of 0.04 g/L.
Apo-B also showed evidence of moderate interstudy hetero-
geneity; however, the statistical significance of heterogeneity
was eliminated by the removal of the 2007 study by Azadbakht
et al.51 We also considered downgrading for indirectness of the
evidence. A relatively large proportion of the available trials
evaluated soy as the sole plant protein source (94 of 112 trials)
and/or dairy as the sole animal protein source (74 of 112 trials).
Subgroup analyses, however, did not reveal evidence of
significant effect modification by protein sources across any
of the 3 end points, which suggests that the effects seen apply
across varying plant and animal protein sources. Several plant
protein sources, however, were not evaluated, including wheat
(gluten), rice, and other grains. In addition, there were limited
studies with extended follow-up duration, which would help
assess issues of long-term adherence.
Taking into account these strengths and limitations, the
evidence was assessed by the GRADE system as moderate
quality for a cholesterol-lowering effect of plant protein in
substitution for animal protein across LDL-C, non–HDL-C, and
Apo-B markers.
Implications
Current adult protein intakes average �80 to 100 g/d in the
United States and Europe. Of this intake, �30% is from plant
protein sources.171,172 The median intervention of 30 g
protein substitution per day across trials included in our
analyses reflects the substitution of 1 to 2 servings of meat for
plant protein substitutes or 3 250-mL cups of dairy milk for soy
milk. This additional substitution would mean a shift to diets
with >50% plant protein, which can be attained by following
healthy dietary patterns, such as vegetarian, Mediterranean,
and Portfolio dietary patterns.173–175 Given the low current
consumption of plant protein-rich foods, such as soy and
pulses, in Canada and the United States, there remains a
significant opportunity to realize the benefits of making such
dietary changes.176–178
Although the reductions in LDL-C, non–HDL-C, and Apo-B on
their own were modest (<5%), plant protein can still contribute
to meaningful reductions in lipids. On the basis of the evidence
from the Portfolio diet, the lipid-lowering effects of individual
food components, which include plant protein from soy, pulses,
and nuts, are additive, such that the LDL-C–lowering effect
(�5%–10%) of each of the 4 components of the Portfolio diet
food can be summed to achieve meaningful reductions.3,147,148
Several large trials and cohort studies have shown that such
reductions are associated with improved cardiovascular out-
comes.179–185 The 2016 Canadian Cardiovascular Guidelines
further highlighted the superior predictive value for CVD of
non–HDL-C and Apo-B, both of which were reduced by plant
protein.3 The implication is that plant protein as part of a
comprehensive lipid-lowering dietary pattern alone or as an
add-on to other lipid-lowering therapy can help people achieve
their lipid targets and reduce CVD risk.
Despite the existing evidence for benefit, current dietary
guidelines do not wholly reflect the demonstrated benefits of
plant protein versus animal protein and tend to place animal
sources of protein on the same level as plant sources.20–22 In
particular, the 2015 to 2020 Dietary Guidelines for Americans
recommend seafood, meats, poultry, eggs, nuts, seeds, and
soy products indiscriminately as options for protein sources
and suggest that the vegetarian dietary patterns described are
only for those already following a vegetarian diet (which is
incongruent with the Scientific Report of the 2015 Dietary
Guidelines Advisory Committee on which the the 2015 to
2020 Dietary Guidelines for Americans is based).8,22,23
Conclusions
In conclusion, our aggregate analyses demonstrate a benefit of
plant protein in substitution for animal protein on established
lipid targets for CVD prevention in adults with and without
hyperlipidemia. To our knowledge, this is the first systematic
review and meta-analysis to directly evaluate the effects of
plant protein as well as plant for animal protein replacement.
These findings presents an opportunity for patients, clinicians,
and guidelines to exploit the lipid-lowering benefits of a
sustainable plant-based dietary strategy that is associated with
improved overall health outcomes. Our confidence in the
evidence for the LDL-C–, non–HDL-C–, and Apo-B–lowering
effects of plant protein, however, is limited by inconsistency for
LDL-C and non–HDL-C and imprecision for Apo-B. Further
large, high-quality, randomized controlled trials investigating
plant protein sources beyond soy, particularly in young and
healthy participants, would be useful to help better understand
the role of plant protein in cardiovascular risk reduction.
Acknowledgments
We thank Teruko Kishibe, an information specialist at the Scotiabank
Health Sciences Library, St. Michael’s Hospital, for help in the
development of search terms used.
DOI: 10.1161/JAHA.117.006659
Journal of the American Heart Association
8
Plant Protein and Blood Lipids
Li et al
SYSTEMATIC REVIEW AND META-ANALYSIS
Downloaded from http://ahajournals.org by on June 4, 2019
 Author Contributions
All authors had full access to all of the data (including
statistical reports and tables) in this study and take full
responsibility for the integrity of the data and the accuracy of
the data analysis. Conception and design: Li and Sievenpiper.
Analysis and interpretation of the data: Li, Blanco Mejia, de
Souza, Leiter, Kendall, Jenkins, and Sievenpiper. Drafting of
the article: Li. Critical revision of the article for important
intellectual content: Li, Lytvyn, Blanco Mejia, Stewart, Vigu-
iliouk, Ha, de Souza, Leiter, Kendall, Jenkins, and Sievenpiper.
Final approval of the article: Li, Lytvyn, Blanco Mejia, Stewart,
Viguiliouk, Ha, de Souza, Leiter, Kendall, Jenkins, and Sieven-
piper. Statistical expertise: de Souza. Attainment of funding:
Kendall, Jenkins, and Sievenpiper. Administrative, technical, or
logistic support: Blanco Mejia. Collection and assembly of
data: Li, Lytvyn, Blanco Mejia, Stewart, Viguiliouk, and Ha.
Guarantor: Sievenpiper.
Sources of Funding
This work was funded by the Canadian Institutes of Health
Research (CIHR; funding reference number 129920) through
the Canada-Wide Human Nutrition Trialists’ Network. The
Diet, Digestive Tract, and Disease Centre, funded through the
Canada Foundation for Innovation and the Ministry of
Research and Innovation’s Ontario Research Fund, provided
the infrastructure for the conduct of this project. Jenkins was
funded by the Government of Canada through the Canada
Research Chair Endowment. Sievenpiper was funded by a PSI
Graham
Farquharson
Knowledge
Translation
Fellowship,
Diabetes Canada Clinician Scientist award, CIHR INMD/
Canadian Nutrition Society New Investigator Partnership
Prize, and Banting & Best Diabetes Centre Sun Life Financial
New Investigator Award. Viguiliouk was supported by a
Toronto 3D Knowledge Synthesis and Clinical Trials Founda-
tion Internship Award. None of the sponsors had a role in any
aspect of the present study, including design and conduct of
the study; collection, management, analysis, and interpreta-
tion of the data; and preparation, review, and approval of the
article or decision to publish.
Disclosures
Lytvyn is part of the Grading of Recommendations Assessment,
Development, and Evaluation Working Group. Ha received
support from a Canadian Institutes of Health Research (CIHR)
doctoral award, David Sackett scholarship, and Ashbaugh
Graduate scholarship. She has received payment from the
World Health Organization (WHO) for work on a systematic
review and meta-analysis commissioned by the WHO for work
on the relation of saturated fatty acids and polyunsaturated
fatty acids with health outcomes. She and her peers received a
cash prize for placing second in the regional “Mission Impul-
sible” Competition hosted by Pulse Canada, where they
conceived and developed a marketable food product that
contained dietary pulses. She received a travel award to attend
the “Journey Through Science Day,” hosted by PepsiCo and the
New York Academy of Sciences, and the Nutrica Travel Award
from the Diabetes and Nutrition Study Group of the European
Association for the Study of Diabetes (EASD). de Souza has
served as an external resource person to the World Health
Organization’s Nutrition Guidelines Advisory Group on trans
fats, saturated fats, and polyunsaturated fats. The WHO paid
for his travel and accommodation to attend meetings from
2012-2017 to present and discuss this work. He has also done
contract research for the Canadian Institutes of Health
Research’s Institute of Nutrition, Metabolism, and Diabetes,
Health Canada, and the World Health Organization for which he
received remuneration. He has held a grant from the Canadian
Foundation for Dietetic Research as a principal investigator, and
is a co-investigator on several funded team grants from
Canadian Institutes of Health Research. He received compen-
sation for a lecture on dietary fat given at McMaster Pediatric
Nutrition Days in 2016. Kendall has received research support
from the Advanced Foods and Materials Network, Agricultural
Bioproducts Innovation Program through the Pulse Research
Network, Agriculture and Agri-Food Canada, Almond Board of
California, Barilla, Calorie Control Council, CIHR, Canola Council
of Canada, INC International Nut and Dried Fruit Council
Foundation, National Dried Fruit Trade Association, Kellogg,
Loblaw Companies Ltd., Pulse Canada, Saskatchewan Pulse
Growers and Unilever. He has received consultant fees from
American Pistachio Growers; speaker fees from American
Peanut Council, Tate & Lyle and The WhiteWave Foods
Company; and travel funding from Sabra Dipping Company,
Tate & Lyle, International Tree Nut Council Research &
Education Foundation, California Walnut Commission, Sun-
Maid, The Peanut Institute, General Mills, Oldways Foundation
and International Nut and Dried Fruit Council Foundation. He is
a member of the Clinical Practice Guidelines Expert Committee
for Nutrition Therapy of the European Association for the Study
of Diabetes (EASD), the Diabetes and Nutrition Study Group of
the EASD and the International Carbohydrate Quality Consor-
tium, and is the Director for the Toronto 3D Knowledge
Synthesis and Clinical Trials Foundation. Jenkins has received
research grants from Saskatchewan Pulse Growers, the
Agricultural Bioproducts Innovation Program through the Pulse
Research Network, the Advanced Foods and Material Network,
Loblaw Companies Ltd., Unilever, Barilla, the Almond Board of
California, Agriculture and Agri-food Canada, Pulse Canada,
Kellogg’s Company, Canada, Quaker Oats, Canada, Procter &
Gamble
Technical
Centre
Ltd.,
Bayer
Consumer
Care,
DOI: 10.1161/JAHA.117.006659
Journal of the American Heart Association
9
Plant Protein and Blood Lipids
Li et al
SYSTEMATIC REVIEW AND META-ANALYSIS
Downloaded from http://ahajournals.org by on June 4, 2019
 Springfield, NJ, Pepsi/Quaker, International Nut & Dried Fruit
(INC), Soy Foods Association of North America, the Coca-Cola
Company (investigator initiated, unrestricted grant), Solae,
Haine Celestial, the Sanitarium Company, Orafti, the Interna-
tional Tree Nut Council Nutrition Research and Education
Foundation, the Peanut Institute, the Canola and Flax Councils
of Canada, the Calorie Control Council, the CIHR, the Canada
Foundation for Innovation and the Ontario Research Fund. He
has received in-kind supplies for trial as a research support from
the Almond board of California, Walnut Council of California,
American Peanut Council, Barilla, Unilever, Unico, Primo,
Loblaw Companies, Quaker (Pepsico), Pristine Gourmet, Bunge
Limited, Kellogg Canada, WhiteWave Foods. He has been on the
speaker’s panel, served on the scientific advisory board and/or
received travel support and/or honoraria from the Almond
Board of California, Canadian Agriculture Policy Institute,
Loblaw Companies Ltd, the Griffin Hospital (for the develop-
ment of the NuVal scoring system, the Coca-Cola Company,
EPICURE, Danone, Diet Quality Photo Navigation (DQPN),
FareWell, Verywell, True Health Initiative, Saskatchewan Pulse
Growers, Sanitarium Company, Orafti, the Almond Board of
California, the American Peanut Council, the International Tree
Nut Council Nutrition Research and Education Foundation, the
Peanut Institute, Herbalife International, Pacific Health Labora-
tories, Nutritional Fundamental for Health, Barilla, Metagenics,
Bayer Consumer Care, UnileverCanada and Netherlands, Solae,
Kellogg, Quaker Oats, Procter & Gamble, the Coca-Cola
Company, the Griffin Hospital, Abbott Laboratories, the Canola
Council of Canada, Dean Foods, the California Strawberry
Commission, Haine Celestial, PepsiCo, the Alpro Foundation,
Pioneer Hi-Bred International, DuPont Nutrition and Health,
Spherix Consulting and WhiteWave Foods, the Advanced Foods
and Material Network, the Canola and Flax Councils of Canada,
the Nutritional Fundamentals for Health, Agri-Culture and Agri-
Food Canada, the Canadian Agri-Food Policy Institute, Pulse
Canada, the Saskatchewan Pulse Growers, the Soy Foods
Association of North America, the Nutrition Foundation of Italy
(NFI), Nutra-Source Diagnostics, the McDougall Program, the
Toronto Knowledge Translation Group (St. Michael’s Hospital),
the Canadian College of Naturopathic Medicine, The Hospital
for Sick Children, the Canadian Nutrition Society (CNS), the
American Society of Nutrition (ASN), Arizona State University,
Paolo Sorbini Foundation and the Institute of Nutrition,
Metabolism and Diabetes. He received an honorarium from
the United States Department of Agriculture to present the
2013 W.O. Atwater Memorial Lecture. He received the 2013
Award for Excellence in Research from the International Nut and
Dried Fruit Council. He received funding and travel support from
the Canadian Society of Endocrinology and Metabolism to
produce mini cases for the Canadian Diabetes Association
(CDA). He isa member of theInternational CarbohydrateQuality
Consortium (ICQC). His wife is a director and partner of
Glycemic Index Laboratories, Inc., and his sister received
funding through a grant from the St. Michael’s Hospital
Foundation to develop a cookbook for one of his studies.Sieven-
piper has received research support from the Canadian
Institutes of health Research (CIHR), Diabetes Canada, PSI
Foundation, Banting and Best Diabetes Centre (BBDC), Cana-
dian Nutrition Society (CNS), American Society for Nutrition
(ASN), Calorie Control Council, INC International Nut and Dried
Fruit Council Foundation, National Dried Fruit Trade Associa-
tion, The Tate and Lyle Nutritional Research Fund at the
University of Toronto, and The Glycemic Control and Cardio-
vascular Disease in Type 2 Diabetes Fund at the University of
Toronto (a fund established by the Alberta Pulse Growers). He
has received speaker fees and/or honoraria from Diabetes
Canada, Canadian Nutrition Society (CNS), Dr. Pepper Snapple
Group, Dairy Farmers of Canada, Nutrition Foundation of Italy
(NFI), C3 Collaborating for Health, Sprim Brasil, WhiteWave
Foods, Rippe Lifestyle, mdBriefcase, Alberta Milk, FoodMinds
LLC, Memac Ogilvy & Mather LLC, PepsiCo, The Ginger Network
LLC, International Sweeteners Association, and Pulse Canada.
He has ad hoc consulting arrangements with Winston & Strawn
LLP, Perkins Coie LLP, and Tate & Lyle. He is a member of the
European Fruit Juice Association Scientific Expert Panel. He is
on the Clinical Practice Guidelines Expert Committees of
Diabetes Canada, European Association for the study of
Diabetes (EASD), and Canadian Cardiovascular Society (CCS),
as well as an expert writing panel of the American Society for
Nutrition (ASN). He serves as an unpaid scientific advisor for the
Food, Nutrition, and Safety Program (FNSP) and the Technical
Committee on Carbohydrates of the International Life Science
Institute (ILSI) North America. He is a member of the Interna-
tional Carbohydrate Quality Consortium (ICQC), Executive
Board Member of the Diabetes and Nutrition Study Group
(DNSG) of the EASD, and Director of the Toronto 3D Knowledge
Synthesis and Clinical Trials foundation. His wife is an employee
of Unilever Canada. No competing interests were declared by Li,
Blanco Mejia, Stewart, Viguiliouk, and Leiter. There are no
patents, products in development, or marketed products to
declare.
References
1. World Health Statistics 2012. Geneva, Switzerland: World Health Organiza-
tion; 2012.
2. Global Status Report on Noncommunicable Diseases 2010. Geneva, Switzer-
land: World Health Organization; 2011.
3. Anderson TJ, Gr�
egoire J, Pearson GJ, Barry AR, Couture P, Dawes M, Francis
GA, Genest J Jr, Grover S, Gupta M, Hegele RA, Lau DC, Leiter LA, Lonn E,
Mancini GBJ, McPherson R, Ngui D, Poirier P, Sievenpiper JL, Stone JA,
Thanassoulis G, Ward R. 2016 Canadian Cardiovascular Society guidelines for
the management of dyslipidemia for the prevention of cardiovascular disease
in the adult. Can J Cardiol. 2016;32:1263–1282.
4. Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB,
Pasternak RC, Smith SC, Stone NJ; National Heart, Lung, and Blood Institute;
American College of Cardiology Foundation; American Heart Association.
Implications of recent clinical trials for the National Cholesterol Education
Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227–239.
DOI: 10.1161/JAHA.117.006659
Journal of the American Heart Association
10
Plant Protein and Blood Lipids
Li et al
SYSTEMATIC REVIEW AND META-ANALYSIS
Downloaded from http://ahajournals.org by on June 4, 2019
 5. King CK, Glass R, Bresee JS, Duggan C. Managing acute gastroenteritis
among children: oral rehydration, maintenance, and nutritional therapy.
MMWR Recomm Rep. 2003;52:1–16.
6. Ferdowsian HR, Barnard ND. Effects of plant-based diets on plasma lipids. Am
J Cardiol. 2009;104:947–956.
7. Mahon AK, Flynn MG, Stewart LK, McFarlin BK, Iglay HB, Mattes RD, Lyle RM,
Considine RV, Campbell WW. Protein intake during energy restriction: effects
on body composition and markers of metabolic and cardiovascular health in
postmenopausal women. J Am Coll Nutr. 2008;26:182–189.
8. USDA. Scientific Report of the 2015 Dietary Guidelines Advisory Committee.
In: DGAC-USDA, editor. 2015. https://health.gov/dietaryguidelines/2015-
scientific-report/pdfs/scientific-report-of-the-2015-dietary-guidelines-advisory-
committee.pdf. Access date: June 3, 2017
9. Jenkins DJ, Mirrahimi A, Srichaikul K, Berryman CE, Wang L, Carleton A,
Abdulnour S, Sievenpiper JL, Kendall CW, Kris-Etherton PM. Soy protein
reduces serum cholesterol by both intrinsic and food displacement mech-
anisms. J Nutr. 2010;140:2302s–2311s.
10. Sabat�
e J, Oda K, Ros E. Nut consumption and blood lipid levels: a pooled
analysis of 25 intervention trials. Arch Intern Med. 2010;170:821–827.
11. Blanco Mejia S, Kendall CWC, Viguiliouk E, Augustin LS, Ha V, Cozma AI,
Mirrahimi A, Maroleanu A, Chiavaroli L, Leiter LA, de Souza RJ, Jenkins DJA,
Sievenpiper JL. Effect of tree nuts on metabolic syndrome criteria: a
systematic review and meta-analysis of randomised controlled trials. BMJ
Open. 2014;4:e004660.
12. Ha V, Sievenpiper JL, de Souza RJ, Jayalath VH, Mirrahimi A, Agarwal A,
Chiavaroli L, Mejia SB, Sacks FM, Di Buono M, Bernstein AM, Leiter LA, Kris-
Etherton PM, Vuksan V, Bazinet RP, Josse RG, Beyene J, Kendall CW, Jenkins
DJ. Effect of dietary pulse intake on established therapeutic lipid targets for
cardiovascular risk reduction: a systematic review and meta-analysis of
randomized controlled trials. CMAJ. 2014;186:E252–E262.
13. Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R. Efficacy and
safety of plant stanols and sterols in the management of blood cholesterol
levels. Mayo Clin Proc. 2003;78:965–978.
14. Sol�
a R, Bruckert E, Valls R-M, Narejos S, Luque X, Castro-Cabezas M,
Dom�
enech G, Torres F, Heras M, Farr�
es X, Vaquer J-V, Mart�
ınez J-M, Almaraz
M-C, Anguera A. Soluble fibre (Plantago ovata husk) reduces plasma low-
density lipoprotein (LDL) cholesterol, triglycerides, insulin, oxidised LDL and
systolic blood pressure in hypercholesterolaemic patients: a randomised
trial. Atherosclerosis. 2010;211:630–637.
15. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and
carbohydrates on the ratio of serum total to HDL cholesterol and on serum
lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin
Nutr. 2003;77:1146–1155.
16. Vega-L�
opez S, Lichtenstein AH. Dietary protein type and cardiovascular
disease risk factors. Prev Cardiol. 2005;8:31–40.
17. Forsythe
WA,
Green
MS,
Anderson
JJ.
Dietary
protein
effects
on
cholesterol and lipoprotein concentrations: a review. J Am Coll Nutr.
1986;5:533–549.
18. Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M.
Soy protein, isoflavones, and cardiovascular health: an American Heart
Association Science Advisory for professionals from the Nutrition Committee.
Circulation. 2006;113:1034–1044.
19. EFSA Panel on Dietetic Products N, Allergies. Scientific Opinion on the
substantiation of a health claim related to isolated soy protein and reduction
of blood LDL-cholesterol concentrations pursuant to Article 14 of Regulation
(EC) No 1924/2006. EFSA J. 2012;10:2555 [17 pp.].
20. The American Heart Association’s Diet and Lifestyle Recommendations.
Chicago, IL: American Heart Association; 2014.
21. Canada’s Food Guide. Health Canada; Ottawa, Ontario 2007.
22. U.S. Department of Health and Human Services and U.S. Department of
Agriculture. 2015–2020 Dietary Guidelines for Americans. 8 ed. December
2015. Available at http://health.gov/dietaryguidelines/2015/guidelines/.
Access date: 3 June 2017.
23. Katz D. 2015 dietary guidelines: a plate full of politics. TheHuffingtonPost.-
com; 2016. http://www.huffingtonpost.com/david-katz-md/2015-dietary-
guidelines-a_b_8930098.html. Access date: March 16, 2016
24. Anderson TJ, Gr�
egoire J, Hegele RA, Couture P, Mancini GBJ, McPherson R,
Francis GA, Poirier P, Lau DC, Grover S, Genest J Jr, Carpentier AC, Dufour R,
Gupta M, Ward R, Leiter LA, Lonn E, Ng DS, Pearson GJ, Yates GM, Stone JA,
Ur E. 2012 Update of the Canadian Cardiovascular Society guidelines for the
diagnosis and treatment of dyslipidemia for the prevention of cardiovascular
disease in the adult. Can J Cardiol. 2013;29:151–167.
25. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interven-
tions. Version 510. United Kingdom: The Cochrane Collaboration; 2011.
26. Moher D, Liberati A, Tetzlaff J, Altman D; PRISMA Group. Preferred reporting
items for systematic reviews and meta-analyses: the PRISMA statement.
PLoS Med. 2009;6:e1000097.
27. Guidance for Industry: Evidence-Based Review System for the Scientific
Evaluation of Health Claims. In: Food and Drug Administration: Silver Springs,
MD; 2009. https://www.fda.gov/Food/GuidanceRegulation/GuidanceDoc
umentsRegulatoryInformation/LabelingNutrition/ucm073332.htm.
Access
date: June 3, 2017
28. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y,
Glasziou P, DeBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schunemann
HJ. GRADE guidelines, 1: introduction-GRADE evidence profiles and summary
of findings tables. J Clin Epidemiol. 2011;64:383–394.
29. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, Alderson P,
Glasziou P, Falck-Ytter Y, Schunemann HJ. GRADE guidelines, 2: framing the
question
and
deciding
on
important
outcomes.
J
Clin
Epidemiol.
2011;64:395–400.
30. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE,
Falck-Ytter Y, Meerpohl J, Norris S, Guyatt GH. GRADE guidelines, 3: rating
the quality of evidence. J Clin Epidemiol. 2011;64:401–406.
31. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, Montori V, Akl
EA, Djulbegovic B, Falck-Ytter Y, Norris SL, Williams JW Jr, Atkins D, Meerpohl J,
Schunemann HJ. GRADE guidelines, 4: rating the quality of evidence—study
limitations (risk of bias). J Clin Epidemiol. 2011;64:407–415.
32. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, Alonso-Coello P,
Djulbegovic B, Atkins D, Falck-Ytter Y, Williams JW Jr, Meerpohl J, Norris SL,
Akl EA, Schunemann HJ. GRADE guidelines, 5: rating the quality of evidence
—publication bias. J Clin Epidemiol. 2011;64:1277–1282.
33. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, Devereaux
PJ, Montori VM, Freyschuss B, Vist G, Jaeschke R, Williams JW Jr, Murad MH,
Sinclair D, Falck-Ytter Y, Meerpohl J, Whittington C, Thorlund K, Andrews J,
Schunemann HJ. GRADE guidelines 6: rating the quality of evidence—
imprecision. J Clin Epidemiol. 2011;64:1283–1293.
34. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, Alonso-
Coello P, Glasziou P, Jaeschke R, Akl EA, Norris S, Vist G, Dahm P, Shukla VK,
Higgins J, Falck-Ytter Y, Schunemann HJ; GRADE Working Group. GRADE
guidelines, 7: rating the quality of evidence—inconsistency. J Clin Epidemiol.
2011;64:1294–1302.
35. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, Alonso-
Coello P, Falck-Ytter Y, Jaeschke R, Vist G, Akl EA, Post PN, Norris S,
Meerpohl J, Shukla VK, Nasser M, Schunemann HJ; GRADE Working Group.
GRADE guidelines, 8: rating the quality of evidence—indirectness. J Clin
Epidemiol. 2011;64:1303–1310.
36. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, Atkins
D, Kunz R, Brozek J, Montori V, Jaeschke R, Rind D, Dahm P, Meerpohl J, Vist
G, Berliner E, Norris S, Falck-Ytter Y, Murad MH, Schunemann HJ; GRADE
Working Group. GRADE guidelines, 9: rating up the quality of evidence. J Clin
Epidemiol. 2011;64:1311–1316.
37. Brunetti M, Shemilt I, Pregno S, Vale L, Oxman AD, Lord J, Sisk J, Ruiz F, Hill
S, Guyatt GH, Jaeschke R, Helfand M, Harbour R, Davoli M, Amato L, Liberati
A, Schunemann HJ. GRADE guidelines, 10: considering resource use and
rating the quality of economic evidence. J Clin Epidemiol. 2013;66:140–150.
38. Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, Atkins
D, Kunz R, Montori V, Jaeschke R, Rind D, Dahm P, Akl EA, Meerpohl J, Vist G,
Berliner E, Norris S, Falck-Ytter Y, Schunemann HJ. GRADE guidelines, 11:
making an overall rating of confidence in effect estimates for a single
outcome and for all outcomes. J Clin Epidemiol. 2013;66:151–157.
39. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, Brozek J, Norris
S, Meerpohl J, Djulbegovic B, Alonso-Coello P, Post PN, Busse JW, Glasziou P,
Christensen R, Schunemann HJ. GRADE guidelines, 12: preparing summary of
findings tables-binary outcomes. J Clin Epidemiol. 2013;66:158–172.
40. Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA,
Johnston BC, Karanicolas P, Akl EA, Vist G, Kunz R, Brozek J, Kupper LL,
Martin SL, Meerpohl JJ, Alonso-Coello P, Christensen R, Schunemann HJ.
GRADE guidelines, 13: preparing summary of findings tables and evidence
profiles-continuous outcomes. J Clin Epidemiol. 2013;66:173–183.
41. Lane DM. Online statistics education: a multimedia course of study. 2007.
http://onlinestatbook.com/. Access date: June 3, 2017
42. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-
analyses involving cross-over trials: methodological issues. Int J Epidemiol.
2002;31:140–149.
43. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of
testing and adjusting for publication bias in meta-analysis. Biometrics.
2000;56:455–463.
44. Abd-Mishani M, Hosseinpour-Niazi S, Delshad H, Bahadori-Monfared A,
Mirmiran P, Azizi F. Effect of modified diet on lipid profiles in type 2 diabetic
patients. Iran J Endocrinol Metab. 2014;16:103–110.
DOI: 10.1161/JAHA.117.006659
Journal of the American Heart Association
11
Plant Protein and Blood Lipids
Li et al
SYSTEMATIC REVIEW AND META-ANALYSIS
Downloaded from http://ahajournals.org by on June 4, 2019
 45. Abete I, Parra D, Martinez JA. Legume-, fish-, or high-protein-based
hypocaloric diets: effects on weight loss and mitochondrial oxidation in
obese men. J Med Food. 2009;12:100–108.
46. Ahmed MS, Calabria AC, Kirsztajn GM. Short-term effects of soy protein diet in
patients with proteinuric glomerulopathies. J Bras Nefrol. 2011;33:150–159.
47. Allen JK, Becker DM, Kwiterovich PO, Lindenstruth KA, Curtis C. Effect of soy
protein-containing isoflavones on lipoproteins in postmenopausal women.
Menopause. 2007;14:106–114.
48. Appt SE, Tormala R, Franke AA, Mikkola TS, Tikkanen MJ, Ylikorkala O,
Clarkson TB. Soy-tibolone combination: effect on lipids in postmenopausal
monkeys and women. Maturitas. 2008;60:216–222.
49. Ashton E, Ball M. Effects of soy as tofu vs meat on lipoprotein concentra-
tions. Eur J Clin Nutr. 2000;54:14–19.
50. Azadbakht L, Shakerhosseini R, Atabak S, Jamshidian M, Mehrabi Y, Esmaill-
Zadeh A. Beneficiary effect of dietary soy protein on lowering plasma levels of
lipid and improving kidney function in type II diabetes with nephropathy. Eur J
Clin Nutr. 2003;57:1292–1294.
51. Azadbakht L, Kimiagar M, Mehrabi Y, Esmaillzadeh A, Padyab M, Hu FB,
Willett WC. Soy inclusion in the diet improves features of the metabolic
syndrome: a randomized crossover study in postmenopausal women. Am J
Clin Nutr. 2007;85:735–741.
52. Azadbakht L, Atabak S, Esmaillzadeh A. Soy protein intake, cardiorenal
indices, and C-reactive protein in type 2 diabetes with nephropathy. Diabetes
Care. 2008;31:648–654.
53. B€
ahr M, Fechner A, Kr€
amer J, Kiehntopf M, Jahreis G. Lupin protein positively
affects plasma LDL cholesterol and LDL:HDL cholesterol ratio in hyperc-
holesterolemic adults after four weeks of supplementation: a randomized,
controlled crossover study. Nutr J. 2013;12:1–10.
54. B€
ahr M, Fechner A, Kiehntopf M, Jahreis G. Consuming a mixed diet enriched
with lupin protein beneficially affects plasma lipids in hypercholesterolemic
subjects: a randomized controlled trial. Clin Nutr. 2014;34:7–14.
55. Bakhit RM, Klein BP, Essex-Sorlie D, Ham JO, Erdman JW Jr, Potter SM. Intake
of 25 g of soybean protein with or without soybean fiber alters plasma lipids
in men with elevated cholesterol concentrations. J Nutr. 1994;124:213–222.
56. Basaria S, Wisniewski A, Dupree K, Bruno T, Song MY, Yao F, Ojumu A, John
M, Dobs AS. Effect of high-dose isoflavones on cognition, quality of life,
androgens, and lipoprotein in post-menopausal women. J Endocrinol Invest.
2009;32:150–155.
57. Baum JA, Teng H, Erdman JW, Weigel RM, Klein BP, Persky VW, Freels S,
Surya P, Bakhit RM, Ramos E, Shay NF, Potter SM. Long-term intake of soy
protein improves blood lipid profiles and increases mononuclear cell low-
density-lipoprotein receptor messenger RNA in hypercholesterolemic, post-
menopausal women. Am J Clin Nutr. 1998;68:545–551.
58. Beavers KM, Serra MC, Beavers DP, Hudson GM, Willoughby DS. The lipid-
lowering effects of 4 weeks of daily soymilk or dairy milk ingestion in a
postmenopausal female population. J Med Food. 2010;13:650–656.
59. Blum A, Lang N, Peleg A, Vigder F, Israeli P, Gumanovsky M, Lupovitz S, Elgazi
A, Ben-Ami M. Effects of oral soy protein on markers of inflammation in
postmenopausal women with mild hypercholesterolemia. Am Heart J.
2003;145:e7.
60. Borodin EA, Menshikova IG, Dorovskikh VA, Feoktistova NA, Shtarberg MA,
Yamamoto T, Takamatsu K, Mori H, Yamamoto S. Effects of two-month
consumption of 30 g a day of soy protein isolate or skimmed curd protein on
blood lipid concentration in Russian adults with hyperlipidemia. J Nutr Sci
Vitaminol (Tokyo). 2009;55:492–497.
61. Bricarello LP, Kasinski N, Bertolami MC, Faludi A, Pinto LA, Relvas WG, Izar
MC, Ihara SS, Tufik S, Fonseca FA. Comparison between the effects of soy
milk and non-fat cow milk on lipid profile and lipid peroxidation in patients
with primary hypercholesterolemia. Nutrition. 2004;20:200–204.
62. Burns-Whitmore B, Haddad E, Sabat�
e J, Rajaram S. Effects of supplementing
n-3 fatty acid enriched eggs and walnuts on cardiovascular disease risk
markers in healthy free-living lacto-ovo-vegetarians: a randomized, crossover,
free-living intervention study. Nutr J. 2014;13:1–9.
63. Campbell SC, Khalil DA, Payton ME, Arjmandi BH. One-year soy protein
supplementation does not improve lipid profile in postmenopausal women.
Menopause. 2010;17:587–593.
64. Chen ST, Ferng SH, Yang CS, Peng SJ, Lee HR, Chen JR. Variable effects of
soy
protein
on
plasma
lipids
in
hyperlipidemic
and
normolipidemic
hemodialysis patients. Am J Kidney Dis. 2005;46:1099–1106.
65. Chen ST, Chen JR, Yang CS, Peng SJ, Ferng SH. Effect of soya protein on
serum lipid profile and lipoprotein concentrations in patients undergoing
hypercholesterolaemic haemodialysis. Br J Nutr. 2006;95:366–371.
66. Crouse JR III, Morgan T, Terry JG, Ellis J, Vitolins M, Burke GL. A randomized
trial comparing the effect of casein with that of soy protein containing varying
amounts of isoflavones on plasma concentrations of lipids and lipoproteins.
Arch Intern Med. 1999;159:2070–2076.
67. Cuevas AM, Irribarra VL, Castillo OA, Yanez MD, Germain AM. Isolated soy
protein improves endothelial function in postmenopausal hypercholes-
terolemic women. Eur J Clin Nutr. 2003;57:889–894.
68. Dent SB, Peterson CT, Brace LD, Swain JH, Reddy MB, Hanson KB, Robinson
JG, Alekel DL. Soy protein intake by perimenopausal women does not affect
circulating lipids and lipoproteins or coagulation and fibrinolytic factors. J
Nutr. 2001;131:2280–2287.
69. Duane WC. Effects of soybean protein and very low dietary cholesterol on
serum lipids, biliary lipids, and fecal sterols in humans. Metabolism.
1999;48:489–494.
70. Dunn C, Liebman M. Plasma lipid alterations in vegetarian males resulting
from the substitution of tofu for cheese. Nutr Res. 1986;6:1343–1352.
71. Finley JW, Burrell JB, Reeves PG. Pinto bean consumption changes SCFA
profiles in fecal fermentations, bacterial populations of the lower bowel, and
lipid profiles in blood of humans. J Nutr. 2007;137:2391–2398.
72. Gardner CD, Newell KA, Cherin R, Haskell WL. The effect of soy protein with
or without isoflavones relative to milk protein on plasma lipids in
hypercholesterolemic
postmenopausal
women.
Am
J
Clin
Nutr.
2001;73:728–735.
73. Gardner CD, Messina M, Kiazand A, Morris JL, Franke AA. Effect of two types
of soy milk and dairy milk on plasma lipids in hypercholesterolemic adults: a
randomized trial. J Am Coll Nutr. 2007;26:669–677.
74. Giovannetti PM, Carroll KK, Wolfe BM. Constancy of fasting serum
cholesterol of healthy young women upon substitution of soy protein isolate
for meat and dairy protein in medium and low fat diets. Nutr Res.
1986;6:609–618.
75. Goldberg AP, Lim A, Kolar JB, Grundhauser JJ, Steinke FH, Schonfeld G.
Soybean protein independently lowers plasma cholesterol levels in primary
hypercholesterolemia. Atherosclerosis. 1982;43:355–368.
76. Greany KA, Nettleton JA, Wangen KE, Thomas W, Kurzer MS. Probiotic
consumption does not enhance the cholesterol-lowering effect of soy in
postmenopausal women. J Nutr. 2004;134:3277–3283.
77. Haub MD, Wells AM, Campbell WW. Beef and soy-based food supplements
differentially affect serum lipoprotein-lipid profiles because of changes in
carbohydrate intake and novel nutrient intake ratios in older men who
resistive-train. Metabolism. 2005;54:769–774.
78. Hermansen K, Søndergaard M, Høie L, Carstensen M, Brock B. Beneficial
effects of a soy-based dietary supplement on lipid levels and cardiovascular
risk markers in type 2 diabetic subjects. Diabetes Care. 2001;24:228–233.
79. Hill AM, Harris Jackson KA, Roussell MA, West SG, Kris-Etherton PM. Type
and amount of dietary protein in the treatment of metabolic syndrome: a
randomized controlled trial. Am J Clin Nutr. 2015;102:757–770.
80. Hoie LH, Morgenstern EC, Gruenwald J, Graubaum HJ, Busch R, Luder W,
Zunft HJ. A double-blind placebo-controlled clinical trial compares the
cholesterol-lowering effects of two different soy protein preparations in
hypercholesterolemic subjects. Eur J Nutr. 2005;44:65–71.
81. Høie LH, Graubaum H-J, Harde A, Gruenwald J, Wernecke K-D. Lipid-lowering
effect of 2 dosages of a soy protein supplement in hypercholesterolemia. Adv
Ther. 2005;22:175–186.
82. Hoie LH, Guldstrand M, Sjoholm A, Graubaum HJ, Gruenwald J, Zunft HJ,
Lueder W. Cholesterol-lowering effects of a new isolated soy protein with
high levels of nondenaturated protein in hypercholesterolemic patients. Adv
Ther. 2007;24:439–447.
83. Hosseinpour-Niazi S, Mirmiran P, Hedayati M, Azizi F. Substitution of red meat
with legumes in the therapeutic lifestyle change diet based on dietary advice
improves cardiometabolic risk factors in overweight type 2 diabetes patients:
a cross-over randomized clinical trial. Eur J Clin Nutr. 2015;69:592–597.
84. Huff MW, Giovannetti PM, Wolfe BM. Turnover of very low-density lipoprotein-
apoprotein B is increased by substitution of soybean protein for meat and
dairy protein in the diets of hypercholesterolemic men. Am J Clin Nutr.
1984;39:888–897.
85. Jenkins DJA, Wolever TMS, Spiller G, Buckley G, Lam Y, Jenkins AL, Josse RG.
Hypocholesterolemic effect of vegetable protein in a hypocaloric diet.
Atherosclerosis. 1989;78:99–107.
86. Jenkins DJ, Kendall CW, Jackson CJ, Connelly PW, Parker T, Faulkner D, Vidgen
E, Cunnane SC, Leiter LA, Josse RG. Effects of high- and low-isoflavone
soyfoods on blood lipids, oxidized LDL, homocysteine, and blood pressure in
hyperlipidemic men and women. Am J Clin Nutr. 2002;76:365–372.
87. Jenkins DJ, Srichaikul K, Wong JM, Kendall CW, Bashyam B, Vidgen E,
Lamarche B, Rao AV, Jones PJ, Josse RG, Jackson CJ, Ng V, Leong T, Leiter LA.
Supplemental barley protein and casein similarly affect serum lipids in
hypercholesterolemic women and men. J Nutr. 2010;140:1633–1637.
DOI: 10.1161/JAHA.117.006659
Journal of the American Heart Association
12
Plant Protein and Blood Lipids
Li et al
SYSTEMATIC REVIEW AND META-ANALYSIS
Downloaded from http://ahajournals.org by on June 4, 2019
 88. Kestin M, Rouse IL, Correll RA, Nestel PJ. Cardiovascular disease risk factors
in free-living men: comparison of two prudent diets, one based on
lactoovovegetarianism and the other allowing lean meat. Am J Clin Nutr.
1989;50:280–287.
89. Kjolbaek L, Sorensen LB, Sondertoft NB, Rasmussen CK, Lorenzen JK, Serena
A, Astrup A, Larsen LH. Protein supplements after weight loss do not improve
weight maintenance compared with recommended dietary protein intake
despite beneficial effects on appetite sensation and energy expenditure: a
randomized, controlled, double-blinded trial. Am J Clin Nutr. 2017;106:684–
697.
90. Kreijkamp-Kaspers S, Kok L, Grobbee DE, de Haan EH, Aleman A, Lampe JW,
van der Schouw YT. Effect of soy protein containing isoflavones on cognitive
function, bone mineral density, and plasma lipids in postmenopausal women:
a randomized controlled trial. JAMA. 2004;292:65–74.
91. Kurowska EM, Jordan J, Spence JD, Wetmore S, Piche LA, Radzikowski M,
Dandona P, Carroll KK. Effects of substituting dietary soybean protein and oil
for milk protein and fat in subjects with hypercholesterolemia. Clin Invest
Med. 1997;20:162–170.
92. Laidlaw M, Mercer NJH. Serum cholesterol, triglyceride and lipoprotein
response in hypercholesterolemic males to replacement of cow’s milk with a
soy beverage. Fed Proc. 1985;44(5):No. 6360.
93. Laurin D, Jacques H, Moorjani S, Steinke FH, Gagne C, Brun D, Lupien PJ.
Effects of a soy-protein beverage on plasma lipoproteins in children with
familial hypercholesterolemia. Am J Clin Nutr. 1991;54:98–103.
94. Li J, Armstrong CL, Campbell WW. Effects of dietary protein source and
quantity during weight loss on appetite, energy expenditure, and cardio-
metabolic responses. Nutrients. 2016;8:63.
95. Liao FH, Shieh MJ, Yang SC, Lin SH, Chien YW. Effectiveness of a soy-based
compared with a traditional low-calorie diet on weight loss and lipid levels in
overweight adults. Nutrition. 2007;23:551–556.
96. Lichtenstein AH, Jalbert SM, Adlercreutz H, Goldin BR, Rasmussen H,
Schaefer EJ, Ausman LM. Lipoprotein response to diets high in soy or animal
protein with and without isoflavones in moderately hypercholesterolemic
subjects. Arterioscler Thromb Vasc Biol. 2002;22:1852–1858.
97. Liu ZM, Ho SC, Chen YM, Ho YP. The effects of isoflavones combined with soy
protein on lipid profiles, C-reactive protein and cardiovascular risk among
postmenopausal Chinese women. Nutr Metab Cardiovasc Dis. 2012;22:712–
719.
98. Liu ZM, Ho SC, Chen YM, Ho S, To K, Tomlinson B, Woo J. Whole soy, but not
purified daidzein, had a favorable effect on improvement of cardiovascular
risks: a 6-month randomized, double-blind, and placebo-controlled trial in
equol-producing postmenopausal women. Mol Nutr Food Res. 2014;58:709–
717.
99. Lovati MR, Manzoni C, Canavesi A, Sirtori M, Vaccarino V, Marchi M, Gaddi G,
Sirtori CR. Soybean protein diet increases low density lipoprotein receptor
activity in mononuclear cells from hypercholesterolemic patients. J Clin
Invest. 1987;80:1498–1502.
100. Ma Y, Chiriboga D, Olendzki BC, Nicolosi R, Merriam PA, Ockene IS. Effect of
soy protein containing isoflavones on blood lipids in moderately hyperc-
holesterolemic adults: a randomized controlled trial. J Am Coll Nutr.
2005;24:275–285.
101. Ma L, Grann K, Li M, Jiang Z. A pilot study to evaluate the effect of soy isolate
protein on the serum lipid profile and other potential cardiovascular risk
markers in moderately hypercholesterolemic Chinese adults. Ecol Food Nutr.
2011;50:473–485.
102. Maki KC, Butteiger DN, Rains TM, Lawless A, Reeves MS, Schasteen C, Krul
ES. Effects of soy protein on lipoprotein lipids and fecal bile acid excretion in
men and women with moderate hypercholesterolemia. J Clin Lipidol.
2010;4:531–542.
103. Markova MHS, Sucher S, Pivovarova O, Pfeiffer A. Metabolic and molecular
effects of a high-protein diet in subjects with type 2 diabetes. Diabetologia.
2015;58:S335.
104. Matthan NR, Jalbert SM, Ausman LM, Kuvin JT, Karas RH, Lichtenstein AH.
Effect of soy protein from differently processed products on cardiovascular
disease risk factors and vascular endothelial function in hypercholes-
terolemic subjects. Am J Clin Nutr. 2007;85:960–966.
105. McVeigh BL, Dillingham BL, Lampe JW, Duncan AM. Effect of soy protein
varying in isoflavone content on serum lipids in healthy young men. Am J Clin
Nutr. 2006;83:244–251.
106. Mercer NJH, Carroll KK, Giovannetti PM. Effects on human plasma lipids of
substituting soybean protein isolate for milk protein in the diet. Nutr Rep Int.
1987;35:279–287.
107. Meredith L, Liebman M, Graves K. Alterations in plasma lipid levels resulting
from tofu and cheese consumption in adult women. J Am Coll Nutr.
1989;8:573–579.
108. Meyer BJ, Larkin TA, Owen AJ, Astheimer LB, Tapsell LC, Howe PR. Limited
lipid-lowering effects of regular consumption of whole soybean foods. Ann
Nutr Metab. 2004;48:67–78.
109. Miraghajani MS, Esmaillzadeh A, Najafabadi MM, Mirlohi M, Azadbakht L. Soy
milk consumption, inflammation, coagulation, and oxidative stress among type
2 diabetic patients with nephropathy. Diabetes Care. 2012;35:1981–1985.
110. Napora JK, Short RG, Muller DC, Carlson OD, Odetunde JO, Xu X, Carducci M,
Travison TG, Maggio M, Egan JM, Basaria S. High dose isoflavones do not
improve metabolic and inflammatory parameters in androgen deprived men
with prostate cancer. J Androl. 2011;32:40–48.
111. Onning G, Akesson B, Oste R, Lundquist I. Effects of consumption of oat milk,
soya milk, or cow’s milk on plasma lipids and antioxidative capacity in
healthy subjects. Ann Nutr Metab. 1998;42:211–220.
112. Padhi EM, Blewett HJ, Duncan AM, Guzman RP, Hawke A, Seetharaman K,
Tsao R, Wolever TM, Ramdath DD. Whole soy flour incorporated into a muffin
and consumed at 2 doses of soy protein does not lower LDL cholesterol in a
randomized, double-blind controlled trial of hypercholesterolemic adults. J
Nutr. 2015;145:2665–2674.
113. Pipe EA, Gobert CP, Capes SE, Darlington GA, Lampe JW, Duncan AM. Soy
protein reduces serum LDL cholesterol and the LDL cholesterol:HDL
cholesterol and apolipoprotein B:apolipoprotein A-I ratios in adults with type
2 diabetes. J Nutr. 2009;139:1700–1706.
114. Potter SM, Bakhit RM, Essex-Sorlie DL, Weingartner KE, Chapman KM,
Nelson RA, Prabhudesai M, Savage WD, Nelson AI, Winter LW. Depression of
plasma cholesterol in men by consumption of baked products containing soy
protein. Am J Clin Nutr. 1993;58:501–506.
115. Puska P, Korpelainen V, Hoie LH, Skovlund E, Lahti T, Smerud KT. Soy in
hypercholesterolaemia: a double-blind, placebo-controlled trial. Eur J Clin
Nutr. 2002;56:352–357.
116. Puska P, Korpelainen V, Hoie LH, Skovlund E, Smerud KT. Isolated soya
protein with standardised levels of isoflavones, cotyledon soya fibres and
soya phospholipids improves plasma lipids in hypercholesterolaemia: a
double-blind, placebo-controlled trial of a yoghurt formulation. Br J Nutr.
2004;91:393–401.
117. Roughead ZK, Hunt JR, Johnson LK, Badger TM, Lykken GI. Controlled
substitution of soy protein for meat protein: effects on calcium retention,
bone, and cardiovascular health indices in postmenopausal women. J Clin
Endocrinol Metab. 2005;90:181–189.
118. Santo AS, Cunningham AM, Alhassan S, Browne RW, Burton H, Leddy JJ,
Grandjean PW, Horvath SM, Horvath PJ. NMR analysis of lipoprotein particle
size does not increase sensitivity to the effect of soy protein on CVD risk
when compared with the traditional lipid profile. Appl Physiol Nutr Metab.
2008;33:489–500.
119. Shidfar F, Ehramphosh E, Heydari I, Haghighi L, Hosseini S, Shidfar S.
Effects of soy bean on serum paraoxonase 1 activity and lipoproteins in
hyperlipidemic postmenopausal women. Int J Food Sci Nutr. 2009;60:195–
205.
120. Shige H, Ishikawa T, Higashi K, Yamashita T, Tomiyasu K, Yoshida H, Hosoai
H, Ito T, Nakajima K, Ayaori M, Yonemura A, Suzukawa M, Nakamura H.
Effects of soy protein isolate (SPI) and casein on the postprandial lipemia in
normolipidemic men. J Nutr Sci Vitaminol. 1998;44:113–127.
121. Sirtori CR, Agradi E, Conti F. Soybean protein diet in the treatment of type II
hyperlipoproteinaemia. Lancet. 1977;1:275–277.
122. Sirtori CR, Pazzucconi F, Colombo L, Battistin P, Bondioli A, Descheemaeker
K. Double-blind study of the addition of high-protein soya milk v. cows’ milk
to the diet of patients with severe hypercholesterolaemia and resistance to
or intolerance of statins. Br J Nutr. 1999;82:91–96.
123. Sirtori CR, Bosisio R, Pazzucconi F, Bondioli A, Gatti E, Lovati MR, Murphy P.
Soy milk with a high glycitein content does not reduce low-density lipoprotein
cholesterolemia in type II hypercholesterolemic patients. Ann Nutr Metab.
2002;46:88–92.
124. Steele MG. The effect on serum cholesterol levels of substituting milk with a
soya beverage. Aust J Nutr Diet. 1992;49:24–28.
125. Steinberg FM, Guthrie NL, Villablanca AC, Kumar K, Murray MJ. Soy protein
with isoflavones has favorable effects on endothelial function that are
independent of lipid and antioxidant effects in healthy postmenopausal
women. Am J Clin Nutr. 2003;78:123–130.
126. Sucher S, Markova M, Hornemann S, Pivovarova O, Rudovich N, Thomann R,
Schneeweiss R, Rohn S, Pfeiffer AFH. Comparison of the effects of diets high
in animal or plant protein on metabolic and cardiovascular markers in type 2
diabetes: a randomized clinical trial. Diabetes Obes Metab. 2017;19:944–
952.
127. Tabibi H, Imani H, Hedayati M, Atabak S, Rahmani L. Effects of soy
consumption on serum lipids and apoproteins in peritoneal dialysis patients:
a randomized controlled trial. Perit Dial Int. 2010;30:611–618.
DOI: 10.1161/JAHA.117.006659
Journal of the American Heart Association
13
Plant Protein and Blood Lipids
Li et al
SYSTEMATIC REVIEW AND META-ANALYSIS
Downloaded from http://ahajournals.org by on June 4, 2019
 128. Takahira M, Noda K, Fukushima M, Zhang B, Mitsutake R, Uehara Y, Ogawa
M, Kakuma T, Saku K. Randomized, double-blind, controlled, comparative trial
of formula food containing soy protein vs. milk protein in visceral fat obesity:
FLAVO study. Circ J. 2011;75:2235–2243.
129. Teede HJ, Dalais FS, Kotsopoulos D, Liang YL, Davis S, McGrath BP. Dietary
soy has both beneficial and potentially adverse cardiovascular effects: a
placebo-controlled study in men and postmenopausal women. J Clin
Endocrinol Metab. 2001;86:3053–3060.
130. Teixeira SR, Potter SM, Weigel R, Hannum S, Erdman JW, Hasler CM. Effects
of feeding 4 levels of soy protein for 3 and 6 wk on blood lipids and
apolipoproteins in moderately hypercholesterolemic men. Am J Clin Nutr.
2000;71:1077–1084.
131. Teixeira SR, Tappenden KA, Carson L, Jones R, Prabhudesai M, Marshall WP,
Erdman JW. Isolated soy protein consumption reduces urinary albumin
excretion and improves the serum lipid profile in men with type 2 diabetes
mellitus and nephropathy. J Nutr. 2004;134:1874–1880.
132. Thorp AA, Howe PR, Mori TA, Coates AM, Buckley JD, Hodgson J, Mansour J,
Meyer BJ. Soy food consumption does not lower LDL cholesterol in either
equol or nonequol producers. Am J Clin Nutr. 2008;88:298–304.
133. Tonstad S, Smerud K, Hoie L. A comparison of the effects of 2 doses of soy
protein or casein on serum lipids, serum lipoproteins, and plasma total
homocysteine in hypercholesterolemic subjects. Am J Clin Nutr. 2002;76:
78–84.
134. Van Horn L, Liu K, Gerber J, Garside D, Schiffer L, Gernhofer N, Greenland P.
Oats and soy in lipid-lowering diets for women with hypercholesterolemia: is
there synergy? J Am Diet Assoc. 2001;101:1319–1325.
135. van Nielen M, Feskens EJM, Rietman A, Siebelink E, Mensink M. Partly
replacing meat protein with soy protein alters insulin resistance and blood
lipids
in
postmenopausal
women
with
abdominal
obesity.
J
Nutr.
2014;144:1423–1429.
136. van Raaij JM, Katan MB, Hautvast JG, Hermus RJ. Effects of casein versus soy
protein diets on serum cholesterol and lipoproteins in young healthy
volunteers. Am J Clin Nutr. 1981;34:1261–1271.
137. van Raaij JM, Katan MB, West CE, Hautvast JG. Influence of diets containing
casein, soy isolate, and soy concentrate on serum cholesterol and
lipoproteins in middle-aged volunteers. Am J Clin Nutr. 1982;35:925–934.
138. Vega-Lopez S, Matthan NR, Ausman LM, Harding SV, Rideout TC, Ai M,
Otokozawa S, Freed A, Kuvin JT, Jones PJ, Schaefer EJ, Lichtenstein AH.
Altering dietary lysine:arginine ratio has little effect on cardiovascular risk
factors and vascular reactivity in moderately hypercholesterolemic adults.
Atherosclerosis. 2010;210:555–562.
139. Vigna GB, Pansini F, Bonaccorsi G, Albertazzi P, Donega P, Zanotti L, De
Aloysio D, Mollica G, Fellin R. Plasma lipoproteins in soy-treated post-
menopausal women: a double-blind, placebo-controlled trial. Nutr Metab
Cardiovasc Dis. 2000;10:315–322.
140. Weisse K, Brandsch C, Zernsdorf B, Nkengfack Nembongwe GS, Hofmann K,
Eder K, Stangl GI. Lupin protein compared to casein lowers the LDL
cholesterol:HDL cholesterol-ratio of hypercholesterolemic adults. Eur J Nutr.
2010;49:65–71.
141. West SG, Hilpert KF, Juturu V, Bordi PL, Lampe JW, Mousa SA, Kris-Etherton
PM. Effects of including soy protein in a blood cholesterol-lowering diet on
markers of cardiac risk in men and in postmenopausal women with and
without
hormone
replacement
therapy.
J
Womens
Health
(Larchmt).
2005;14:253–262.
142. Wheeler ML, Fineberg SE, Fineberg NS, Gibson RG, Hackward LL. Animal
versus plant protein meals in individuals with type 2 diabetes and
microalbuminuria: effects on renal, glycemic, and lipid parameters. Diabetes
Care. 2002;25:1277–1282.
143. Wiebe SL, Bruce VM, McDonald BE. A comparison of the effect of diets
containing beef protein and plant proteins on blood lipids of healthy young
men. Am J Clin Nutr. 1984;40:982–989.
144. Wofford MR, Rebholz CM, Reynolds K, Chen J, Chen CS, Myers L, Xu J, Jones
DW, Whelton PK, He J. Effect of soy and milk protein supplementation on
serum
lipid
levels:
a
randomized
controlled
trial.
Eur
J
Clin
Nutr.
2012;66:419–425.
145. Wolfe BM, Giovannetti PM, Cheng DCH. Hypolipidemic effect of substituting
soybean protein isolate for all meat and dairy protein in the diets of
hypercholesterolemic men. Nutr Rep Int. 1981;24:1187–1198.
146. Wolfe BM, Giovannetti PM. Elevation of VLDL-cholesterol during substitution
of soy protein for animal protein in diets of hypercholesterolemic Canadians.
Nutr Rep Int. 1985;32:1057–1065.
147. Wong WW, Smith EO, Stuff JE, Hachey DL, Heird WC, Pownell HJ. Cholesterol-
lowering effect of soy protein in normocholesterolemic and hypercholes-
terolemic men. Am J Clin Nutr. 1998;68:1385S–1389S.
148. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins:
benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll
Cardiol. 2005;46:1855–1862.
149. Manson JE, Tosteson H, Ridker PM, Satterfield S, Hebert P, O’Connor GT,
Buring JE, Hennekens CH. The primary prevention of myocardial infarction. N
Engl J Med. 1992;326:1406–1416.
150. Wang F, Zheng J, Yang B, Jiang J, Fu Y, Li D. Effects of vegetarian diets on
blood
lipids:
a
systematic
review
and
meta-analysis
of
randomized
controlled trials. J Am Heart Assoc. 2015;4:e002408. DOI: 10.1161/
JAHA.115.002408.
151. Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, de Souza R, Emam
A, Parker TL, Vidgen E, Lapsley KG, Trautwein EA, Josse RG, Leiter LA,
Connelly PW. Effects of a dietary portfolio of cholesterol-lowering foods vs
lovastatin on serum lipids and C-reactive protein. JAMA. 2003;290:502–510.
152. Jenkins DJ, Jones PJ, Lamarche B, Kendall CW, Faulkner D, Cermakova L,
Gigleux I, Ramprasath V, de Souza R, Ireland C, Patel D, Srichaikul K,
Abdulnour S, Bashyam B, Collier C, Hoshizaki S, Josse RG, Leiter LA, Connelly
PW, Frohlich J. Effect of a dietary portfolio of cholesterol-lowering foods given
at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a
randomized controlled trial. JAMA. 2011;306:831–839.
153. Jenkins DJA, Wong JMW, Kendall CWC, Esfahani A, Ng VWY, Leong TCK,
Faulkner DA, Vidgen E, Paul G, Mukherjea R, Krul ES, Singer W. Effect of a 6-
month vegan low-carbohydrate (“Eco-Atkins”) diet on cardiovascular risk
factors and body weight in hyperlipidaemic adults: a randomised controlled
trial. BMJ Open. 2014;4:e003505.
154. Estruch R, Ros E, Salas-Salvad�
o J, Covas M-I, Corella D, Ar�
os F, G�
omez-Gracia
E, Ruiz-Guti�
errez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L,
Pint�
o X, Basora J, Mu~
noz MA, Sorl�
ı JV, Mart�
ınez JA, Mart�
ınez-Gonz�
alez MA.
Primary prevention of cardiovascular disease with a Mediterranean diet. N
Engl J Med. 2013;368:1279–1290.
155. Knoops KB, de Groot LM, Kromhout D, Perrin AE, Moreiras-Varela O, Menotti
A, van Staveren WA. Mediterranean diet, lifestyle factors, and 10-year
mortality in elderly European men and women: the HALE project. JAMA.
2004;292:1433–1439.
156. Kris-Etherton P, Eckel RH, Howard BV, St. Jeor S, Bazzarre TL. Lyon Diet Heart
Study: benefits of a Mediterranean-style, National Cholesterol Education
Program/American Heart Association Step I dietary pattern on cardiovas-
cular disease. Circulation. 2001;103:1823–1825.
157. Key TJ, Fraser GE, Thorogood M, Appleby PN, Beral V, Reeves G, Burr ML,
Chang-Claude J, Frentzel-Beyme R, Kuzma JW, Mann J, McPherson K.
Mortality in vegetarians and non-vegetarians: a collaborative analysis of 8300
deaths among 76,000 men and women in five prospective studies. Public
Health Nutr. 1998;1:33–41.
158. Crowe FL, Appleby PN, Travis RC, Key TJ. Risk of hospitalization or death from
ischemic heart disease among British vegetarians and nonvegetarians:
results from the EPIC-Oxford cohort study. Am J Clin Nutr. 2013;97:597–603.
159. Fung TT, van Dam RM, Hankinson SE, Stampfer M, Willett WC, Hu FB. Low-
carbohydrate diets and all-cause and cause-specific mortality two cohort
studies. Ann Intern Med. 2010;153:289–298.
160. Kushi LH, Lew RA, Stare FJ, Ellison CR, el Lozy M, Bourke G, Daly L, Graham I,
Hickey N, Mulcahy R, Kevaney J. Diet and 20-year mortality from coronary
heart disease. N Engl J Med. 1985;312:811–818.
161. Pan A, Sun Q, Bernstein AM, Schulze MB, Manson JE, Stampfer MJ, Willett
WC, Hu FB. Red meat consumption and mortality: results from 2 prospective
cohort studies. Arch Intern Med. 2012;172:555–563.
162. Snowdon DA. Animal product consumption and mortality because of all
causes combined, coronary heart disease, stroke, diabetes, and cancer in
Seventh-day Adventists. Am J Clin Nutr. 1988;48:739–748.
163. Kelemen LE, Kushi LH, Jacobs DR, Cerhan JR. Associations of dietary protein
with disease and mortality in a prospective study of postmenopausal women.
Am J Epidemiol. 2005;161:239–249.
164. Armstrong B, Doll R. Environmental factors and cancer incidence and
mortality in different countries, with special reference to dietary practices. Int
J Cancer. 1975;15:617–631.
165. Sanchez A, Rubano DA, Shavlik GW, Hubbard R, Horning MC. Choles-
terolemic effects of the lysine/arginine ratio in rabbits after initial early
growth. Arch Latinoam Nutr. 1988;38:229–238.
166. Kurowska EM, Carroll KK. Effect of high levels of selected dietary essential
amino acids on hypercholesterolemia and down-regulation of hepatic LDL
receptors in rabbits. Biochim Biophys Acta. 1992;1126:185–191.
167. ParkMS,LiepaGU.Effectsofdietaryproteinandaminoacidsonthemetabolism
of cholesterol-carrying lipoproteins in rats. J Nutr. 1982;112:1892–1898.
168. Kohls KJ, Kies C, Fox HM. Blood serum lipid levels of humans given arginine,
lysine and tryptophan supplements without food. Nutr Rep Int. 1987;35:5–
11.
DOI: 10.1161/JAHA.117.006659
Journal of the American Heart Association
14
Plant Protein and Blood Lipids
Li et al
SYSTEMATIC REVIEW AND META-ANALYSIS
Downloaded from http://ahajournals.org by on June 4, 2019
 169. Berryman CE, Preston AG, Karmally W, Deckelbaum RJ, Kris-Etherton PM.
Effects of almond consumption on the reduction of LDL-cholesterol: a
discussion of potential mechanisms and future research directions. Nutr Rev.
2011;69:171–185.
170. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of
soy protein intake on serum lipids. N Engl J Med. 1995;333:276–282.
171. Pasiakos S, Agarwal S, Lieberman H, Fulgoni V. Sources and amounts of
animal, dairy, and plant protein intake of US adults in 2007–2010. Nutrients.
2015;7:5322.
172. Halkjar J, Olsen A, Bjerregaard LJ, Deharveng G, Tjonneland A, Welch AA,
Crowe FL, Wirfalt E, Hellstrom V, Niravong M, Touvier M, Linseisen J, Steffen
A, Ocke MC, Peeters PHM, Chirlaque MD, Larranaga N, Ferrari P, Contiero P,
Frasca G, Engeset D, Lund E, Misirli G, Kosti M, Riboli E, Slimani N, Bingham
S. Intake of total, animal and plant proteins, and their food sources in 10
countries in the European Prospective Investigation into Cancer and
Nutrition. Eur J Clin Nutr. 2015;63:S16–S36.
173. Rizzo NS, Jaceldo-Siegl K, Sabate J, Fraser GE. Nutrient profiles of vegetarian
and nonvegetarian dietary patterns. J Acad Nutr Diet. 2013;113:1610–1619.
174. Estruch R, Mart�
ınez-Gonz�
alez MA, Corella D, Salas-Salvad�
o J, Ruiz-Guti�
errez
V, Covas MI, Fiol M, G�
omez-Gracia E, L�
opez-Sabater MC, Vinyoles E, Ar�
os F,
Conde M, Lahoz C, Lapetra J, S�
aez G, Ros E. Effects of a Mediterranean-style
diet on cardiovascular risk factors: a randomized trial. Ann Intern Med.
2006;145:1–11.
175. Jenkins DJA, Kendall CWC, Faulkner D, Vidgen E, Trautwein EA, Parker TL,
Marchie A, Koumbridis G, Lapsley KG, Josse RG, Leiter LA, Connelly PW. A
dietary portfolio approach to cholesterol reduction: combined effects of plant
sterols, vegetable proteins, and viscous fibers in hypercholesterolemia.
Metabolism. 2002;51:1596–1604.
176. Mudryj AN, Yu N, Hartman TJ, Mitchell DC, Lawrence FR, Aukema HM. Pulse
consumption in Canadian adults influences nutrient intakes. Br J Nutr.
2012;108(suppl 1):S27–S36.
177. Mudryj AN, Aukema HM, Yu N. Intake patterns and dietary associations of
soya protein consumption in adults and children in the Canadian Community
Health Survey, Cycle 2.2. Br J Nutr. 2015;113:299–309.
178. Asif M, Rooney LW, Ali R, Riaz MN. Application and opportunities of pulses in
food system: a review. Crit Rev Food Sci Nutr. 2013;53:1168–1179.
179. Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB.
Prediction of coronary heart disease using risk factor categories. Circulation.
1998;97:1837–1847.
180. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after
myocardial infarction. N Engl J Med. 1990;323:1112–1119.
181. Stamler J, Wentworth D, Neaton JD. Is relationship between serum
cholesterol and risk of premature death from coronary heart disease
continuous and graded? Findings in 356 222 primary screenees of the
Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256:2823–2828.
182. The Lipid Research Clinics Coronary Primary Prevention Trial results, I:
reduction in incidence of coronary heart disease. JAMA. 1984;251:351–
364.
183. The Lipid Research Clinics Coronary Primary Prevention Trial results, II: the
relationship of reduction in incidence of coronary heart disease to
cholesterol lowering. JAMA. 1984;251:365–374.
184. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L,
Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes
J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol:
a meta-analysis of data from 170,000 participants in 26 randomised trials.
Lancet. 2010;376:1670–1681.
185. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P,
Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De
Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA,
Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe added to statin
therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–
2397.
DOI: 10.1161/JAHA.117.006659
Journal of the American Heart Association
15
Plant Protein and Blood Lipids
Li et al
SYSTEMATIC REVIEW AND META-ANALYSIS
Downloaded from http://ahajournals.org by on June 4, 2019
  
 
 
 
 
 
 
 
SUPPLEMENTAL MATERIAL
Downloaded from http://ahajournals.org by on June 4, 2019
 Table S1. Search Strategy. 
 
Medline 
EMBASE 
Cochrane 
1 
(Exp diet, vegetarian/ OR vegetarian*.mp. OR vegan*.mp. OR 
exp vegetable proteins/ OR (vegetable* adj1 protein*).mp. OR 
(plant* adj1 protein*).mp. OR (plant* adj1 food*).mp. OR 
(plant* adj1 based).mp. OR exp Fabaceae/ OR exp soybean 
proteins/ OR soy*.mp. OR tofu*.mp. OR natto*.mp. OR 
tempeh*.mp. OR miso*.mp. OR lentil*.mp. OR bean*.mp. OR 
legume*.mp. OR (meat* adj1 analog*).mp.) OR lactoovo*.mp. 
OR lacto-ovo*.mp. OR ovolacto*.mp. OR ovo-lacto*.mp. OR 
lactoveg*.mp. OR lacto-veg*.mp. OR ovoveg*.mp. OR ovo-
veg*.mp. 
(Exp vegetarian diet/ OR exp vegetarian/ OR 
vegetarian*.mp. OR vegan*.mp. OR exp vegetable protein/ 
OR (vegetable* adj1 protein*).mp. OR (plant* adj1 
protein*).mp. OR (plant* adj1 food*).mp. OR (plant* adj1 
based).mp. OR exp Fabaceae/ OR soy*.mp. OR tofu*.mp. 
OR natto*.mp. OR tempeh*.mp. OR miso*.mp. OR 
lentil*.mp. OR bean*.mp. OR legume*.mp. OR (meat* adj1 
analog*).mp. OR lactoovo*.mp. OR lacto-ovo*.mp. OR 
ovolacto*.mp. OR ovo-lacto*.mp. OR lactoveg*.mp. OR 
lacto-veg*.mp. OR ovoveg*.mp. OR ovo-veg*.mp.) 
(Exp diet, vegetarian/ OR vegetarian*.mp. OR vegan*.mp. OR exp vegetable 
proteins/ OR (vegetable* adj1 protein*).mp. OR (plant* adj1 protein*).mp. OR 
(plant* adj1 food*).mp. OR (plant* adj1 based).mp. OR exp Fabaceae/ OR exp 
soybean proteins/ OR soy*.mp. OR tofu*.mp. OR natto*.mp. OR tempeh*.mp. 
OR miso*.mp. OR lentil*.mp. OR bean*.mp. OR legume*.mp. OR (meat* adj1 
analog*).mp.) OR lactoovo*.mp. OR lacto-ovo*.mp. OR ovolacto*.mp. OR 
ovo-lacto*.mp. OR lactoveg*.mp. OR lacto-veg*.mp. OR ovoveg*.mp. OR ovo-
veg*.mp. 
AND 
 
(omnivor*.mp. OR (conventional adj3 diet*).mp. OR (normal 
adj3 diet*).mp. OR (regular adj3 diet*).mp. OR (mixed adj3 
diet*).mp. OR exp egg proteins, dietary/ OR exp milk proteins/ 
OR exp meat/ OR exp eggS/ OR exp dairy products/ OR exp 
milk/ OR (meat* adj1 protein*).mp. OR (meat* adj1 
product*).mp. OR (animal* adj1 protein*).mp. OR (animal* 
adj1 product*).mp. OR (fish* adj1 protein*).mp. OR (fish* 
adj1 product*).mp. OR (poultry adj1 protein*).mp. OR (poultry 
adj1 product*).mp. OR (chicken* adj1 protein*).mp. OR 
(chicken* adj1 product*).mp. OR (egg* adj1 protein*).mp. OR 
(egg* adj1 product*).mp. OR (milk adj1 protein*).mp. OR 
(milk adj1 product*).mp. OR (dairy adj1 protein*).mp. OR 
(dairy adj1 product*).mp.)  
(exp omnivore/ OR omnivor*.mp. OR (conventional adj3 
diet*).mp. OR (normal adj3 diet*).mp. OR (regular adj3 
diet*).mp. OR (mixed adj3 diet*).mp. OR exp Meat/ OR exp 
egg/ OR exp dairy product/ OR (meat* adj1 protein*).mp. 
OR (meat* adj1 product*).mp. OR (animal* adj1 
protein*).mp. OR (animal* adj1 product*).mp. OR (fish* 
adj1 protein*).mp. OR (fish* adj1 product*).mp. OR 
(poultry adj1 protein*).mp. OR (poultry adj1 product*).mp. 
OR (chicken* adj1 protein*).mp. OR (chicken* adj1 
product*).mp. OR (egg* adj1 protein*).mp. OR (egg* adj1 
product*).mp. OR (milk adj1 protein*).mp. OR (milk adj1 
product*).mp. OR (dairy adj1 protein*).mp. OR (dairy adj1 
product*).mp.) 
(omnivor*.mp. OR (conventional adj3 diet*).mp. OR (normal adj3 diet*).mp. 
OR (regular adj3 diet*).mp. OR (mixed adj3 diet*).mp. OR exp egg proteins, 
dietary/ OR exp milk proteins/ OR exp meat/ OR exp eggS/ OR exp dairy 
products/ OR exp milk/ OR (meat* adj1 protein*).mp. OR (meat* adj1 
product*).mp. OR (animal* adj1 protein*).mp. OR (animal* adj1 product*).mp. 
OR (fish* adj1 protein*).mp. OR (fish* adj1 product*).mp. OR (poultry adj1 
protein*).mp. OR (poultry adj1 product*).mp. OR (chicken* adj1 protein*).mp. 
OR (chicken* adj1 product*).mp. OR (egg* adj1 protein*).mp. OR (egg* adj1 
product*).mp. OR (milk adj1 protein*).mp. OR (milk adj1 product*).mp. OR 
(dairy adj1 protein*).mp. OR (dairy adj1 product*).mp.) 
AND 
 
(exp lipoproteins/ OR exp cholesterol/ OR exp 
hyperlipidemias/ OR (lipid or lipids).mp. OR (cholesterol or 
cholesterols).mp. OR hdl.mp. OR ("high density lipoprotein" or 
"high density lipoproteins").mp. OR ldl.mp. OR ("low density 
lipoprotein" or "low density lipoproteins").mp. OR 
apolipoprotein*.mp. OR (hyperlipemia* or 
hyperlipaemia*).mp. OR (hyperlipidemia* or 
hyperlipidaemia*).mp. OR (lipidemia* or lipidaemia*).mp. OR 
(lipemia* or lipaemia*).mp. OR (lipemic or lipaemic).mp.)  
(exp lipoproteins/ OR exp cholesterol/ OR exp 
hyperlipidemias/ OR (lipid or lipids).mp. OR (cholesterol or 
cholesterols).mp. OR hdl.mp. OR ("high density lipoprotein" 
or "high density lipoproteins").mp. OR ldl.mp. OR ("low 
density lipoprotein" or "low density lipoproteins").mp. OR 
apolipoprotein*.mp. OR (hyperlipemia* or 
hyperlipaemia*).mp. OR (hyperlipidemia* or 
hyperlipidaemia*).mp. OR (lipidemia* or 
lipidaemia*).mp. OR (lipemia* or lipaemia*).mp. OR 
(lipemic or lipaemic).mp.) 
(exp lipoproteins/ OR exp cholesterol/ OR exp hyperlipidemias/ OR (lipid or 
lipids).mp. OR (cholesterol or cholesterols).mp. OR hdl.mp. OR ("high density 
lipoprotein" or "high density lipoproteins").mp. OR ldl.mp. OR ("low density 
lipoprotein" or "low density lipoproteins").mp. OR apolipoprotein*.mp. OR 
(hyperlipemia* or hyperlipaemia*).mp. OR (hyperlipidemia* or 
hyperlipidaemia*).mp. OR (lipidemia* or lipidaemia*).mp. OR (lipemia* or 
lipaemia*).mp. OR (lipemic or lipaemic).mp.) 
2 
limit 1 to animals 
limit 1 to animals 
1 not (exp infant formula/ OR exp milk, human/) 
3 
limit 2 to human 
limit 2 to human 
 
4 
2 not 3 
2 not 3 
 
5 
1 not 4 
1 not 4 
 
6 
5 not (exp infant formula/ OR exp milk, human/)  
5 not (exp breast milk/ or exp infant formula/) 
 
For all databases, the original search date was December 6, 2016; updated search was performed on September 10, 2017. 
 
 
 
Downloaded from http://ahajournals.org by on June 4, 2019
 Table S2. Full Table of Characteristics. 
Study, year 
Participants 
Mean Age 
(SD or 
range), y * 
Mean BMI or 
Body Weight 
(SD) † 
Setting 
Design 
Plant 
Protein 
Source 
Animal 
Protein 
Source ‡ 
Food 
Form § 
Amount of 
substitution || 
Background 
Diet ¶ 
Energy 
Balance 
Follow-
up 
Funding # 
Abd-Mishani et al. 2014 
(1) 
24 DM2 
(6M,18W) 
61.7 (6) 
74.5 (7.1) kg 
OP, Iran 
C 
Pulses 
Meat 
Whole 
2 servings pulses 
3d/wk 
(55:30:15) 
Neutral 
8 wks 
Agency 
Abete et al. 2009 (2)** 
26 O (26M) 
38 (35.7) 
31.8 (3) kg/m² 
OP, 
Spain 
P 
Legumes 
Meat, Fatty 
fish 
Whole 
Legumes 4d/wk 
(53:30:17) 
Negative 
8 wks 
Agency 
Ahmed et al. 2011 (3) 
27 CKD 
(4M,23W) 
46 (12) 
25.6 (4.6) kg/m² 
OP, 
Brazil 
P 
Soy 
Various 
Protein 
0.8g/kg 
Nephropathy 
diet 
Negative 
8 wks 
N/A 
Allen et al. 2007 (4)** 
191 PM 
(191W) 
56.8 (5.6) 
27.9 (4.7) kg/m² 
OP, 
USA 
P 
Soy 
Dairy 
Protein 
20g 
LF 
Neutral 
12 wks 
Agency & 
Industry 
Appt et al. 2008 (5) 
32 PM 
(32W) 
57.7 (4.5) 
24.6 (3.2) kg/m² 
OP, 
USA 
C 
Soy 
Dairy 
Protein 
52g 
Habitual 
Neutral 
8 wks 
Agency & 
Industry 
Ashton et al. 2000 (6) 
42 N (42M) 
45.8 (7.8) 
26.2 (3.3) kg/m² 
OP, 
Australia 
C 
Soy 
Lean meat 
Whole 
290g tofu 
Plant-based 
diet 
(44:32:17) 
Neutral 
4 wks 
N/A 
Azadbakht et al. 2003 (7) 
14 
DM2,CKD 
(10M,4W) 
62.5 (12.1) 
26.6 (4) kg/m² 
OP, Iran 
C 
Soy 
Various 
Protein 
35% 
Nephropathy 
diet 
Neutral 
7 wks 
Agency 
Azadbakht et al. 2007 (8) 
42 MS,PM 
(42W) 
PM 
N/A 
OP, Iran 
C 
Soy 
Red meat 
Whole & 
protein 
11-15g 
DASH 
Neutral 
8 wks 
Agency 
Azadbakht et al. 2008 (9) 
41 
DM2,CKD 
(18M,23W) 
62 (12) 
N/A 
OP, Iran 
P 
Soy 
Various 
Protein 
35% 
Nephropathy 
diet 
Neutral 
4 y 
N/A 
Bahr et al. 2013 (10) 
33 HC 
(15M,18W) 
49.5 (13.4) 
28 (5.9) kg/m² 
OP, 
German
y 
C 
Lupin 
Dairy 
Protein 
20g 
Habitual 
Neutral 
8 wks 
Agency & 
Industry 
Bahr et al. 2014 (11) 
68 HC 
(28M,40W) 
56.9 (10.7) 
26.5 (2.7) kg/m² 
OP, 
German
y 
C 
Lupin 
Dairy 
Protein 
20g 
Habitual 
Neutral 
4 wks 
Agency & 
Industry 
Bakhit et al. 1994  (12) 
(Cotyledon) 
21 HC 
(21M) 
43 (14) 
27.1 (3) kg/m² 
OP, 
USA 
C 
Soy 
Dairy 
Protein 
25g 
LF, LC 
(55:30:15) 
Neutral 
4 wks 
Industry 
Bakhit et al. 1994 (12) 
(Cellulose) 
21 HC 
(21M) 
43 (14) 
27.1 (3) kg/m² 
OP, 
USA 
C 
Soy 
Dairy 
Protein 
25g 
LF, LC 
(55:30:15) 
Neutral 
4 wks 
Industry 
Basaria et al. 2009 (13) 
84 PM 
(84W) 
55.7 (10.8) 
26 (5.2) kg/m² 
OP, 
USA 
P 
Soy 
Dairy 
Protein 
20g 
Habitual 
Neutral 
12 wks 
N/A 
Baum et al. 1998 (14) 
66 PM 
(66W) 
60.9 (8) 
28.2 (5.3) kg/m² 
OP, 
USA 
P 
Soy 
Dairy 
Protein 
40g 
NCEP Step 1 
Neutral 
24 wks 
Agency & 
Industry 
Downloaded from http://ahajournals.org by on June 4, 2019
 Table S2. Full Table of Characteristics (Continued). 
 
Study, year 
Participants 
Mean Age 
(SD or 
range), y * 
Mean BMI or 
Body Weight 
(SD) † 
Setting 
Design 
Plant 
Protein 
Source 
Animal 
Protein 
Source ‡ 
Food 
Form § 
Amount of 
substitution || 
Background 
Diet ¶ 
Energy 
Balance 
Follow-
up 
Funding # 
Beavers et al. 2010 (15) 
32 N,PM 
(32W) 
54.4 (3.3) 
25.8 (3.8) kg/m² 
OP, 
USA 
P 
Soy 
Dairy 
Whole 
18g 
Habitual 
Neutral 
4 wks 
Industry 
Blum et al. 2003 (16) 
24 HC,PM 
(24W) 
55 (5) 
N/A 
OP, 
Israel 
C 
Soy 
Dairy 
Protein 
25g 
Habitual 
Neutral 
6 wks 
Industry 
Borodin et al. 2009 (17) 
28 HC,O 
(9M,19W) 
50 (10.6) 
29 (3.9) kg/m² 
OP, 
Russia 
C 
Soy 
Dairy 
Protein 
30g 
Habitual 
Neutral 
2 mos 
Industry 
Bricarello et al. 2004 (18) 
60 HC 
(15M,45W) 
56 (7.7) 
24.9 (2.3) kg/m² 
OP, 
Brazil 
C 
Soy 
Dairy 
Whole 
25g 
NCEP TLC 
Neutral 
6 wks 
Agency & 
Industry 
Burns-Whitmore et al. 
2014 (19) 
20 N 
(4M,16W) 
38 (3) 
23 (4.5) kg/m² 
OP, 
USA 
C 
Walnut 
Egg 
(Standard, 
N3 FA) 
Whole 
28g walnut 
6x/wk 
Habitual 
Neutral 
8 wks 
Agency & 
Industry 
Campbell et al. 2010 (20) 
62 HC,PM 
(62W) 
54.3 (33.2) 
28 (5.2) kg/m² 
OP, 
USA 
P 
Soy 
Dairy 
Protein 
25g 
Habitual 
Neutral 
1 y 
Agency & 
Industry 
Chen et al. 2005 (HC) 
(21) 
19 HC,CKD 
(5M,14W) 
63.6 (9.4) 
24 (2.1) kg/m² 
OP, 
Taiwan 
P 
Soy 
Dairy 
Protein 
30g 
Hemodialysi
s diet 
Neutral 
12 wks 
Agency & 
Industry 
Chen et al. 2005 (N) (21) 
18 CKD 
(5M,13W) 
59.5 (11.9) 
21.3 (5) kg/m² 
OP, 
Taiwan 
P 
Soy 
Dairy 
Protein 
30g 
Hemodialysi
s diet 
Neutral 
12 wks 
Agency & 
Industry 
Chen et al. 2006 (22) 
26 HC,CKD 
(19M,7W) 
58.6 (11.4) 
23.1 (2.7) kg/m² 
OP, 
Taiwan 
P 
Soy 
Dairy 
Protein 
30g 
Hemodialysi
s diet 
Neutral 
12 wks 
Agency 
Crouse et al. 1999 (23)** 
146 HC 
(94M,62W) 
52 (11) 
26 (3) kg/m² 
OP, 
USA 
P 
Soy 
Dairy 
Protein 
25g 
NCEP Step 1 
Neutral 
9 wks 
Agency & 
Industry 
Cuevas et al. 2003 (24) 
18 HC,PM 
(18W) 
59 (47-70) 
29.3 (3.4) kg/m² 
OP, 
Chile 
C 
Soy 
Dairy 
Protein 
40g 
NCEP Step 1 
N/A 
4 wks 
Agency & 
Industry 
Dent et al. 2001 (25) 
69 PeriM 
(69W) 
50.2 (3.6) 
24.1 (3.2) kg/m² 
OP, 
USA 
P 
Soy 
Dairy 
Protein 
40g 
Habitual 
Neutral 
24 wks 
Agency & 
Industry 
Duane et al. 1999 (26) 
8 N (8M) 
60.3 (11.9) 
26.3 (4) kg/m² 
IP, USA 
C 
Soy 
Various 
Whole 
>75% 
American 
diet 
Neutral 
6-7 wks 
Agency 
Dunn et al. 1986 (27) 
12 N (12M) 
31.8 (6.4) 
24.9 (4.6) kg/m² 
OP, 
USA 
C 
Soy 
Dairy 
Whole 
26.7g 
Habitual 
Neutral 
3 wks 
N/A 
Finley et al. 2007 (N) (28) 
40 N 
(20M,20W) 
37.4 (10.1) 
24.5 (2.8) kg/m² 
OP, 
USA 
P 
Pinto 
beans 
Chicken 
noodle soup 
Whole 
130g pinto beans 
Habitual 
Neutral 
12 wks 
Agency 
Finley et al. 2007 (Pre-
MS) (28) 
40 Pre-MS 
(20M,20W) 
42.4 (9.9) 
32.8 (3.8) kg/m² 
OP, 
USA 
P 
Pinto 
beans 
Chicken 
noodle soup 
Whole 
130g pinto beans 
Habitual 
Neutral 
12 wks 
Agency 
Downloaded from http://ahajournals.org by on June 4, 2019
 Table S2. Full Table of Characteristics (Continued). 
Study, year 
Participants 
Mean Age 
(SD or 
range), y * 
Mean BMI or 
Body Weight 
(SD) † 
Setting 
Design 
Plant 
Protein 
Source 
Animal 
Protein 
Source ‡ 
Food 
Form § 
Amount of 
substitution || 
Background 
Diet ¶ 
Energy 
Balance 
Follow-
up 
Funding # 
Gardner et al. 2001(29) 
94 HC,PM 
(94W) 
59.1 (6.9) 
26.3 (4.4) kg/m² 
OP, 
USA 
P 
Soy 
Dairy 
Protein 
42g 
Habitual 
Neutral 
12 wks 
Agency & 
Industry 
Gardner et al. 2007 (30) 
28 HC 
(6M,22W) 
52 (9) 
26 (4) kg/m² 
OP, 
USA 
C 
Soy 
Dairy 
Whole & 
protein 
25g 
Habitual 
Positive 
4 wks 
Agency & 
Industry 
Giovannetti et al. 1986  
(31) (N) 
12 N (12W) 
22.1 (2.1) 
59.5 (8) kg 
OP, 
Canada 
C 
Soy 
Dairy 
Protein 
88% 
(44:38:18) 
Neutral 
4 wks 
Agency & 
Industry 
Giovannetti et al. 1986 
(31) (LF) 
12 N (12W) 
22.1 (2.1) 
59.5 (8) kg 
OP, 
Canada 
C 
Soy 
Dairy & 
meat 
Protein 
88% 
(59:23:18) 
Neutral 
4 wks 
Agency & 
Industry 
Goldberg et al. 1982 (32) 
(N) 
4 N 
(3M,1W) 
36.8 (16.1) 
N/A 
OP, 
USA 
C 
Soy 
Dairy & 
meat 
Protein 
75% 
(40:40:20) 
Neutral 
6 wks 
Agency & 
Industry 
Goldberg et al. 1982 (32) 
(HC) 
12 HC 
(7M,5W) 
43.6 (12.2) 
N/A 
OP, 
USA 
C 
Soy 
Dairy & 
meat 
Protein 
75% 
(40:40:20) 
Neutral 
6 wks 
Agency & 
Industry 
Greany et al. 2004 (33) 
37 PM 
(37W) 
57.5 (13.4) 
25.4 (6.7) kg/m² 
OP, 
USA 
C 
Soy 
Dairy 
Protein 
0.4g/kg  
Habitual 
Neutral 
6 wks 
Agency & 
Industry 
Haub et al. 2005 (34) 
21 N (21M) 
65 (5) 
28.2 (2.6) kg/m² 
OP, 
USA 
P 
Soy 
Beef 
products 
Whole 
0.6g/kg  
Plant-based 
diet 
Neutral 
12 wks 
Agency & 
Industry 
Hermansen et al. 2001 
(35) 
20 DM2 
(14M,6W) 
63.6 (7.5) 
30.2 (4.1) kg/m² 
OP, 
Denmar
k 
C 
Soy 
Dairy 
Protein 
50g 
(~42:29:26) 
Neutral 
6 wks 
Agency & 
Industry 
Hill et al. 2015 (36)†† 
62 O,MS 
(28M,34W) 
45.8 (21.4) 
34.8 (3.7) kg/m² 
OP, 
USA 
P 
Lean 
beef 
Various 
Whole 
67% 
DASH or 
(45:27:27) 
Neutral 5 
wk, 
Negative 
18 wk 
6 mos 
Agency & 
Industry 
Hoie et al. 2005 (37)- A 
double-blind placebo-
controlled…. 
116 HC 
(54M,62W) 
55.2 (9.5) 
76.9 (12.4) kg 
OP, 
German
y 
P 
Soy 
Dairy 
Protein 
25g  
Habitual 
Neutral 
8 wks 
N/A 
Høie et al. 2005 (38)- 
Lipid Lowering…  
117 HC 
(63M,54W) 
53.6 (9.6) 
76.3 (12.5) kg 
OP, 
German
y 
P 
Soy 
Dairy 
Protein 
15g, 25g 
Habitual 
Neutral 
8 wks 
N/A 
Hoie et al. 2007 (39) 
88 HC 
(34M,54W) 
54.6 (9.6) 
75.2 (12.5) kg 
OP, 
German
y 
P 
Soy 
Dairy 
Protein 
25g 
Habitual 
Neutral 
8 wks 
Industry 
Hosseinpour-Niazi et al. 
2014 (40) 
31 DM2 
(7M,24W) 
58.1 (33.4) 
27.8 (3.3) kg/m² 
OP, Iran 
C 
Non-soy 
legumes 
Meat 
Whole 
2 servings 
legumes 3x/wk 
NCEP TLC 
Neutral 
8 wks 
Agency 
 
Downloaded from http://ahajournals.org by on June 4, 2019
 Table S2. Full Table of Characteristics (Continued). 
Study, year 
Participants 
Mean Age 
(SD or 
range), y * 
Mean BMI or 
Body Weight 
(SD) † 
Setting 
Design 
Plant 
Protein 
Source 
Animal 
Protein 
Source ‡ 
Food 
Form § 
Amount of 
substitution || 
Background 
Diet ¶ 
Energy 
Balance 
Follow-
up 
Funding # 
Huff et al. 1984 (41) 
5 HC (5M) 
49 (11.2) 
82 (15.7) kg 
OP, 
Canada 
C 
Soy 
Various 
Whole 
41g 
(49:37:15) 
Negative 
6 wks 
Agency 
Jenkins et al. 1989 (42) 
11 O (11W) 
38 (13.3) 
32.8 (4.1) kg/m² 
OP, 
Canada 
C 
Soy 
Various 
Protein 
17.4g  
1000kcal 
diet 
Negative 
4 wks 
Agency & 
Industry 
Jenkins et al. 2002 (43) 
41 HC,PM 
(23M,18W) 
62 (12.8) 
25.3 (3.2) kg/m² 
OP, 
Canada 
C 
Soy 
Dairy 
Whole & 
protein 
50-52g 
NCEP Step 2 
Neutral 
4 wks 
Agency & 
Industry 
Jenkins et al. 2010 (44) 
23 HC,PM 
(7M,16W) 
57 (9.6) 
26 (4.8) kg/m² 
OP, 
Canada 
C 
Barley 
Dairy 
Whole 
30g/2000kcal 
LF, LC, 
plant-based 
diet 
Neutral 
4 wks 
Agency & 
Industry 
Kestin et al. 1989 (45) 
26 N (26M) 
44 (10) 
25.5 (3.2) 
OP, 
Australia 
P §§ 
Various 
Meat 
Whole 
60% 
Plant-based 
diet 
Neutral 
6 wks 
Agency & 
Industry 
Kjolbaek et al. 2017 (46) 
113 O 
(60M:91F) 
42.4 
33.1 
OP, 
Denmar
k 
P 
Soy 
Dairy 
Protein 
45g 
Habitual 
Neutral 
24 wks 
Agency & 
Industry 
Kreijkamp-Kaspers et 
al. 2004 (47) 
175 PM 
(175W) 
66.6 (4.7) 
26.2 (3.8) kg/m² 
OP, 
Netherla
nds 
P 
Soy 
Dairy 
Protein 
25.6g 
Habitual 
Neutral 
1 y 
Agency & 
Industry 
Kurowska et al. 1997 (48) 
34 HC 
(17M,17W) 
55 (11) 
N/A 
OP, 
Canada 
C 
Soy 
Dairy 
Whole 
31g 
Habitual 
Neutral 
4 wks 
Industry 
Laidlaw et al. 1985 (49) 
19 HC 
(19M) 
47.4 (11.3) 
81.5 (11.7) kg 
OP, 
Canada 
C 
Soy 
Dairy 
Protein 
18.4g 
Habitual 
Neutral 
8 wks 
Agency & 
Industry 
Laurin et al. 1991 (50)** 
9 FHC 
(6M,4W) 
8 (3) 
16.7 (2.6) kg/m² 
OP, 
Canada 
C 
Soy 
Dairy 
Protein 
35% 
LC 
(52:28:20) 
Neutral 
4 wks 
Agency 
Li et al. 2016 (51) 
34 O 
(11M:23F) 
53.5 (3.2) 
30.9 (0.7) kg/m² 
OP, 
USA 
P 
Legumes 
Meat 
Whole 
30% 
(55:25:20) 
Negative 
12 wks 
Agency & 
Industry 
Liao et al. 2007 (52) 
30 O 
(6M,24W) 
33.4 (10.8) 
29.8 (3.4) kg/m² 
OP, 
Taiwan 
P 
Soy 
Various 
Whole 
30g 
(60:25:15) 
Negative 
8 wks 
Industry 
Lichenstein et al. 2002  
(53) (No IF) 
42 HC 
(18M,24W) 
62.7 (8.8) 
26.6 (3.4) kg/m² 
OP, 
USA 
C 
Soy 
Dairy & 
meat 
Protein 
50g/2000kcal 
(46.5:37:16) 
Neutral 
6 wks 
Agency & 
Industry 
Lichenstein et al. 2002 
(53) (IF) 
42 HC 
(18M,24W) 
62.7 (8.8) 
26.6 (3.4) kg/m² 
OP, 
USA 
C 
Soy 
Dairy & 
meat 
Protein 
50g/2000kcal 
(46.5:37:16) 
Neutral 
6 wks 
Agency & 
Industry 
Liu et al. 2012 (54) 
180 Pre-
DM2,PM 
(180W) 
56.2 (4.4) 
24.4 (3.7) kg/m² 
OP, 
China 
P 
Soy 
Dairy 
Protein 
15g 
Habitual 
Neutral 
6 mos 
Agency & 
Industry 
 
Downloaded from http://ahajournals.org by on June 4, 2019
 Table S2. Full Table of Characteristics (Continued). 
Study, year 
Participants 
Mean Age 
(SD or 
range), y * 
Mean BMI or 
Body Weight 
(SD) † 
Setting 
Design 
Plant 
Protein 
Source 
Animal 
Protein 
Source ‡ 
Food 
Form § 
Amount of 
substitution || 
Background 
Diet ¶ 
Energy 
Balance 
Follow-
up 
Funding # 
Liu et al. 2014 (55) 
270 PM 
(270W) 
57.9 (5.1) 
N/A 
OP, 
China 
P 
Soy 
Dairy 
Whole 
12.8g  
Habitual 
Neutral 
6 mos 
Agency 
Lovati et al. 1987 (56) 
12 HC 
(5M,7W) 
45 (12.5) 
61.4 (1.7) kg 
OP, Italy 
C 
Soy 
Dairy & 
meat 
Protein 
N/A 
LF 
(54:26:20) 
Neutral 
4 wks 
Agency & 
Industry 
Ma et al. 2005 (57) 
159 HC 
(70M,89W) 
56.6 (8.4) 
28.9 (4.3) kg/m² 
OP, 
USA 
P 
Soy 
Dairy 
Protein 
31.5g  
Habitual 
Neutral 
5 wks 
Industry 
Ma et al. 2011 (58) 
90 HC 
(26M,64W) 
51.7 (10.6) 
23.6 (3.3) kg/m² 
OP, 
China 
P 
Soy 
Dairy 
Protein 
18g 
Habitual 
Neutral 
8 wks 
Industry 
Maki et al. 2010 (59) 
58 HC 
(26M,32W) 
50.8 (12) 
27.7 (4.8) kg/m² 
OP, 
USA 
P 
Soy 
Dairy 
Protein 
25g 
NCEP TLC 
Neutral 
4 wks 
Industry 
Markova et al. 2015 
(60)‡‡ 
37 DM2 
(24M,13W) 
64.3 (6.1) 
30.5 (3.6) kg/m² 
OP, 
German
y 
P 
Pulses 
Dairy & 
meat 
Whole 
>65-70% 
(40:30:30) 
Neutral 
6 wks 
N/A 
Matthan et al. 2007 (61) 
28 HC 
(2M,26W) 
65 (6) 
27 (3) kg/m² 
OP, 
USA 
C 
Soy 
Various 
Whole 
37.5g 
NCEP TLC 
Neutral 
6 wks 
Agency 
McVeigh et al. 2006 (62) 
35 N (35M) 
27.9 (5.7) 
25.4 (3) kg/m² 
OP, 
Canada 
C 
Soy 
Dairy 
Protein 
32g 
Habitual 
Neutral 
57 d 
Agency & 
Industry 
Mercer et al. 1987 (63) 
33 N 
(23M,10W) 
46.7 (10.8) 
N/A 
OP, 
Canada 
C 
Soy 
Dairy 
Protein 
19g 
Habitual 
Neutral 
6 wks 
Agency 
Meredith et al. 1989 (64) 
10 N (10W) 
27.3 (6.3) 
22.5 (2.6) kg/m² 
OP, 
USA 
C 
Soy 
Dairy 
Whole 
22g 
Plant-based 
diet 
Neutral 
3 wks 
Agency 
Meyer et al. 2004 (65) 
23 HC 
and/or HTN 
(13M,10W) 
54 (8.6) 
26.2 (2.9) kg/m² 
OP, 
Australia 
C 
Soy 
Dairy 
Whole 
>30g 
Habitual 
Neutral 
5 wks 
Agency & 
Industry 
Miraghajani et al. 2013 
(66) 
25 
DM2,CKD 
(10M,15W) 
51 (10) 
28 (4) kg/m² 
OP, Iran 
C 
Soy 
Dairy 
Whole 
2.5g 
Nephropathy 
diet  
Neutral 
4 wks 
Agency 
Napora et al. 2011 (67) 
33 ADT 
(33M) 
69.1 (9.3) 
29.4 (5.3) kg/m² 
IP, USA 
P 
Soy 
Dairy 
Protein 
20g 
Habitual 
Neutral 
12 wks 
N/A 
Onning et al. 1998 (68) 
22 N 
(11M,11W) 
31.5 (23-
54) 
(20-25)) kg/m² 
OP, 
Sweden 
P 
Soy 
Dairy 
Whole 
22.5g-30g 
Habitual 
Neutral 
4 wks 
Agency 
Padhi et al. 2015 (69) 
213 HC 
(78M,135W) 
55 (8.8) 
28 (4.6) kg/m² 
OP, 
Canada 
P 
Soy 
Dairy 
Whole 
12.5g, 25g 
Habitual 
Neutral 
6 wks 
Agency & 
Industry 
 
 
Downloaded from http://ahajournals.org by on June 4, 2019
 Table S2. Full Table of Characteristics (Continued). 
Study, year 
Participants 
Mean Age 
(SD or 
range), y * 
Mean BMI or 
Body Weight 
(SD) † 
Setting 
Design 
Plant 
Protein 
Source 
Animal 
Protein 
Source ‡ 
Food 
Form § 
Amount of 
substitution || 
Background 
Diet ¶ 
Energy 
Balance 
Follow-
up 
Funding # 
Pipe et al. 2009 (70)** 
29 DM2,PM 
(16M,13W) 
60.1 (9.6) 
29.6 (4.1) kg/m² 
OP, 
Canada 
C 
Soy 
Dairy 
Protein 
40g 
Habitual 
Neutral 
57 d 
Agency & 
Industry 
Potter et al. 1993 (71) 
25 HC 
(25M) 
61 (48-78) 
30.2 (6.7) kg/m² 
IP, USA 
C 
Soy 
Dairy 
Protein 
50g 
(55:<30:15) 
Neutral 
4 wks 
Industry 
Puska et al. 2002 (72) 
52 HC 
(31M,21W) 
55.8 (35-
70) 
N/A 
OP, 
Finland 
P 
Soy 
Dairy 
Protein 
52g 
Habitual 
Neutral 
6 wks 
Industry 
Puska et al. 2004 (73)** 
132 HC 
(77M,66W) 
Median 58 
(30-70) 
27 (9.1) kg/m² 
OP, 
Finland 
P 
Soy 
Dairy 
Protein 
41.4g 
Habitual 
Neutral 
8 wks 
Agency & 
Industry 
Roughead et al. 2005 (74) 
13 PM 
(13W) 
59.9 (5) 
26 kg/m² 
OP, 
USA 
C 
Soy 
Meat 
Protein 
25g 
(55:30:15) 
Neutral 
7 wks 
Agency & 
Industry 
Santo et al. 2008 (75) 
30 N (30M) 
24.2 (2.3) 
23.8 (3.7) kg/m² 
OP, 
USA 
P 
Soy 
Dairy 
Protein 
25g  
Habitual 
N/A 
4 wks 
Industry 
Shidfar et al. 2009 (76) 
42 HC,PM 
(42W) 
55 (4.8) 
27 (3.1) kg/m² 
OP, Iran 
P 
Soy 
Dairy 
Whole 
50g 
Habitual 
Neutral 
10 wks 
N/A 
Shige et al. 1998 (77) 
11 N (11M) 
32.6 (6.4) 
24.6 (2.8) kg/m² 
OP, 
Japan 
C 
Soy 
Dairy 
Protein 
20g 
Japanese diet 
Neutral 
3 wks 
Industry 
Sirtori et al. 1977 (78) 
20 HC 
(10M,10W) 
 (22-68) 
N/A 
IP, Italy 
C 
Soy 
Various 
Protein 
55% 
LF, LC, 
HPUFA 
N/A 
3 wks 
Agency & 
Industry 
Sirtori et al. 1999 (79) 
21 HC 
(8M,13W) 
51.9 (13.5) 
24.4 (3.6) kg/m² 
OP, Italy 
C 
Soy 
Dairy 
Whole 
35g 
LC, HPUFA 
Neutral 
4 wks 
Agency 
Sirtori et al. 2002 (80) 
20 FHC 
(4M,16W) 
59.5 (8.4) 
24.2 (3.5) kg/m² 
OP, Italy 
C 
Soy 
Dairy 
Whole 
25g 
LC, HPUFA 
Neutral 
4 wks 
Agency & 
Industry 
Steele et al. 1992 (81) 
32 N 
(15M,17W) 
42.2 (16.2) 
N/A 
OP, 
Australia 
C 
Soy 
Dairy 
Whole 
>16.5g 
Habitual 
Neutral 
4 wks 
Agency 
Steinberg et al. 2003 (82) 
28 PM 
(28W) 
54.9 (5.3) 
24.6 (3.2) kg/m² 
OP, 
USA 
C 
Soy 
Dairy 
Protein 
25g 
Habitual 
Neutral 
6 wks 
Industry 
Sucher et al. 2017 (83)  
37 DM2 
(24M:13F) 
64.3 (6.3) 
30.2 (3.9) kg/m² 
OP, 
German
y 
P 
Pea 
Dairy & 
meat 
Whole 
72% 
(40:30:30) 
Neutral 
6 wks 
Agency & 
Industry 
Tabibi et al. 2010 (84) 
36 CKD 
(18M,18W) 
52 (15) 
26 (5) kg/m² 
OP, Iran 
P 
Soy 
Meat 
Whole 
14g 
Habitual 
Neutral 
8 wks 
Agency 
Takahira et al. 2011 (85) 
46 O 
(11M,35W) 
55.5 (12.4) 
29.2 (4) kg/m² 
OP, 
Japan 
P 
Soy 
Dairy 
Protein 
12g 
Habitual 
Neutral 
20 wks 
Agency 
 
Downloaded from http://ahajournals.org by on June 4, 2019
 Table S2. Full Table of Characteristics (Continued). 
Study, year 
Participants 
Mean Age 
(SD or 
range), y * 
Mean BMI or 
Body Weight 
(SD) † 
Setting 
Design 
Plant 
Protein 
Source 
Animal 
Protein 
Source ‡ 
Food 
Form § 
Amount of 
substitution || 
Background 
Diet ¶ 
Energy 
Balance 
Follow-
up 
Funding # 
Teede et al. 2001 (86) 
179 N,PM 
(96M,83W) 
60.5 (9.6) 
25.5 (2.6) kg/m² 
OP, 
Australia 
P 
Soy 
Dairy 
Protein 
40g 
Habitual 
Neutral 
3 mos 
Agency 
Teixeira et al. 2000 (87) 
81 HC 
(81M) 
45.4 (11.4) 
27.4 (3.7) kg/m² 
OP, 
USA 
P 
Soy 
Dairy 
Protein 
20g, 30g, 40g, 
50g 
NCEP Step 1 
Neutral 
6 wks 
Agency & 
Industry 
Teixeira et al. 2004 (88) 
14 
DM2,CKD 
(14M) 
 (53-73) 
29.8 (3) kg/m² 
OP, 
USA 
C 
Soy 
Dairy 
Protein 
0.5g/kg 
1g 
protein/kg, 
LF, LC 
Neutral 
8 wks 
Agency & 
Industry 
Thorp et al. 2008 (89) 
91 HC 
(34M,57W) 
52.7 (1) 
27.3 (4.5) kg/m² 
OP, 
Australia 
C 
Soy 
Dairy 
Protein 
12g, 24g 
Habitual 
Neutral 
6 wks 
Agency & 
Industry 
Tonstad et al. 2002 (90) 
130 HC,PM 
(108M,22W) 
52.5 (8.4) 
25.3 (2.1) kg/m² 
OP, 
Norway 
P 
Soy 
Dairy 
Protein 
30g, 50g 
AHA Step 1 
Neutral 
16 wks 
Industry 
Van Horn et al. 2001 (91) 
(Oats) 
64 HC,PM 
(64W) 
66.6 (10.3) 
26.9 (3.8) kg/m² 
OP, 
USA 
P 
Soy 
Dairy 
Protein 
29g 
NCEP Step 1 
Neutral 
6 wks 
Industry 
Van Horn et al. 2001 (91) 
(Wheat) 
63 HC,PM 
(63W) 
66.6 (10.3) 
26.9 (3.8) kg/m² 
OP, 
USA 
P 
Soy 
Dairy 
Protein 
29g 
NCEP Step 1 
Neutral 
6 wks 
Industry 
van Nielen et al. 2014 
(92) 
15 O,PM 
(15W) 
61 (5) 
Waist 
circumference: 
90 (10) cm 
OP, 
Netherla
nds 
C 
Soy 
Dairy & 
meat 
Whole 
30g 
(49:21:30) 
Neutral 
4 wks 
Industry 
van Raaij et al. 1981 
(93)** 
69 N 
(46M,30W) 
 (18-28) 
N/A 
OP, 
Netherla
nds 
P 
Soy 
Dairy 
Protein 
65% 
Western diet 
Neutral 
4 wks 
Agency & 
Industry 
van Raaij et al. 1982 
(94)** 
57 N 
(32M,29W) 
46 (9) 
N/A 
OP, 
Netherla
nds 
P 
Soy 
Dairy 
Protein 
60% 
Western diet 
Negative 
4 wks 
Agency & 
Industry 
Vega-Lopez et al. 2010 
(95) 
30 HC 
(9M,21W) 
61.8 (6.5) 
26.7 (3.2) kg/m² 
OP, 
USA 
C 
Various 
(Low 
Lys:Arg) 
Various 
(High 
Lys:Arg) 
Whole 
>75% 
(50:30:20) 
Neutral 
5 wks 
Agency 
Vigna et al. 2000 (96) 
77 PM 
(77W) 
53.4 (3.3) 
25.9 (3.5) kg/m² 
OP, Italy 
P 
Soy 
Dairy 
Protein 
40g 
Habitual 
Neutral 
12 wks 
Industry 
Weisse et al. 2010 (97) 
43 HC 
(20M,23W) 
43.9 (11.8) 
25.9 (4.5) kg/m² 
OP, 
German
y 
P 
Lupin 
Dairy 
Protein 
35g 
Habitual 
Neutral 
6 wks 
Agency 
West et al. 2005 (98) 
32 HC,PM 
(14M,18W) 
58 (5.2) 
26.3 (3.1) kg/m² 
OP, 
USA 
C 
Soy 
Dairy 
Protein 
25g 
NCEP Step 
1, HF 
N/A 
6 wks 
Industry 
 
Downloaded from http://ahajournals.org by on June 4, 2019
 Table S2. Full Table of Characteristics (Continued). 
Study, year 
Participants 
Mean Age 
(SD or 
range), y * 
Mean BMI or 
Body Weight 
(SD) † 
Setting 
Design 
Plant 
Protein 
Source 
Animal 
Protein 
Source ‡ 
Food 
Form § 
Amount of 
substitution || 
Background 
Diet ¶ 
Energy 
Balance 
Follow-
up 
Funding # 
Wheeler et al. 2002 (99) 
17 
DM2,CKD 
(14M,3W) 
56 (12.4) 
33.1 (5.8) kg/m² 
OP, 
USA 
C 
Legumes 
Dairy & 
meat 
Whole 
60% 
(53:30:17) 
Neutral 
6 wks 
Agency & 
Industry 
Wiebe et al. 1984 (100) 
8 N (8M) 
21 (3.2) 
N/A 
OP, 
Canada 
C 
Various 
Dairy 
Whole 
55% 
Western diet 
Neutral 
3 wks 
Agency 
Wofford et al. 2012 
(101)** 
352 N 
(205M,147
W) 
47.7 (10.4) 
29.3 (4.5) kg/m² 
OP, 
USA 
C 
Soy 
Dairy 
Protein 
40g 
Habitual 
Neutral 
8 wks 
Agency & 
Industry 
Wolfe et al. 1981 (102) 
7 HC (7M) 
41.9 (10.8) 
76 (13.2) kg 
OP, 
Canada 
C 
Soy 
Dairy & 
meat 
Protein 
47g 
Habitual, LC 
Neutral 
7 wks 
Agency & 
Industry 
Wolfe et al. 1985 (103) 
5 HC 
(2M,3W) 
56 (8.9) 
84 (13.4) kg 
OP, 
Canada 
C 
Soy 
Dairy & 
meat 
Protein 
72g 
Habitual, LC 
Neutral 
5 wks 
Agency & 
Industry 
Wong et al. 1998 (104) 
(N) 
13 N (13M) 
35.5 (7.2) 
N/A 
OP, 
USA 
C 
Soy 
Dairy & 
meat 
Protein 
>75% 
NCEP Step 1 
Neutral 
5 wks 
Agency & 
Industry 
Wong et al. 1998 (104) 
(HC) 
13 HC 
(13M) 
41.4 (7.8) 
N/A 
OP, 
USA 
C 
Soy 
Dairy & 
meat 
Protein 
>75% 
NCEP Step 1 
Neutral 
5 wks 
Agency & 
Industry 
 
ADT = androgen deprivation therapy, C = crossover, CKD = chronic kidney disease, DM2 = diabetes mellitus, FHC = familial hypercholesterolemia, HC = hypercholesterolemic, 
HF = high fibre, HPUFA = high polyunsaturated fat:saturated fat ratio, HTN = hypertension, IF = isoflavones, IP = inpatient, LC = low cholesterol, LF = low fat, LOV = lacto-
ovo-vegetarian, N = normal, N/A = data not available, NP = not published, M = men, MS = metabolic syndrome, O = overweight/obese, OP = outpatient, P = parallel, PM = post-
menopausal, Peri-M = peri-menopausal, W = women  
* Mean age and SD or range were used as available; where unavailable, post-menopausal (PM) was used for Azadbakht et al. 2007(8), and median age and range were used for Puksa et al. 2004(73).  
† Baseline BMI values (kg/m2). Baseline body weight (kg) values are only reported when no data on body weight were available. Waist circumference (cm) was used for the study by van Nielen et al. 
2014(92) as neither were available.  
‡ Animal protein source. Multiple animal protein intervention arms within the same trial are separated by a comma.  
§ Food form indicates whether test foods were in the form of whole foods (whole) and/or isolated protein supplements (protein). 
|| Amount of protein substitution, per day unless otherwise indicated. Where data for grams of substitution was unavailable, grams/2000kcal, percentage protein replacement, grams per kilogram body 
weight, or serving sizes were used as available. Studies describing replacement of "most" protein are displayed as >75%. Multiple dosage levels within the same trial are separated by a comma.  
¶ Background diet as described by study protocol. Where specific diets were not indicated, dietary breakdowns are listed as energy from (carbohydrate:fat:protein) where given, and where no 
information was given habitual diets were assumed. NCEP Step 1 diet has <30% fat, <1/3 saturated fat, and <300mg cholesterol. NCEP Step 2 diet has <30% fat, <1/4 saturated fat, and <200mg 
cholesterol. Nephropathy diet contains 0.8g protein/kg body weight. Hemodialysis diet contains 35%F, 1.2g protein/kg body weight, and 32-35kcal/kg body weight. Plant-based diet includes 
vegetarian, lacto-vegetarian, and lacto-ovo-vegetarian.  
# Agency funding consists of funding from government, university, or not-for-profit health agency sources. The following studies had declared conflicts of interest: Gardner et al 2007(30), Haub et al 
2005(34), Hermansen et al 2001(35), Jenkins et al 2010(44), Maki et al 2010(59), Mercer et al 1987(63), Padhi et al 2015(69), Tonstad et al 2002(90), and West et al 2005(98). None of the other studies declared 
any conflicts of interest.  
** Includes baseline data before drop-outs where final data were not available for study characteristics  
†† For Hill et al. 2015(36), the background diet followed the DASH diet except for one arm of the animal protein arm which had increased protein content  
‡‡ The data from Markova et al. 2015 (60) are not yet published; BMI data from this study describe the first 30 patients enrolled  
§§ Kestin et al. 1989 (45) used an incomplete crossover design with three arms 
 
Downloaded from http://ahajournals.org by on June 4, 2019
 Table S3. Bootstrap Analyses. 
LDL-C 
Total (95% CI): -0.16 [-0.20, -0.12] 
Heterogeneity: Chi² = 235.60, df = 107 (P < 0.0001); I² = 55% 
Test for overall effect: Z = -8.597 (P < 0.0001) 
Modified H² = 1.218  
tau² = 0.0160  
non-HDL-C 
Total (95% CI): -0.18 [-0.22, -0.14] 
Heterogeneity: Chi² = 209.96, df = 101 (P < 0.0005); I² = 51% 
Test for overall effect: Z = -8.463 (P < 0.0005) 
Modified H² = 1.035  
tau² = 0.0164 
ApoB 
Total (95% CI): -0.05 [-0.06, -0.03] 
Heterogeneity: Chi² = 51.36, df = 36 (P = 0.05); I² = 30% 
Test for overall effect: Z = -6.587 (P < 0.0005) 
Modified H² = 0.449  
tau² = 0.0004 
Data are expressed in mmol/L for LDL-C and non-HDL-C, and g/L for ApoB. Paired analyses were applied to all 
crossover trials. Data are expressed as MDs with 95% CIs, using generic inverse-variance random-effects models. 
Inter-study heterogeneity was tested using the Cochran Q statistic (chi-square) at a significance level of P<0.10. 
 
 
Downloaded from http://ahajournals.org by on June 4, 2019
 Table S4. Post-Hoc Dose Response. 
LDL 
Dose threshold, 
grams AP replaced 
with PP 
Dose ranges, 
grams AP 
replaced with PP 
β (95% CIs) * 
Residual I2 † 
p-value 
15 
≤15 
0.003 (-0.020, 0.026) 
57.58% 
0.704 
>15 
-0.002 (-0.004, 0.001) 
25 
≤25 
0.001 (-0.008, 0.011) 
57.57% 
0.535 
>25 
-0.002 (-0.005, 0.001) 
35 
≤35 
-0.001 (-0.007, 0.005) 
57.59% 
0.846 
>35 
-0.002 (-0.006, 0.002) 
45 
≤45 
-0.002 (-0.006, 0.002) 
57.47% 
0.744 
>45 
-0.001 (-0.006, 0.005) 
55 
≤55 
-0.002 (-0.005, 0.001) 
57.03% 
0.512 
>55 
0.001 (-0.007, 0.009) 
Non-HDL 
Dose threshold, 
grams AP replaced 
with PP 
Dose ranges, 
grams AP 
replaced with PP 
β (95% CIs) * 
Residual I2 † 
p-value 
15 
≤15 
0.006 (-0.018, 0.029) 
44.61% 
0.685 
>15 
0.001 (-0.002, 0.003) 
25 
≤25 
0.002 (-0.007, 0.010) 
42.15% 
0.839 
>25 
0.001 (-0.002, 0.003) 
35 
≤35 
-0.001 (-0.007, 0.005) 
44.29% 
0.462 
>35 
0.002 (-0.002, 0.006) 
45 
≤45 
-0.002 (-0.006, 0.002) 
45.25% 
0.112 
>45 
0.005 (-0.001, 0.010) 
55 
≤55 
-0.001 (-0.004, 0.002) 
45.16% 
0.076 
>55 
0.007 (0, 0.015) 
Apo B 
Dose threshold, 
grams AP replaced 
with PP 
Dose ranges, 
grams AP 
replaced with PP 
β (95% CIs) * 
Residual I2 † 
p-value 
15 
≤15 
0.001 (-0.006, 0.008) 
37.42% 
0.836 
>15 
0 (-0.001, 0.001) 
25 
≤25 
0 (-0.003, 0.003) 
37.42% 
0.922 
>25 
0 (-0.001, 0.001) 
35 
≤35 
0 (-0.002, 0.002) 
37.42% 
0.899 
>35 
0 (-0.001, 0.001) 
45 
≤45 
0 (-0.002, 0.001) 
36.88% 
0.615 
>45 
0.001 (-0.001, 0.002) 
55 
≤55 
0 (-0.001, 0.001) 
36.11% 
0.519 
>55 
0.001 (-0.002, 0.003) 
AP = animal protein; PP = plant protein 
* β is the slope derived from the piecewise linear meta-regression analyses and represents the treatment effect on LDL-C 
for doses above and below each dose-threshold representing grams animal protein replaced with plant protein 
† The residual I2 value indicates heterogeneity unexplained by each dose-threshold. 
 
 
 
Downloaded from http://ahajournals.org by on June 4, 2019
 Table S4. GRADE Assessment.  
Quality assessment 
№ of patients 
Effect 
Quality 
№ of 
studies 
Study 
design 
Risk 
of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
Plant 
protein 
Animal 
protein 
Absolute 
(95% 
CI) 
Effects of vegetable protein compared to animal protein intake on LDL-C 
108  
randomised 
trials  
not 
serious  
serious 1 
not serious  
not serious  
potential 
publication 
bias 2 
3637  
3764  
MD 0.16 
mmol/L 
lower 
(0.2 
lower to 
0.12 
lower)  
⊕⊕⊕⊝ 
MODERATE 
due to 
inconsistency  
Effects of vegetable protein compared to animal protein intake on non-HDL-C 
102  
randomised 
trials  
not 
serious  
serious 1 
not serious  
not serious  
none  
3502  
3643  
MD 0.18 
mmol/L 
lower 
(0.22 
lower to 
0.14 
lower)  
⊕⊕⊕⊝ 
MODERATE  
due to 
inconsistency 
Effects of vegetable protein compared to animal protein intake on apo B 
37  
randomised 
trials  
not 
serious  
not serious  
not serious  
serious 3 
none  
937  
1083  
MD 0.05 
g/L 
lower 
(0.06 
lower to 
0.03 
lower)  
⊕⊕⊕⊝ 
MODERATE  
due to imprecision 
 
CI: Confidence interval; MD: Mean difference  
1. Significant (P<0.05) and substantial (I-squared>50%) heterogeneity  
2. Egger’s test for publication bias was significant (P<0.05). However, significance is dependent upon one study 
with missing variance data, and additional Duval and Tweedie trim-and-fill analyses did not substantially alter the 
effect size or significance. Therefore there was no further downgrading.  
3. 95% CI for risk estimates overlap a minimally important difference of 0.04g/L for apolipoprotein B 
 
 
Downloaded from http://ahajournals.org by on June 4, 2019
  
 
Figure S1. Cochrane Risk of Bias. Risk of bias assessment using Cochrane Risk of Bias Tool.  
 
 
 
 
 
 
 
Downloaded from http://ahajournals.org by on June 4, 2019
  
Figure S2. LDL-C Forest Plot, random-effects model.  
Mean Difference IV,
 Random, 95% CI  
Abd-Mishani 2014 (1)
24
24
1.2%
-0.20 [-0.43, 0.02]
Abete 2009 (2)
18
8
0.4%
-0.73 [-1.26, -0.20]
Ahmed 2011 (3)
9
18
0.2%
0.07 [-0.76, 0.91]
Allen 2007 (4)
98
93
1.5%
-0.06 [-0.22, 0.11]
Appt 2008 (5)
32
32
1.5%
-0.24 [-0.40, -0.08]
Ashton 2000 (6)
42
42
1.0%
-0.09 [-0.35, 0.17]
Azadbakht 2003 (7)
14
14
1.4%
-0.22 [-0.41, -0.03]
Azadbakht 2007 (8)
42
42
1.6%
-0.30 [-0.45, -0.14]
Azadbakht 2008 (9)
21
20
0.6%
-0.78 [-1.15, -0.40]
Bahr 2013 (10)
33
33
1.6%
-0.02 [-0.17, 0.13]
Bahr 2014 (11)
68
68
1.2%
-0.03 [-0.24, 0.19]
Bakhit 1994 (Cellulose) (12)
21
21
1.2%
0.04 [-0.18, 0.26]
Bakhit 1994 (Cotyledon) (12)
21
21
1.0%
-0.20 [-0.47, 0.07]
Basaria 2009 (13)
46
38
0.6%
-0.05 [-0.44, 0.34]
Beavers 2010 (15)
16
16
0.3%
-0.29 [-0.86, 0.29]
Blum 2003 (16)
24
24
0.9%
0.14 [-0.17, 0.44]
Bricarello 2004 (18)
60
60
1.1%
-0.26 [-0.51, -0.01]
Burns-Whitmore 2014 (19)
20
20
1.5%
-0.14 [-0.29, 0.02]
Campbell 2010 (20)
27
35
0.5%
-0.15 [-0.60, 0.30]
Chen 2005 (HC) (21)
9
10
0.3%
-0.07 [-0.67, 0.52]
Chen 2005 (N) (21)
10
8
0.2%
-0.73 [-1.48, 0.03]
Chen 2006 (22)
13
13
0.4%
-0.42 [-0.96, 0.12]
Crouse 1999 (23)
31
115
1.2%
-0.16 [-0.39, 0.07]
Cuevas 2003 (24)
18
18
0.6%
-0.02 [-0.40, 0.36]
Dent 2001 (25)
21
48
0.4%
-0.05 [-0.53, 0.43]
Duane 1999 (26)
8
8
0.2%
-0.26 [-0.96, 0.44]
Dunn 1986 (27)
12
12
0.6%
-0.41 [-0.82, 0.01]
Finley 2007 (N) (28)
20
20
1.3%
-0.17 [-0.37, 0.02]
Finley 2007 (Pre-MS) (28)
20
20
1.3%
-0.22 [-0.43, -0.01]
Gardner 2001 (29)
30
64
1.0%
-0.05 [-0.32, 0.23]
Gardner 2007 (30)
28
28
1.2%
-0.23 [-0.46, -0.01]
Giovanetti 1986 (LF) (31)
12
12
0.4%
-0.13 [-0.64, 0.38]
Giovanetti 1986 (N) (31)
12
12
0.4%
-0.16 [-0.66, 0.35]
Goldberg 1982 (HC) (32)
4
4
1.2%
-0.26 [-0.49, -0.03]
Goldberg 1982 (N) (32)
12
12
0.3%
0.08 [-0.59, 0.74]
Greany 2004 (33)
71
72
0.3%
-0.12 [-0.75, 0.51]
Haub 2005 (34)
10
11
0.5%
-0.38 [-0.81, 0.05]
Hermansen 2001 (35)
20
20
0.8%
-0.32 [-0.63, -0.01]
Hill 2015 (36)
41
21
0.9%
0.31 [0.02, 0.61]
Hoie 2005 (37)
38
78
1.2%
-0.37 [-0.59, -0.15]
Hoie 2005B (38)
38
78
0.8%
-0.30 [-0.64, 0.03]
Hoie 2007 (39)
28
60
1.2%
-0.28 [-0.50, -0.07]
Hosseinpour-Niazi 2014 (40)
31
31
1.6%
-0.18 [-0.32, -0.04]
Huff 1984 (41)
5
5
0.3%
-0.59 [-1.27, 0.08]
Jenkins 1989 (42)
11
11
0.2%
-0.20 [-0.90, 0.50]
Jenkins 2002 (43)
41
41
1.2%
-0.31 [-0.52, -0.10]
Jenkins 2010 (44)
23
23
0.8%
0.02 [-0.31, 0.35]
Kestin 1989 (45)
18
17
1.1%
-0.34 [-0.58, -0.10]
Kjolbaek 2017 (46)
77
36
1.2%
0.04 [-0.17, 0.26]
Kreijkamp-Kaspers 2004 (47)
87
88
1.4%
0.14 [-0.05, 0.33]
Kurowska 1997 (48)
34
34
0.7%
-0.07 [-0.43, 0.30]
Laidlaw 1985 (49)
19
19
0.9%
-0.57 [-0.87, -0.28]
Laurin 1991 (50)
9
9
0.2%
0.04 [-0.66, 0.74]
Li 2016 (51)
17
17
0.7%
-0.25 [-0.60, 0.10]
Liao 2007 (52)
15
15
1.1%
-0.17 [-0.40, 0.07]
Lichenstein 2002 (IF) (53)
42
42
0.9%
-0.08 [-0.37, 0.21]
Lichenstein 2002 (NIF) (53)
42
42
0.9%
-0.15 [-0.45, 0.15]
Liu 2012 (54)
120
60
1.0%
0.17 [-0.08, 0.42]
Liu 2014 (55)
180
90
1.4%
-0.28 [-0.45, -0.10]
Lovati 1987 (56)
12
12
0.3%
-1.84 [-2.41, -1.27]
               -2               -1                0                  1                 2
         Favours plant protein         Favours animal protein
Study or subgroup
Plant 
protein N
Animal 
protein N
Weight
Mean Difference (95% CI) in LDL-C, mmol/L
Study or Subgroup
Abd-Mishani 2014
Abete 2009
Ahmed 2011
Allen 2007
Appt 2008
Ashton 2000
Azadbakht 2003
Azadbakht 2007
Azadbakht 2008
Bahr 2013
Bahr 2014
Bakhit 1994 (Cellulose)
Bakhit 1994 (Cotyledon)
Basaria 2009
Beavers 2010
Blum 2003
Bricarello 2004
Burns-Whitmore 2014
Campbell 2010
Chen 2005 (HC)
Chen 2005 (N)
Chen 2006
Crouse 1999
Cuevas 2003
Dent 2001
Duane 1999
Dunn 1986
Finley 2007 (N)
Finley 2007 (Pre-MS)
Gardner 2001
Gardner 2007
Giovanetti 1986 (LF)
Giovanetti 1986 (N)
Goldberg 1982 (HC)
Goldberg 1982 (N)
Greany 2004
Haub 2005
Hermansen 2001
Hill 2015
Hoie 2005
Hoie 2005B
Hoie 2007
Hosseinpour-Niazi 2014
Huff 1984
Jenkins 1989
Jenkins 2002
Jenkins 2010
Kestin 1989
Kjolbaek 2017
Kreijkamp-Kaspers 2004
Kurowska 1997
Laidlaw 1985
Laurin 1991
Li 2016
Liao 2007
Lichenstein 2002 (IF)
Lichenstein 2002 (NIF)
Liu 2012
Liu 2014
Lovati 1987
Ma 2005
Ma 2011
Maki 2010
Markova 2015
Matthan 2007
McVeigh 2006
Mercer 1987
Meredith 1989
Meyer 2004
Miraghajani 2013
Napora 2011
Onning 1998
Padhi 2015
Pipe 2009
Potter 1993
Puska 2002
Puska 2004
Roughead 2005
Santo 2008
Shidfar 2009
Shige 1998
Sirtori 1977
Sirtori 1999
Sirtori 2002
Steele 1992
Steinberg 2003
Sucher 2016
Tabibi 2010
Takahira 2011
Teede 2001
Teixeira 2004
Thorp 2008
Tonstad 2002
Van Horn 2001 (Oats)
Van Horn 2001 (Wheat)
van Nielen 2014
van Raaij 1981
van Raaij 1982
Vega-Lopez 2010
Vigna 2000
Weisse 2010
West 2005
Wiebe 1984
Wofford 2012
Wolfe 1981
Wolfe 1985
Wong 1998 (HC)
Wong 1998 (N)
Total (95% CI)
Heterogeneity: Tau² = 0.02; Chi² = 233.79, df = 107 (P < 0.00001); I² = 54%
Test for overall effect: Z = 8.64 (P < 0.00001)
Mean Difference
-0.20429
-0.73356
0.074994
-0.05922
-0.24
-0.09
-0.21722
-0.29739
-0.7758
-0.02
-0.025
0.04
-0.2
-0.05172
-0.28756
0.135248
-0.2586
-0.135
-0.14844
-0.07499
-0.72667
-0.42
-0.15687
-0.02069
-0.04967
-0.2586
-0.40514
-0.17326
-0.21981
-0.04531
-0.23274
-0.1293
-0.15516
-0.2586
0.07758
-0.12
-0.38
-0.32
0.313474
-0.37
-0.305
-0.28333
-0.17843
-0.59478
-0.2
-0.31
0.02
-0.34
0.040519
0.14
-0.065
-0.57409
0.04
-0.25
-0.1655
-0.08
-0.15
0.17
-0.275
-1.84284
-0.03164
0.15
-0.18645
0.14
-0.08333
-0.18
-0.05172
-0.33618
-0.05
-0.14171
0.566334
-0.1
0.025
-0.12
-0.43333
-0.27
-0.39
0.210063
0.147279
-0.53194
-0.02
-0.89
-0.3
-0.27951
-0.525
-0.075
0.29
0.01293
-0.15516
-0.14
-0.08
-0.075
-0.26
-0.04
0.04
-0.3
-0.16033
-0.02198
-0.02586
-0.03
-0.16
-0.0025
0
-0.06336
-1.12676
0.263772
-0.25
-0.16
SE
0.11452535
0.26987818
0.426344
0.084345
0.0813546
0.131158
0.09606812
0.079559
0.19276
0.07698878
0.109846
0.111505
0.138633
0.197426
0.292276
0.154629
0.12865
0.081302
0.22893
0.304249
0.386834
0.274633
0.117133
0.193242
0.246534
0.357197
0.211496
0.09888703
0.106026
0.138911
0.114886
0.2586
0.2586
0.116879
0.339151
0.322438
0.22115218
0.156716
0.15163
0.11067581
0.16966043
0.11072121
0.07261498
0.345693
0.355949
0.109683
0.17088
0.120044
0.10974299
0.09449112
0.183995
0.14884671
0.355949
0.177352
0.12157684
0.14597
0.152136
0.130039
0.08952853
0.29165
0.12145
0.15811388
0.10597332
0.16459601
0.106917
0.049949
0.680762
0.219582
0.1
0.152259
0.350227
0.14142136
0.06339256
0.1253
0.160601
0.10969388
0.07653061
0.41584262
0.463726
0.123114
0.222445
0.546361
0.143124
0.225911
0.16034175
0.099549
0.611153
0.16737012
0.229805
0.09899495
0.06
0.069928
0.08673469
0.12628833
0.12728667
0.169312
0.079964
0.0956362
0.047847
0.17214256
0.18182265
0.106516
0.198875
0.03291872
0.240536
0.299954
0.100839
0.064537
Total
24
18
9
98
32
42
14
42
21
33
68
21
21
46
16
24
60
20
27
9
10
13
31
18
21
8
12
20
20
30
28
12
12
4
12
71
10
20
41
38
38
28
31
5
11
41
23
18
77
87
34
19
9
17
15
42
42
120
180
12
78
45
28
18
28
35
33
10
23
25
16
10
71
29
25
28
73
13
9
21
11
20
21
20
32
28
18
18
24
93
14
91
65
32
32
15
25
17
30
37
21
32
8
352
7
5
13
13
3637
Total
24
8
18
93
32
42
14
42
20
33
68
21
21
38
16
24
60
20
35
10
8
13
115
18
48
8
12
20
20
64
28
12
12
4
12
72
11
20
21
78
78
60
31
5
11
41
23
17
36
88
34
19
9
17
15
42
42
60
90
12
81
45
30
19
28
35
33
10
23
25
17
12
142
29
25
24
59
13
21
21
11
20
21
20
32
28
19
18
22
86
14
91
65
32
31
15
20
40
30
40
22
32
8
352
7
5
13
13
3764
Weight
1.2%
0.4%
0.2%
1.5%
1.5%
1.0%
1.4%
1.6%
0.6%
1.6%
1.2%
1.2%
1.0%
0.6%
0.3%
0.9%
1.1%
1.5%
0.5%
0.3%
0.2%
0.4%
1.2%
0.6%
0.4%
0.2%
0.6%
1.3%
1.3%
1.0%
1.2%
0.4%
0.4%
1.2%
0.3%
0.3%
0.5%
0.8%
0.9%
1.2%
0.8%
1.2%
1.6%
0.3%
0.2%
1.2%
0.8%
1.1%
1.2%
1.4%
0.7%
0.9%
0.2%
0.7%
1.1%
0.9%
0.9%
1.0%
1.4%
0.3%
1.1%
0.8%
1.3%
0.8%
1.3%
1.9%
0.1%
0.5%
1.3%
0.9%
0.2%
1.0%
1.7%
1.1%
0.8%
1.2%
1.6%
0.2%
0.1%
1.1%
0.5%
0.1%
0.9%
0.5%
0.8%
1.3%
0.1%
0.8%
0.5%
1.3%
1.8%
1.7%
1.5%
1.1%
1.1%
0.8%
1.5%
1.4%
1.9%
0.8%
0.7%
1.3%
0.6%
2.0%
0.5%
0.3%
1.3%
1.7%
100.0%
IV, Random, 95% CI
-0.20 [-0.43, 0.02]
-0.73 [-1.26, -0.20]
0.07 [-0.76, 0.91]
-0.06 [-0.22, 0.11]
-0.24 [-0.40, -0.08]
-0.09 [-0.35, 0.17]
-0.22 [-0.41, -0.03]
-0.30 [-0.45, -0.14]
-0.78 [-1.15, -0.40]
-0.02 [-0.17, 0.13]
-0.03 [-0.24, 0.19]
0.04 [-0.18, 0.26]
-0.20 [-0.47, 0.07]
-0.05 [-0.44, 0.34]
-0.29 [-0.86, 0.29]
0.14 [-0.17, 0.44]
-0.26 [-0.51, -0.01]
-0.14 [-0.29, 0.02]
-0.15 [-0.60, 0.30]
-0.07 [-0.67, 0.52]
-0.73 [-1.48, 0.03]
-0.42 [-0.96, 0.12]
-0.16 [-0.39, 0.07]
-0.02 [-0.40, 0.36]
-0.05 [-0.53, 0.43]
-0.26 [-0.96, 0.44]
-0.41 [-0.82, 0.01]
-0.17 [-0.37, 0.02]
-0.22 [-0.43, -0.01]
-0.05 [-0.32, 0.23]
-0.23 [-0.46, -0.01]
-0.13 [-0.64, 0.38]
-0.16 [-0.66, 0.35]
-0.26 [-0.49, -0.03]
0.08 [-0.59, 0.74]
-0.12 [-0.75, 0.51]
-0.38 [-0.81, 0.05]
-0.32 [-0.63, -0.01]
0.31 [0.02, 0.61]
-0.37 [-0.59, -0.15]
-0.30 [-0.64, 0.03]
-0.28 [-0.50, -0.07]
-0.18 [-0.32, -0.04]
-0.59 [-1.27, 0.08]
-0.20 [-0.90, 0.50]
-0.31 [-0.52, -0.10]
0.02 [-0.31, 0.35]
-0.34 [-0.58, -0.10]
0.04 [-0.17, 0.26]
0.14 [-0.05, 0.33]
-0.07 [-0.43, 0.30]
-0.57 [-0.87, -0.28]
0.04 [-0.66, 0.74]
-0.25 [-0.60, 0.10]
-0.17 [-0.40, 0.07]
-0.08 [-0.37, 0.21]
-0.15 [-0.45, 0.15]
0.17 [-0.08, 0.42]
-0.28 [-0.45, -0.10]
-1.84 [-2.41, -1.27]
-0.03 [-0.27, 0.21]
0.15 [-0.16, 0.46]
-0.19 [-0.39, 0.02]
0.14 [-0.18, 0.46]
-0.08 [-0.29, 0.13]
-0.18 [-0.28, -0.08]
-0.05 [-1.39, 1.28]
-0.34 [-0.77, 0.09]
-0.05 [-0.25, 0.15]
-0.14 [-0.44, 0.16]
0.57 [-0.12, 1.25]
-0.10 [-0.38, 0.18]
0.03 [-0.10, 0.15]
-0.12 [-0.37, 0.13]
-0.43 [-0.75, -0.12]
-0.27 [-0.48, -0.06]
-0.39 [-0.54, -0.24]
0.21 [-0.60, 1.03]
0.15 [-0.76, 1.06]
-0.53 [-0.77, -0.29]
-0.02 [-0.46, 0.42]
-0.89 [-1.96, 0.18]
-0.30 [-0.58, -0.02]
-0.28 [-0.72, 0.16]
-0.53 [-0.84, -0.21]
-0.07 [-0.27, 0.12]
0.29 [-0.91, 1.49]
0.01 [-0.32, 0.34]
-0.16 [-0.61, 0.30]
-0.14 [-0.33, 0.05]
-0.08 [-0.20, 0.04]
-0.07 [-0.21, 0.06]
-0.26 [-0.43, -0.09]
-0.04 [-0.29, 0.21]
0.04 [-0.21, 0.29]
-0.30 [-0.63, 0.03]
-0.16 [-0.32, -0.00]
-0.02 [-0.21, 0.17]
-0.03 [-0.12, 0.07]
-0.03 [-0.37, 0.31]
-0.16 [-0.52, 0.20]
-0.00 [-0.21, 0.21]
0.00 [-0.39, 0.39]
-0.06 [-0.13, 0.00]
-1.13 [-1.60, -0.66]
0.26 [-0.32, 0.85]
-0.25 [-0.45, -0.05]
-0.16 [-0.29, -0.03]
-0.16 [-0.20, -0.12]
Favours plant protein Animal Protein
Mean Difference
Mean Difference
IV, Random, 95% CI
-2
-1
0
1
2
Favours plant protein
Favours animal protein
Study or Subgroup
Abd-Mishani 2014
Abete 2009
Ahmed 2011
Allen 2007
Appt 2008
Ashton 2000
Azadbakht 2003
Azadbakht 2007
Azadbakht 2008
Bahr 2013
Bahr 2014
Bakhit 1994 (Cellulose)
Bakhit 1994 (Cotyledon)
Basaria 2009
Beavers 2010
Blum 2003
Bricarello 2004
Burns-Whitmore 2014
Campbell 2010
Chen 2005 (HC)
Chen 2005 (N)
Chen 2006
Crouse 1999
Cuevas 2003
Dent 2001
Duane 1999
Dunn 1986
Finley 2007 (N)
Finley 2007 (Pre-MS)
Gardner 2001
Gardner 2007
Giovanetti 1986 (LF)
Giovanetti 1986 (N)
Goldberg 1982 (HC)
Goldberg 1982 (N)
Greany 2004
Haub 2005
Hermansen 2001
Hill 2015
Hoie 2005
Hoie 2005B
Hoie 2007
Hosseinpour-Niazi 2014
Huff 1984
Jenkins 1989
Jenkins 2002
Jenkins 2010
Kestin 1989
Kjolbaek 2017
Kreijkamp-Kaspers 2004
Kurowska 1997
Laidlaw 1985
Laurin 1991
Li 2016
Liao 2007
Lichenstein 2002 (IF)
Lichenstein 2002 (NIF)
Liu 2012
Liu 2014
Lovati 1987
Ma 2005
Ma 2011
Maki 2010
Markova 2015
Matthan 2007
McVeigh 2006
Mercer 1987
Meredith 1989
Meyer 2004
Miraghajani 2013
Napora 2011
Onning 1998
Padhi 2015
Pipe 2009
Potter 1993
Puska 2002
Puska 2004
Roughead 2005
Santo 2008
Shidfar 2009
Shige 1998
Sirtori 1977
Sirtori 1999
Sirtori 2002
Steele 1992
Steinberg 2003
Sucher 2016
Tabibi 2010
Takahira 2011
Teede 2001
Teixeira 2004
Thorp 2008
Tonstad 2002
Van Horn 2001 (Oats)
Van Horn 2001 (Wheat)
van Nielen 2014
van Raaij 1981
van Raaij 1982
Vega-Lopez 2010
Vigna 2000
Weisse 2010
West 2005
Wiebe 1984
Wofford 2012
Wolfe 1981
Wolfe 1985
Wong 1998 (HC)
Wong 1998 (N)
Total (95% CI)
Heterogeneity: Tau² = 0.02; Chi² = 233.79, df = 107 (P < 0.00001); I² = 54%
Test for overall effect: Z = 8.64 (P < 0.00001)
Mean Difference
-0.20429
-0.73356
0.074994
-0.05922
-0.24
-0.09
-0.21722
-0.29739
-0.7758
-0.02
-0.025
0.04
-0.2
-0.05172
-0.28756
0.135248
-0.2586
-0.135
-0.14844
-0.07499
-0.72667
-0.42
-0.15687
-0.02069
-0.04967
-0.2586
-0.40514
-0.17326
-0.21981
-0.04531
-0.23274
-0.1293
-0.15516
-0.2586
0.07758
-0.12
-0.38
-0.32
0.313474
-0.37
-0.305
-0.28333
-0.17843
-0.59478
-0.2
-0.31
0.02
-0.34
0.040519
0.14
-0.065
-0.57409
0.04
-0.25
-0.1655
-0.08
-0.15
0.17
-0.275
-1.84284
-0.03164
0.15
-0.18645
0.14
-0.08333
-0.18
-0.05172
-0.33618
-0.05
-0.14171
0.566334
-0.1
0.025
-0.12
-0.43333
-0.27
-0.39
0.210063
0.147279
-0.53194
-0.02
-0.89
-0.3
-0.27951
-0.525
-0.075
0.29
0.01293
-0.15516
-0.14
-0.08
-0.075
-0.26
-0.04
0.04
-0.3
-0.16033
-0.02198
-0.02586
-0.03
-0.16
-0.0025
0
-0.06336
-1.12676
0.263772
-0.25
-0.16
SE
0.11452535
0.26987818
0.426344
0.084345
0.0813546
0.131158
0.09606812
0.079559
0.19276
0.07698878
0.109846
0.111505
0.138633
0.197426
0.292276
0.154629
0.12865
0.081302
0.22893
0.304249
0.386834
0.274633
0.117133
0.193242
0.246534
0.357197
0.211496
0.09888703
0.106026
0.138911
0.114886
0.2586
0.2586
0.116879
0.339151
0.322438
0.22115218
0.156716
0.15163
0.11067581
0.16966043
0.11072121
0.07261498
0.345693
0.355949
0.109683
0.17088
0.120044
0.10974299
0.09449112
0.183995
0.14884671
0.355949
0.177352
0.12157684
0.14597
0.152136
0.130039
0.08952853
0.29165
0.12145
0.15811388
0.10597332
0.16459601
0.106917
0.049949
0.680762
0.219582
0.1
0.152259
0.350227
0.14142136
0.06339256
0.1253
0.160601
0.10969388
0.07653061
0.41584262
0.463726
0.123114
0.222445
0.546361
0.143124
0.225911
0.16034175
0.099549
0.611153
0.16737012
0.229805
0.09899495
0.06
0.069928
0.08673469
0.12628833
0.12728667
0.169312
0.079964
0.0956362
0.047847
0.17214256
0.18182265
0.106516
0.198875
0.03291872
0.240536
0.299954
0.100839
0.064537
Total
24
18
9
98
32
42
14
42
21
33
68
21
21
46
16
24
60
20
27
9
10
13
31
18
21
8
12
20
20
30
28
12
12
4
12
71
10
20
41
38
38
28
31
5
11
41
23
18
77
87
34
19
9
17
15
42
42
120
180
12
78
45
28
18
28
35
33
10
23
25
16
10
71
29
25
28
73
13
9
21
11
20
21
20
32
28
18
18
24
93
14
91
65
32
32
15
25
17
30
37
21
32
8
352
7
5
13
13
3637
Total
24
8
18
93
32
42
14
42
20
33
68
21
21
38
16
24
60
20
35
10
8
13
115
18
48
8
12
20
20
64
28
12
12
4
12
72
11
20
21
78
78
60
31
5
11
41
23
17
36
88
34
19
9
17
15
42
42
60
90
12
81
45
30
19
28
35
33
10
23
25
17
12
142
29
25
24
59
13
21
21
11
20
21
20
32
28
19
18
22
86
14
91
65
32
31
15
20
40
30
40
22
32
8
352
7
5
13
13
3764
Weight
1.2%
0.4%
0.2%
1.5%
1.5%
1.0%
1.4%
1.6%
0.6%
1.6%
1.2%
1.2%
1.0%
0.6%
0.3%
0.9%
1.1%
1.5%
0.5%
0.3%
0.2%
0.4%
1.2%
0.6%
0.4%
0.2%
0.6%
1.3%
1.3%
1.0%
1.2%
0.4%
0.4%
1.2%
0.3%
0.3%
0.5%
0.8%
0.9%
1.2%
0.8%
1.2%
1.6%
0.3%
0.2%
1.2%
0.8%
1.1%
1.2%
1.4%
0.7%
0.9%
0.2%
0.7%
1.1%
0.9%
0.9%
1.0%
1.4%
0.3%
1.1%
0.8%
1.3%
0.8%
1.3%
1.9%
0.1%
0.5%
1.3%
0.9%
0.2%
1.0%
1.7%
1.1%
0.8%
1.2%
1.6%
0.2%
0.1%
1.1%
0.5%
0.1%
0.9%
0.5%
0.8%
1.3%
0.1%
0.8%
0.5%
1.3%
1.8%
1.7%
1.5%
1.1%
1.1%
0.8%
1.5%
1.4%
1.9%
0.8%
0.7%
1.3%
0.6%
2.0%
0.5%
0.3%
1.3%
1.7%
100.0%
IV, Random, 95% CI
-0.20 [-0.43, 0.02]
-0.73 [-1.26, -0.20]
0.07 [-0.76, 0.91]
-0.06 [-0.22, 0.11]
-0.24 [-0.40, -0.08]
-0.09 [-0.35, 0.17]
-0.22 [-0.41, -0.03]
-0.30 [-0.45, -0.14]
-0.78 [-1.15, -0.40]
-0.02 [-0.17, 0.13]
-0.03 [-0.24, 0.19]
0.04 [-0.18, 0.26]
-0.20 [-0.47, 0.07]
-0.05 [-0.44, 0.34]
-0.29 [-0.86, 0.29]
0.14 [-0.17, 0.44]
-0.26 [-0.51, -0.01]
-0.14 [-0.29, 0.02]
-0.15 [-0.60, 0.30]
-0.07 [-0.67, 0.52]
-0.73 [-1.48, 0.03]
-0.42 [-0.96, 0.12]
-0.16 [-0.39, 0.07]
-0.02 [-0.40, 0.36]
-0.05 [-0.53, 0.43]
-0.26 [-0.96, 0.44]
-0.41 [-0.82, 0.01]
-0.17 [-0.37, 0.02]
-0.22 [-0.43, -0.01]
-0.05 [-0.32, 0.23]
-0.23 [-0.46, -0.01]
-0.13 [-0.64, 0.38]
-0.16 [-0.66, 0.35]
-0.26 [-0.49, -0.03]
0.08 [-0.59, 0.74]
-0.12 [-0.75, 0.51]
-0.38 [-0.81, 0.05]
-0.32 [-0.63, -0.01]
0.31 [0.02, 0.61]
-0.37 [-0.59, -0.15]
-0.30 [-0.64, 0.03]
-0.28 [-0.50, -0.07]
-0.18 [-0.32, -0.04]
-0.59 [-1.27, 0.08]
-0.20 [-0.90, 0.50]
-0.31 [-0.52, -0.10]
0.02 [-0.31, 0.35]
-0.34 [-0.58, -0.10]
0.04 [-0.17, 0.26]
0.14 [-0.05, 0.33]
-0.07 [-0.43, 0.30]
-0.57 [-0.87, -0.28]
0.04 [-0.66, 0.74]
-0.25 [-0.60, 0.10]
-0.17 [-0.40, 0.07]
-0.08 [-0.37, 0.21]
-0.15 [-0.45, 0.15]
0.17 [-0.08, 0.42]
-0.28 [-0.45, -0.10]
-1.84 [-2.41, -1.27]
-0.03 [-0.27, 0.21]
0.15 [-0.16, 0.46]
-0.19 [-0.39, 0.02]
0.14 [-0.18, 0.46]
-0.08 [-0.29, 0.13]
-0.18 [-0.28, -0.08]
-0.05 [-1.39, 1.28]
-0.34 [-0.77, 0.09]
-0.05 [-0.25, 0.15]
-0.14 [-0.44, 0.16]
0.57 [-0.12, 1.25]
-0.10 [-0.38, 0.18]
0.03 [-0.10, 0.15]
-0.12 [-0.37, 0.13]
-0.43 [-0.75, -0.12]
-0.27 [-0.48, -0.06]
-0.39 [-0.54, -0.24]
0.21 [-0.60, 1.03]
0.15 [-0.76, 1.06]
-0.53 [-0.77, -0.29]
-0.02 [-0.46, 0.42]
-0.89 [-1.96, 0.18]
-0.30 [-0.58, -0.02]
-0.28 [-0.72, 0.16]
-0.53 [-0.84, -0.21]
-0.07 [-0.27, 0.12]
0.29 [-0.91, 1.49]
0.01 [-0.32, 0.34]
-0.16 [-0.61, 0.30]
-0.14 [-0.33, 0.05]
-0.08 [-0.20, 0.04]
-0.07 [-0.21, 0.06]
-0.26 [-0.43, -0.09]
-0.04 [-0.29, 0.21]
0.04 [-0.21, 0.29]
-0.30 [-0.63, 0.03]
-0.16 [-0.32, -0.00]
-0.02 [-0.21, 0.17]
-0.03 [-0.12, 0.07]
-0.03 [-0.37, 0.31]
-0.16 [-0.52, 0.20]
-0.00 [-0.21, 0.21]
0.00 [-0.39, 0.39]
-0.06 [-0.13, 0.00]
-1.13 [-1.60, -0.66]
0.26 [-0.32, 0.85]
-0.25 [-0.45, -0.05]
-0.16 [-0.29, -0.03]
-0.16 [-0.20, -0.12]
Favours plant protein Animal Protein
Mean Difference
Mean Difference
IV, Random, 95% CI
-2
-1
0
1
2
Favours plant protein
Favours animal protein
Downloaded from http://ahajournals.org by on June 4, 2019
  
Figure S2 (Continued). LDL-C Forest Plot, random-effects model. HC=hypercholesterolemic; IF=isoflavones; LF=low-
fat; N=normal; NIF=no isoflavones; Pre-MS=pre-metabolic syndrome. The pooled effect estimate (diamond) is shown. 
Paired analyses were applied to all crossover trials. The studies by Duane et al. 1999 (26), Lovati et al. 1987 (56), Sirtori et 
al. 2002 (80), and Van Horn et al. 2001 (91) were missing variance data, which were imputed using the average standard of 
the mean differences across included trials based on the respective trial’s sample size. Data are expressed as MDs with 
95% CIs, using generic inverse-variance random-effects models. Inter-study heterogeneity was tested using the Cochran 
Q statistic (chi-square) at a significance level of P<0.10 and quantified by I2, levels of ≥50% represented substantial 
heterogeneity. 
Mean Difference IV,
 Random, 95% CI  
Ma 2005 (57)
78
81
1.1%
-0.03 [-0.27, 0.21]
Ma 2011 (58)
45
45
0.8%
0.15 [-0.16, 0.46]
Maki 2010 (59)
28
30
1.3%
-0.19 [-0.39, 0.02]
Markova 2015 (60)
18
19
0.8%
0.14 [-0.18, 0.46]
Matthan 2007 (61)
28
28
1.3%
-0.08 [-0.29, 0.13]
McVeigh 2006 (62)
35
35
1.9%
-0.18 [-0.28, -0.08]
Mercer 1987 (63)
33
33
0.1%
-0.05 [-1.39, 1.28]
Meredith 1989 (64)
10
10
0.5%
-0.34 [-0.77, 0.09]
Meyer 2004 (65)
23
23
1.3%
-0.05 [-0.25, 0.15]
Miraghajani 2013 (66)
25
25
0.9%
-0.14 [-0.44, 0.16]
Napora 2011 (67)
16
17
0.2%
0.57 [-0.12, 1.25]
Onning 1998 (68)
10
12
1.0%
-0.10 [-0.38, 0.18]
Padhi 2015 (69)
71
142
1.7%
0.03 [-0.10, 0.15]
Pipe 2009 (70)
29
29
1.1%
-0.12 [-0.37, 0.13]
Potter 1993 (71)
25
25
0.8%
-0.43 [-0.75, -0.12]
Puska 2002 (72)
28
24
1.2%
-0.27 [-0.48, -0.06]
Puska 2004 (73)
73
59
1.6%
-0.39 [-0.54, -0.24]
Roughead 2005 (74)
13
13
0.2%
0.21 [-0.60, 1.03]
Santo 2008 (75)
9
21
0.1%
0.15 [-0.76, 1.06]
Shidfar 2009 (76)
21
21
1.1%
-0.53 [-0.77, -0.29]
Shige 1998 (77)
11
11
0.5%
-0.02 [-0.46, 0.42]
Sirtori 1977 (78)
20
20
0.1%
-0.89 [-1.96, 0.18]
Sirtori 1999 (79)
21
21
0.9%
-0.30 [-0.58, -0.02]
Sirtori 2002 (80)
20
20
0.5%
-0.28 [-0.72, 0.16]
Steele 1992 (81)
32
32
0.8%
-0.53 [-0.84, -0.21]
Steinberg 2003 (82)
28
28
1.3%
-0.07 [-0.27, 0.12]
Sucher 2016 (83)
18
19
0.1%
0.29 [-0.91, 1.49]
Tabibi 2010 (84)
18
18
0.8%
0.01 [-0.32, 0.34]
Takahira 2011 (85)
24
22
0.5%
-0.16 [-0.61, 0.30]
Teede 2001 (86)
93
86
1.3%
-0.14 [-0.33, 0.05]
Teixeira 2004 (88)
14
14
1.8%
-0.08 [-0.20, 0.04]
Thorp 2008 (89)
91
91
1.7%
-0.07 [-0.21, 0.06]
Tonstad 2002 (90)
65
65
1.5%
-0.26 [-0.43, -0.09]
Van Horn 2001 (Oats) (91)
32
32
1.1%
-0.04 [-0.29, 0.21]
Van Horn 2001 (Wheat) (91)
32
31
1.1%
0.04 [-0.21, 0.29]
van Nielen 2014 (92)
15
15
0.8%
-0.30 [-0.63, 0.03]
van Raaij 1981 (93)
25
20
1.5%
-0.16 [-0.32, -0.00]
van Raaij 1982 (93)
17
40
1.4%
-0.02 [-0.21, 0.17]
Vega-Lopez 2010 (95)
30
30
1.9%
-0.03 [-0.12, 0.07]
Vigna 2000 (96)
37
40
0.8%
-0.03 [-0.37, 0.31]
Weisse 2010 (97)
21
22
0.7%
-0.16 [-0.52, 0.20]
West 2005 (98)
32
32
1.3%
-0.00 [-0.21, 0.21]
Wiebe 1984 (100)
8
8
0.6%
0.00 [-0.39, 0.39]
Wofford 2012 (101)
352
352
2.0%
-0.06 [-0.13, 0.00]
Wolfe 1981 (102)
7
7
0.5%
-1.13 [-1.60, -0.66]
Wolfe 1985 (103)
5
5
0%
0.26 [-0.32, 0.85]
Wong 1998 (HC) (104)
13
13
1.3%
-0.25 [-0.45, -0.05]
Wong 1998 (N) (104)
13
13
1.7%
-0.16 [-0.29, -0.03]
Total (95% CI)
3637
3764
100.0%
-0.16 [-0.20, -0.12]
Heterogeneity: Tau² = 0.02; Chi² = 233.79, df = 107 (P < 0.00001); I² = 54%
Test for overall effect: Z = 8.64 (P < 0.00001)
             -2                -1                 0                  1                 2 
          Favours plant protein         Favours animal protein
Study or subgroup
Plant 
protein N
Animal 
protein N
Weight
Mean Difference (95% CI) in LDL-C, mmol/L
Study or Subgroup
Abd-Mishani 2014
Abete 2009
Ahmed 2011
Allen 2007
Appt 2008
Ashton 2000
Azadbakht 2003
Azadbakht 2007
Azadbakht 2008
Bahr 2013
Bahr 2014
Bakhit 1994 (Cellulose)
Bakhit 1994 (Cotyledon)
Basaria 2009
Beavers 2010
Blum 2003
Bricarello 2004
Burns-Whitmore 2014
Campbell 2010
Chen 2005 (HC)
Chen 2005 (N)
Chen 2006
Crouse 1999
Cuevas 2003
Dent 2001
Duane 1999
Dunn 1986
Finley 2007 (N)
Finley 2007 (Pre-MS)
Gardner 2001
Gardner 2007
Giovanetti 1986 (LF)
Giovanetti 1986 (N)
Goldberg 1982 (HC)
Goldberg 1982 (N)
Greany 2004
Haub 2005
Hermansen 2001
Hill 2015
Hoie 2005
Hoie 2005B
Hoie 2007
Hosseinpour-Niazi 2014
Huff 1984
Jenkins 1989
Jenkins 2002
Jenkins 2010
Kestin 1989
Kjolbaek 2017
Kreijkamp-Kaspers 2004
Kurowska 1997
Laidlaw 1985
Laurin 1991
Li 2016
Liao 2007
Lichenstein 2002 (IF)
Lichenstein 2002 (NIF)
Liu 2012
Liu 2014
Lovati 1987
Ma 2005
Ma 2011
Maki 2010
Markova 2015
Matthan 2007
McVeigh 2006
Mercer 1987
Meredith 1989
Meyer 2004
Miraghajani 2013
Napora 2011
Onning 1998
Padhi 2015
Pipe 2009
Potter 1993
Puska 2002
Puska 2004
Roughead 2005
Santo 2008
Shidfar 2009
Shige 1998
Sirtori 1977
Sirtori 1999
Sirtori 2002
Steele 1992
Steinberg 2003
Sucher 2016
Tabibi 2010
Takahira 2011
Teede 2001
Teixeira 2004
Thorp 2008
Tonstad 2002
Van Horn 2001 (Oats)
Van Horn 2001 (Wheat)
van Nielen 2014
van Raaij 1981
van Raaij 1982
Vega-Lopez 2010
Vigna 2000
Weisse 2010
West 2005
Wiebe 1984
Wofford 2012
Wolfe 1981
Wolfe 1985
Wong 1998 (HC)
Wong 1998 (N)
Total (95% CI)
Heterogeneity: Tau² = 0.02; Chi² = 233.79, df = 107 (P < 0.00001); I² = 54%
Test for overall effect: Z = 8.64 (P < 0.00001)
Mean Difference
-0.20429
-0.73356
0.074994
-0.05922
-0.24
-0.09
-0.21722
-0.29739
-0.7758
-0.02
-0.025
0.04
-0.2
-0.05172
-0.28756
0.135248
-0.2586
-0.135
-0.14844
-0.07499
-0.72667
-0.42
-0.15687
-0.02069
-0.04967
-0.2586
-0.40514
-0.17326
-0.21981
-0.04531
-0.23274
-0.1293
-0.15516
-0.2586
0.07758
-0.12
-0.38
-0.32
0.313474
-0.37
-0.305
-0.28333
-0.17843
-0.59478
-0.2
-0.31
0.02
-0.34
0.040519
0.14
-0.065
-0.57409
0.04
-0.25
-0.1655
-0.08
-0.15
0.17
-0.275
-1.84284
-0.03164
0.15
-0.18645
0.14
-0.08333
-0.18
-0.05172
-0.33618
-0.05
-0.14171
0.566334
-0.1
0.025
-0.12
-0.43333
-0.27
-0.39
0.210063
0.147279
-0.53194
-0.02
-0.89
-0.3
-0.27951
-0.525
-0.075
0.29
0.01293
-0.15516
-0.14
-0.08
-0.075
-0.26
-0.04
0.04
-0.3
-0.16033
-0.02198
-0.02586
-0.03
-0.16
-0.0025
0
-0.06336
-1.12676
0.263772
-0.25
-0.16
SE
0.11452535
0.26987818
0.426344
0.084345
0.0813546
0.131158
0.09606812
0.079559
0.19276
0.07698878
0.109846
0.111505
0.138633
0.197426
0.292276
0.154629
0.12865
0.081302
0.22893
0.304249
0.386834
0.274633
0.117133
0.193242
0.246534
0.357197
0.211496
0.09888703
0.106026
0.138911
0.114886
0.2586
0.2586
0.116879
0.339151
0.322438
0.22115218
0.156716
0.15163
0.11067581
0.16966043
0.11072121
0.07261498
0.345693
0.355949
0.109683
0.17088
0.120044
0.10974299
0.09449112
0.183995
0.14884671
0.355949
0.177352
0.12157684
0.14597
0.152136
0.130039
0.08952853
0.29165
0.12145
0.15811388
0.10597332
0.16459601
0.106917
0.049949
0.680762
0.219582
0.1
0.152259
0.350227
0.14142136
0.06339256
0.1253
0.160601
0.10969388
0.07653061
0.41584262
0.463726
0.123114
0.222445
0.546361
0.143124
0.225911
0.16034175
0.099549
0.611153
0.16737012
0.229805
0.09899495
0.06
0.069928
0.08673469
0.12628833
0.12728667
0.169312
0.079964
0.0956362
0.047847
0.17214256
0.18182265
0.106516
0.198875
0.03291872
0.240536
0.299954
0.100839
0.064537
Total
24
18
9
98
32
42
14
42
21
33
68
21
21
46
16
24
60
20
27
9
10
13
31
18
21
8
12
20
20
30
28
12
12
4
12
71
10
20
41
38
38
28
31
5
11
41
23
18
77
87
34
19
9
17
15
42
42
120
180
12
78
45
28
18
28
35
33
10
23
25
16
10
71
29
25
28
73
13
9
21
11
20
21
20
32
28
18
18
24
93
14
91
65
32
32
15
25
17
30
37
21
32
8
352
7
5
13
13
3637
Total
24
8
18
93
32
42
14
42
20
33
68
21
21
38
16
24
60
20
35
10
8
13
115
18
48
8
12
20
20
64
28
12
12
4
12
72
11
20
21
78
78
60
31
5
11
41
23
17
36
88
34
19
9
17
15
42
42
60
90
12
81
45
30
19
28
35
33
10
23
25
17
12
142
29
25
24
59
13
21
21
11
20
21
20
32
28
19
18
22
86
14
91
65
32
31
15
20
40
30
40
22
32
8
352
7
5
13
13
3764
Weight
1.2%
0.4%
0.2%
1.5%
1.5%
1.0%
1.4%
1.6%
0.6%
1.6%
1.2%
1.2%
1.0%
0.6%
0.3%
0.9%
1.1%
1.5%
0.5%
0.3%
0.2%
0.4%
1.2%
0.6%
0.4%
0.2%
0.6%
1.3%
1.3%
1.0%
1.2%
0.4%
0.4%
1.2%
0.3%
0.3%
0.5%
0.8%
0.9%
1.2%
0.8%
1.2%
1.6%
0.3%
0.2%
1.2%
0.8%
1.1%
1.2%
1.4%
0.7%
0.9%
0.2%
0.7%
1.1%
0.9%
0.9%
1.0%
1.4%
0.3%
1.1%
0.8%
1.3%
0.8%
1.3%
1.9%
0.1%
0.5%
1.3%
0.9%
0.2%
1.0%
1.7%
1.1%
0.8%
1.2%
1.6%
0.2%
0.1%
1.1%
0.5%
0.1%
0.9%
0.5%
0.8%
1.3%
0.1%
0.8%
0.5%
1.3%
1.8%
1.7%
1.5%
1.1%
1.1%
0.8%
1.5%
1.4%
1.9%
0.8%
0.7%
1.3%
0.6%
2.0%
0.5%
0.3%
1.3%
1.7%
100.0%
IV, Random, 95% CI
-0.20 [-0.43, 0.02]
-0.73 [-1.26, -0.20]
0.07 [-0.76, 0.91]
-0.06 [-0.22, 0.11]
-0.24 [-0.40, -0.08]
-0.09 [-0.35, 0.17]
-0.22 [-0.41, -0.03]
-0.30 [-0.45, -0.14]
-0.78 [-1.15, -0.40]
-0.02 [-0.17, 0.13]
-0.03 [-0.24, 0.19]
0.04 [-0.18, 0.26]
-0.20 [-0.47, 0.07]
-0.05 [-0.44, 0.34]
-0.29 [-0.86, 0.29]
0.14 [-0.17, 0.44]
-0.26 [-0.51, -0.01]
-0.14 [-0.29, 0.02]
-0.15 [-0.60, 0.30]
-0.07 [-0.67, 0.52]
-0.73 [-1.48, 0.03]
-0.42 [-0.96, 0.12]
-0.16 [-0.39, 0.07]
-0.02 [-0.40, 0.36]
-0.05 [-0.53, 0.43]
-0.26 [-0.96, 0.44]
-0.41 [-0.82, 0.01]
-0.17 [-0.37, 0.02]
-0.22 [-0.43, -0.01]
-0.05 [-0.32, 0.23]
-0.23 [-0.46, -0.01]
-0.13 [-0.64, 0.38]
-0.16 [-0.66, 0.35]
-0.26 [-0.49, -0.03]
0.08 [-0.59, 0.74]
-0.12 [-0.75, 0.51]
-0.38 [-0.81, 0.05]
-0.32 [-0.63, -0.01]
0.31 [0.02, 0.61]
-0.37 [-0.59, -0.15]
-0.30 [-0.64, 0.03]
-0.28 [-0.50, -0.07]
-0.18 [-0.32, -0.04]
-0.59 [-1.27, 0.08]
-0.20 [-0.90, 0.50]
-0.31 [-0.52, -0.10]
0.02 [-0.31, 0.35]
-0.34 [-0.58, -0.10]
0.04 [-0.17, 0.26]
0.14 [-0.05, 0.33]
-0.07 [-0.43, 0.30]
-0.57 [-0.87, -0.28]
0.04 [-0.66, 0.74]
-0.25 [-0.60, 0.10]
-0.17 [-0.40, 0.07]
-0.08 [-0.37, 0.21]
-0.15 [-0.45, 0.15]
0.17 [-0.08, 0.42]
-0.28 [-0.45, -0.10]
-1.84 [-2.41, -1.27]
-0.03 [-0.27, 0.21]
0.15 [-0.16, 0.46]
-0.19 [-0.39, 0.02]
0.14 [-0.18, 0.46]
-0.08 [-0.29, 0.13]
-0.18 [-0.28, -0.08]
-0.05 [-1.39, 1.28]
-0.34 [-0.77, 0.09]
-0.05 [-0.25, 0.15]
-0.14 [-0.44, 0.16]
0.57 [-0.12, 1.25]
-0.10 [-0.38, 0.18]
0.03 [-0.10, 0.15]
-0.12 [-0.37, 0.13]
-0.43 [-0.75, -0.12]
-0.27 [-0.48, -0.06]
-0.39 [-0.54, -0.24]
0.21 [-0.60, 1.03]
0.15 [-0.76, 1.06]
-0.53 [-0.77, -0.29]
-0.02 [-0.46, 0.42]
-0.89 [-1.96, 0.18]
-0.30 [-0.58, -0.02]
-0.28 [-0.72, 0.16]
-0.53 [-0.84, -0.21]
-0.07 [-0.27, 0.12]
0.29 [-0.91, 1.49]
0.01 [-0.32, 0.34]
-0.16 [-0.61, 0.30]
-0.14 [-0.33, 0.05]
-0.08 [-0.20, 0.04]
-0.07 [-0.21, 0.06]
-0.26 [-0.43, -0.09]
-0.04 [-0.29, 0.21]
0.04 [-0.21, 0.29]
-0.30 [-0.63, 0.03]
-0.16 [-0.32, -0.00]
-0.02 [-0.21, 0.17]
-0.03 [-0.12, 0.07]
-0.03 [-0.37, 0.31]
-0.16 [-0.52, 0.20]
-0.00 [-0.21, 0.21]
0.00 [-0.39, 0.39]
-0.06 [-0.13, 0.00]
-1.13 [-1.60, -0.66]
0.26 [-0.32, 0.85]
-0.25 [-0.45, -0.05]
-0.16 [-0.29, -0.03]
-0.16 [-0.20, -0.12]
Favours plant protein Animal Protein
Mean Difference
Mean Difference
IV, Random, 95% CI
-2
-1
0
1
2
Favours plant protein
Favours animal protein
Downloaded from http://ahajournals.org by on June 4, 2019
  
 
Figure S3. LDL-C Forest Plot, fixed-effects model. 
Mean Difference IV,
Fixed, 95% CI  
Abd-Mishani 2014 (1)
24
24
0.9%
-0.20 [-0.43, 0.02]
Abete 2009 (2)
18
8
0.2%
-0.73 [-1.26, -0.20]
Ahmed 2011 (3)
9
18
0.1%
0.07 [-0.76, 0.91]
Allen 2007 (4)
98
93
1.7%
-0.06 [-0.22, 0.11]
Appt 2008 (5)
32
32
1.8%
-0.24 [-0.40, -0.08]
Ashton 2000 (6)
42
42
0.7%
-0.09 [-0.35, 0.17]
Azadbakht 2003 (7)
14
14
1.3%
-0.22 [-0.41, -0.03]
Azadbakht 2007 (8)
42
42
1.9%
-0.30 [-0.45, -0.14]
Azadbakht 2008 (9)
21
20
0.3%
-0.78 [-1.15, -0.40]
Bahr 2013 (10)
33
33
2.0%
-0.02 [-0.17, 0.13]
Bahr 2014 (11)
68
68
1.0%
-0.03 [-0.24, 0.19]
Bakhit 1994 (Cellulose) (12)
21
21
1.0%
0.04 [-0.18, 0.26]
Bakhit 1994 (Cotyledon) (12)
21
21
0.6%
-0.20 [-0.47, 0.07]
Basaria 2009 (13)
46
38
0.3%
-0.05 [-0.44, 0.34]
Beavers 2010 (15)
16
16
0.1%
-0.29 [-0.86, 0.29]
Blum 2003 (16)
24
24
0.5%
0.14 [-0.17, 0.44]
Bricarello 2004 (18)
60
60
0.7%
-0.26 [-0.51, -0.01]
Burns-Whitmore 2014 (19)
20
20
1.8%
-0.14 [-0.29, 0.02]
Campbell 2010 (20)
27
35
0.2%
-0.15 [-0.60, 0.30]
Chen 2005 (HC) (21)
9
10
0.1%
-0.07 [-0.67, 0.52]
Chen 2005 (N) (21)
10
8
0.1%
-0.73 [-1.48, 0.03]
Chen 2006 (22)
13
13
0.2%
-0.42 [-0.96, 0.12]
Crouse 1999 (23)
31
115
0.9%
-0.16 [-0.39, 0.07]
Cuevas 2003 (24)
18
18
0.3%
-0.02 [-0.40, 0.36]
Dent 2001 (25)
21
48
0.2%
-0.05 [-0.53, 0.43]
Duane 1999 (26)
8
8
0.1%
-0.26 [-0.96, 0.44]
Dunn 1986 (27)
12
12
0.3%
-0.41 [-0.82, 0.01]
Finley 2007 (N) (28)
20
20
1.2%
-0.17 [-0.37, 0.02]
Finley 2007 (Pre-MS) (28)
20
20
1.1%
-0.22 [-0.43, -0.01]
Gardner 2001 (29)
30
64
0.6%
-0.05 [-0.32, 0.23]
Gardner 2007 (30)
28
28
0.9%
-0.23 [-0.46, -0.01]
Giovanetti 1986 (LF) (31)
12
12
0.2%
-0.13 [-0.64, 0.38]
Giovanetti 1986 (N) (31)
12
12
0.2%
-0.16 [-0.66, 0.35]
Goldberg 1982 (HC) (32)
4
4
0.9%
-0.26 [-0.49, -0.03]
Goldberg 1982 (N) (32)
12
12
0.1%
0.08 [-0.59, 0.74]
Greany 2004 (33)
71
72
0.1%
-0.12 [-0.75, 0.51]
Haub 2005 (34)
10
11
0.2%
-0.38 [-0.81, 0.05]
Hermansen 2001 (35)
20
20
0.5%
-0.32 [-0.63, -0.01]
Hill 2015 (36)
41
21
0.5%
0.31 [0.02, 0.61]
Hoie 2005 (37)
38
78
1.0%
-0.37 [-0.59, -0.15]
Hoie 2005B (38)
38
78
0.4%
-0.30 [-0.64, 0.03]
Hoie 2007 (39)
28
60
1.0%
-0.28 [-0.50, -0.07]
Hosseinpour-Niazi 2014 (40)
31
31
2.3%
-0.18 [-0.32, -0.04]
Huff 1984 (41)
5
5
0.1%
-0.59 [-1.27, 0.08]
Jenkins 1989 (42)
11
11
0.1%
-0.20 [-0.90, 0.50]
Jenkins 2002 (43)
41
41
1.0%
-0.31 [-0.52, -0.10]
Jenkins 2010 (44)
23
23
0.4%
0.02 [-0.31, 0.35]
Kestin 1989 (45)
18
17
0.8%
-0.34 [-0.58, -0.10]
Kjolbaek 2017 (46)
77
36
1.0%
0.04 [-0.17, 0.26]
Kreijkamp-Kaspers 2004 (47)
87
88
1.3%
0.14 [-0.05, 0.33]
Kurowska 1997 (48)
34
34
0.4%
-0.07 [-0.43, 0.30]
Laidlaw 1985 (49)
19
19
0.5%
-0.57 [-0.87, -0.28]
Laurin 1991 (50)
9
9
0.1%
0.04 [-0.66, 0.74]
Li 2016 (51)
17
17
0.4%
-0.25 [-0.60, 0.10]
Liao 2007 (52)
15
15
0.8%
-0.17 [-0.40, 0.07]
Lichenstein 2002 (IF) (53)
42
42
0.6%
-0.08 [-0.37, 0.21]
Lichenstein 2002 (NIF) (53)
42
42
0.5%
-0.15 [-0.45, 0.15]
Liu 2012 (54)
120
60
0.7%
0.17 [-0.08, 0.42]
Liu 2014 (55)
180
90
1.5%
-0.28 [-0.45, -0.10]
Lovati 1987 (56)
12
12
0.1%
-1.84 [-2.41, -1.27]
               -2               -1                 0                 1                 2
         Favours plant protein         Favours animal protein
Study or subgroup
Plant 
protein N
Animal 
protein N
Weight
Mean Difference (95% CI) in LDL-C, mmol/L
Study or Subgroup
Abd-Mishani 2014
Abete 2009
Ahmed 2011
Allen 2007
Appt 2008
Ashton 2000
Azadbakht 2003
Azadbakht 2007
Azadbakht 2008
Bahr 2013
Bahr 2014
Bakhit 1994 (Cellulose)
Bakhit 1994 (Cotyledon)
Basaria 2009
Beavers 2010
Blum 2003
Bricarello 2004
Burns-Whitmore 2014
Campbell 2010
Chen 2005 (HC)
Chen 2005 (N)
Chen 2006
Crouse 1999
Cuevas 2003
Dent 2001
Duane 1999
Dunn 1986
Finley 2007 (N)
Finley 2007 (Pre-MS)
Gardner 2001
Gardner 2007
Giovanetti 1986 (LF)
Giovanetti 1986 (N)
Goldberg 1982 (HC)
Goldberg 1982 (N)
Greany 2004
Haub 2005
Hermansen 2001
Hill 2015
Hoie 2005
Hoie 2005B
Hoie 2007
Hosseinpour-Niazi 2014
Huff 1984
Jenkins 1989
Jenkins 2002
Jenkins 2010
Kestin 1989
Kjolbaek 2017
Kreijkamp-Kaspers 2004
Kurowska 1997
Laidlaw 1985
Laurin 1991
Li 2016
Liao 2007
Lichenstein 2002 (IF)
Lichenstein 2002 (NIF)
Liu 2012
Liu 2014
Lovati 1987
Ma 2005
Ma 2011
Maki 2010
Markova 2015
Matthan 2007
McVeigh 2006
Mercer 1987
Meredith 1989
Meyer 2004
Miraghajani 2013
Napora 2011
Onning 1998
Padhi 2015
Pipe 2009
Potter 1993
Puska 2002
Puska 2004
Roughead 2005
Santo 2008
Shidfar 2009
Shige 1998
Sirtori 1977
Sirtori 1999
Sirtori 2002
Steele 1992
Steinberg 2003
Sucher 2016
Tabibi 2010
Takahira 2011
Teede 2001
Teixeira 2004
Thorp 2008
Tonstad 2002
Van Horn 2001 (Oats)
Van Horn 2001 (Wheat)
van Nielen 2014
van Raaij 1981
van Raaij 1982
Vega-Lopez 2010
Vigna 2000
Weisse 2010
West 2005
Wiebe 1984
Wofford 2012
Wolfe 1981
Wolfe 1985
Wong 1998 (HC)
Wong 1998 (N)
Total (95% CI)
Heterogeneity: Tau² = 0.02; Chi² = 233.79, df = 107 (P < 0.00001); I² = 54%
Test for overall effect: Z = 8.64 (P < 0.00001)
Mean Difference
-0.20429
-0.73356
0.074994
-0.05922
-0.24
-0.09
-0.21722
-0.29739
-0.7758
-0.02
-0.025
0.04
-0.2
-0.05172
-0.28756
0.135248
-0.2586
-0.135
-0.14844
-0.07499
-0.72667
-0.42
-0.15687
-0.02069
-0.04967
-0.2586
-0.40514
-0.17326
-0.21981
-0.04531
-0.23274
-0.1293
-0.15516
-0.2586
0.07758
-0.12
-0.38
-0.32
0.313474
-0.37
-0.305
-0.28333
-0.17843
-0.59478
-0.2
-0.31
0.02
-0.34
0.040519
0.14
-0.065
-0.57409
0.04
-0.25
-0.1655
-0.08
-0.15
0.17
-0.275
-1.84284
-0.03164
0.15
-0.18645
0.14
-0.08333
-0.18
-0.05172
-0.33618
-0.05
-0.14171
0.566334
-0.1
0.025
-0.12
-0.43333
-0.27
-0.39
0.210063
0.147279
-0.53194
-0.02
-0.89
-0.3
-0.27951
-0.525
-0.075
0.29
0.01293
-0.15516
-0.14
-0.08
-0.075
-0.26
-0.04
0.04
-0.3
-0.16033
-0.02198
-0.02586
-0.03
-0.16
-0.0025
0
-0.06336
-1.12676
0.263772
-0.25
-0.16
SE
0.11452535
0.26987818
0.426344
0.084345
0.0813546
0.131158
0.09606812
0.079559
0.19276
0.07698878
0.109846
0.111505
0.138633
0.197426
0.292276
0.154629
0.12865
0.081302
0.22893
0.304249
0.386834
0.274633
0.117133
0.193242
0.246534
0.357197
0.211496
0.09888703
0.106026
0.138911
0.114886
0.2586
0.2586
0.116879
0.339151
0.322438
0.22115218
0.156716
0.15163
0.11067581
0.16966043
0.11072121
0.07261498
0.345693
0.355949
0.109683
0.17088
0.120044
0.10974299
0.09449112
0.183995
0.14884671
0.355949
0.177352
0.12157684
0.14597
0.152136
0.130039
0.08952853
0.29165
0.12145
0.15811388
0.10597332
0.16459601
0.106917
0.049949
0.680762
0.219582
0.1
0.152259
0.350227
0.14142136
0.06339256
0.1253
0.160601
0.10969388
0.07653061
0.41584262
0.463726
0.123114
0.222445
0.546361
0.143124
0.225911
0.16034175
0.099549
0.611153
0.16737012
0.229805
0.09899495
0.06
0.069928
0.08673469
0.12628833
0.12728667
0.169312
0.079964
0.0956362
0.047847
0.17214256
0.18182265
0.106516
0.198875
0.03291872
0.240536
0.299954
0.100839
0.064537
Total
24
18
9
98
32
42
14
42
21
33
68
21
21
46
16
24
60
20
27
9
10
13
31
18
21
8
12
20
20
30
28
12
12
4
12
71
10
20
41
38
38
28
31
5
11
41
23
18
77
87
34
19
9
17
15
42
42
120
180
12
78
45
28
18
28
35
33
10
23
25
16
10
71
29
25
28
73
13
9
21
11
20
21
20
32
28
18
18
24
93
14
91
65
32
32
15
25
17
30
37
21
32
8
352
7
5
13
13
3637
Total
24
8
18
93
32
42
14
42
20
33
68
21
21
38
16
24
60
20
35
10
8
13
115
18
48
8
12
20
20
64
28
12
12
4
12
72
11
20
21
78
78
60
31
5
11
41
23
17
36
88
34
19
9
17
15
42
42
60
90
12
81
45
30
19
28
35
33
10
23
25
17
12
142
29
25
24
59
13
21
21
11
20
21
20
32
28
19
18
22
86
14
91
65
32
31
15
20
40
30
40
22
32
8
352
7
5
13
13
3764
Weight
1.2%
0.4%
0.2%
1.5%
1.5%
1.0%
1.4%
1.6%
0.6%
1.6%
1.2%
1.2%
1.0%
0.6%
0.3%
0.9%
1.1%
1.5%
0.5%
0.3%
0.2%
0.4%
1.2%
0.6%
0.4%
0.2%
0.6%
1.3%
1.3%
1.0%
1.2%
0.4%
0.4%
1.2%
0.3%
0.3%
0.5%
0.8%
0.9%
1.2%
0.8%
1.2%
1.6%
0.3%
0.2%
1.2%
0.8%
1.1%
1.2%
1.4%
0.7%
0.9%
0.2%
0.7%
1.1%
0.9%
0.9%
1.0%
1.4%
0.3%
1.1%
0.8%
1.3%
0.8%
1.3%
1.9%
0.1%
0.5%
1.3%
0.9%
0.2%
1.0%
1.7%
1.1%
0.8%
1.2%
1.6%
0.2%
0.1%
1.1%
0.5%
0.1%
0.9%
0.5%
0.8%
1.3%
0.1%
0.8%
0.5%
1.3%
1.8%
1.7%
1.5%
1.1%
1.1%
0.8%
1.5%
1.4%
1.9%
0.8%
0.7%
1.3%
0.6%
2.0%
0.5%
0.3%
1.3%
1.7%
100.0%
IV, Random, 95% CI
-0.20 [-0.43, 0.02]
-0.73 [-1.26, -0.20]
0.07 [-0.76, 0.91]
-0.06 [-0.22, 0.11]
-0.24 [-0.40, -0.08]
-0.09 [-0.35, 0.17]
-0.22 [-0.41, -0.03]
-0.30 [-0.45, -0.14]
-0.78 [-1.15, -0.40]
-0.02 [-0.17, 0.13]
-0.03 [-0.24, 0.19]
0.04 [-0.18, 0.26]
-0.20 [-0.47, 0.07]
-0.05 [-0.44, 0.34]
-0.29 [-0.86, 0.29]
0.14 [-0.17, 0.44]
-0.26 [-0.51, -0.01]
-0.14 [-0.29, 0.02]
-0.15 [-0.60, 0.30]
-0.07 [-0.67, 0.52]
-0.73 [-1.48, 0.03]
-0.42 [-0.96, 0.12]
-0.16 [-0.39, 0.07]
-0.02 [-0.40, 0.36]
-0.05 [-0.53, 0.43]
-0.26 [-0.96, 0.44]
-0.41 [-0.82, 0.01]
-0.17 [-0.37, 0.02]
-0.22 [-0.43, -0.01]
-0.05 [-0.32, 0.23]
-0.23 [-0.46, -0.01]
-0.13 [-0.64, 0.38]
-0.16 [-0.66, 0.35]
-0.26 [-0.49, -0.03]
0.08 [-0.59, 0.74]
-0.12 [-0.75, 0.51]
-0.38 [-0.81, 0.05]
-0.32 [-0.63, -0.01]
0.31 [0.02, 0.61]
-0.37 [-0.59, -0.15]
-0.30 [-0.64, 0.03]
-0.28 [-0.50, -0.07]
-0.18 [-0.32, -0.04]
-0.59 [-1.27, 0.08]
-0.20 [-0.90, 0.50]
-0.31 [-0.52, -0.10]
0.02 [-0.31, 0.35]
-0.34 [-0.58, -0.10]
0.04 [-0.17, 0.26]
0.14 [-0.05, 0.33]
-0.07 [-0.43, 0.30]
-0.57 [-0.87, -0.28]
0.04 [-0.66, 0.74]
-0.25 [-0.60, 0.10]
-0.17 [-0.40, 0.07]
-0.08 [-0.37, 0.21]
-0.15 [-0.45, 0.15]
0.17 [-0.08, 0.42]
-0.28 [-0.45, -0.10]
-1.84 [-2.41, -1.27]
-0.03 [-0.27, 0.21]
0.15 [-0.16, 0.46]
-0.19 [-0.39, 0.02]
0.14 [-0.18, 0.46]
-0.08 [-0.29, 0.13]
-0.18 [-0.28, -0.08]
-0.05 [-1.39, 1.28]
-0.34 [-0.77, 0.09]
-0.05 [-0.25, 0.15]
-0.14 [-0.44, 0.16]
0.57 [-0.12, 1.25]
-0.10 [-0.38, 0.18]
0.03 [-0.10, 0.15]
-0.12 [-0.37, 0.13]
-0.43 [-0.75, -0.12]
-0.27 [-0.48, -0.06]
-0.39 [-0.54, -0.24]
0.21 [-0.60, 1.03]
0.15 [-0.76, 1.06]
-0.53 [-0.77, -0.29]
-0.02 [-0.46, 0.42]
-0.89 [-1.96, 0.18]
-0.30 [-0.58, -0.02]
-0.28 [-0.72, 0.16]
-0.53 [-0.84, -0.21]
-0.07 [-0.27, 0.12]
0.29 [-0.91, 1.49]
0.01 [-0.32, 0.34]
-0.16 [-0.61, 0.30]
-0.14 [-0.33, 0.05]
-0.08 [-0.20, 0.04]
-0.07 [-0.21, 0.06]
-0.26 [-0.43, -0.09]
-0.04 [-0.29, 0.21]
0.04 [-0.21, 0.29]
-0.30 [-0.63, 0.03]
-0.16 [-0.32, -0.00]
-0.02 [-0.21, 0.17]
-0.03 [-0.12, 0.07]
-0.03 [-0.37, 0.31]
-0.16 [-0.52, 0.20]
-0.00 [-0.21, 0.21]
0.00 [-0.39, 0.39]
-0.06 [-0.13, 0.00]
-1.13 [-1.60, -0.66]
0.26 [-0.32, 0.85]
-0.25 [-0.45, -0.05]
-0.16 [-0.29, -0.03]
-0.16 [-0.20, -0.12]
Favours plant protein Animal Protein
Mean Difference
Mean Difference
IV, Random, 95% CI
-2
-1
0
1
2
Favours plant protein
Favours animal protein
Study or Subgroup
Abd-Mishani 2014
Abete 2009
Ahmed 2011
Allen 2007
Appt 2008
Ashton 2000
Azadbakht 2003
Azadbakht 2007
Azadbakht 2008
Bahr 2013
Bahr 2014
Bakhit 1994 (Cellulose)
Bakhit 1994 (Cotyledon)
Basaria 2009
Beavers 2010
Blum 2003
Bricarello 2004
Burns-Whitmore 2014
Campbell 2010
Chen 2005 (HC)
Chen 2005 (N)
Chen 2006
Crouse 1999
Cuevas 2003
Dent 2001
Duane 1999
Dunn 1986
Finley 2007 (N)
Finley 2007 (Pre-MS)
Gardner 2001
Gardner 2007
Giovanetti 1986 (LF)
Giovanetti 1986 (N)
Goldberg 1982 (HC)
Goldberg 1982 (N)
Greany 2004
Haub 2005
Hermansen 2001
Hill 2015
Hoie 2005
Hoie 2005B
Hoie 2007
Hosseinpour-Niazi 2014
Huff 1984
Jenkins 1989
Jenkins 2002
Jenkins 2010
Kestin 1989
Kjolbaek 2017
Kreijkamp-Kaspers 2004
Kurowska 1997
Laidlaw 1985
Laurin 1991
Li 2016
Liao 2007
Lichenstein 2002 (IF)
Lichenstein 2002 (NIF)
Liu 2012
Liu 2014
Lovati 1987
Ma 2005
Ma 2011
Maki 2010
Markova 2015
Matthan 2007
McVeigh 2006
Mercer 1987
Meredith 1989
Meyer 2004
Miraghajani 2013
Napora 2011
Onning 1998
Padhi 2015
Pipe 2009
Potter 1993
Puska 2002
Puska 2004
Roughead 2005
Santo 2008
Shidfar 2009
Shige 1998
Sirtori 1977
Sirtori 1999
Sirtori 2002
Steele 1992
Steinberg 2003
Sucher 2016
Tabibi 2010
Takahira 2011
Teede 2001
Teixeira 2004
Thorp 2008
Tonstad 2002
Van Horn 2001 (Oats)
Van Horn 2001 (Wheat)
van Nielen 2014
van Raaij 1981
van Raaij 1982
Vega-Lopez 2010
Vigna 2000
Weisse 2010
West 2005
Wiebe 1984
Wofford 2012
Wolfe 1981
Wolfe 1985
Wong 1998 (HC)
Wong 1998 (N)
Total (95% CI)
Heterogeneity: Chi² = 233.79, df = 107 (P < 0.00001); I² = 54%
Test for overall effect: Z = 12.63 (P < 0.00001)
Mean Difference
-0.20429
-0.73356
0.074994
-0.05922
-0.24
-0.09
-0.21722
-0.29739
-0.7758
-0.02
-0.025
0.04
-0.2
-0.05172
-0.28756
0.135248
-0.2586
-0.135
-0.14844
-0.07499
-0.72667
-0.42
-0.15687
-0.02069
-0.04967
-0.2586
-0.40514
-0.17326
-0.21981
-0.04531
-0.23274
-0.1293
-0.15516
-0.2586
0.07758
-0.12
-0.38
-0.32
0.313474
-0.37
-0.305
-0.28333
-0.17843
-0.59478
-0.2
-0.31
0.02
-0.34
0.040519
0.14
-0.065
-0.57409
0.04
-0.25
-0.1655
-0.08
-0.15
0.17
-0.275
-1.84284
-0.03164
0.15
-0.18645
0.14
-0.08333
-0.18
-0.05172
-0.33618
-0.05
-0.14171
0.566334
-0.1
0.025
-0.12
-0.43333
-0.27
-0.39
0.210063
0.147279
-0.53194
-0.02
-0.89
-0.3
-0.27951
-0.525
-0.075
0.29
0.01293
-0.15516
-0.14
-0.08
-0.075
-0.26
-0.04
0.04
-0.3
-0.16033
-0.02198
-0.02586
-0.03
-0.16
-0.0025
0
-0.06336
-1.12676
0.263772
-0.25
-0.16
SE
0.11452535
0.26987818
0.426344
0.084345
0.0813546
0.131158
0.09606812
0.079559
0.19276
0.07698878
0.109846
0.111505
0.138633
0.197426
0.292276
0.154629
0.12865
0.081302
0.22893
0.304249
0.386834
0.274633
0.117133
0.193242
0.246534
0.357197
0.211496
0.09888703
0.106026
0.138911
0.114886
0.2586
0.2586
0.116879
0.339151
0.322438
0.22115218
0.156716
0.15163
0.11067581
0.16966043
0.11072121
0.07261498
0.345693
0.355949
0.109683
0.17088
0.120044
0.10974299
0.09449112
0.183995
0.14884671
0.355949
0.177352
0.12157684
0.14597
0.152136
0.130039
0.08952853
0.29165
0.12145
0.15811388
0.10597332
0.16459601
0.106917
0.049949
0.680762
0.219582
0.1
0.152259
0.350227
0.14142136
0.06339256
0.1253
0.160601
0.10969388
0.07653061
0.41584262
0.463726
0.123114
0.222445
0.546361
0.143124
0.225911
0.16034175
0.099549
0.611153
0.16737012
0.229805
0.09899495
0.06
0.069928
0.08673469
0.12628833
0.12728667
0.169312
0.079964
0.0956362
0.047847
0.17214256
0.18182265
0.106516
0.198875
0.03291872
0.240536
0.299954
0.100839
0.064537
Total
24
18
9
98
32
42
14
42
21
33
68
21
21
46
16
24
60
20
27
9
10
13
31
18
21
8
12
20
20
30
28
12
12
4
12
71
10
20
41
38
38
28
31
5
11
41
23
18
77
87
34
19
9
17
15
42
42
120
180
12
78
45
28
18
28
35
33
10
23
25
16
10
71
29
25
28
73
13
9
21
11
20
21
20
32
28
18
18
24
93
14
91
65
32
32
15
25
17
30
37
21
32
8
352
7
5
13
13
3637
Total
24
8
18
93
32
42
14
42
20
33
68
21
21
38
16
24
60
20
35
10
8
13
115
18
48
8
12
20
20
64
28
12
12
4
12
72
11
20
21
78
78
60
31
5
11
41
23
17
36
88
34
19
9
17
15
42
42
60
90
12
81
45
30
19
28
35
33
10
23
25
17
12
142
29
25
24
59
13
21
21
11
20
21
20
32
28
19
18
22
86
14
91
65
32
31
15
20
40
30
40
22
32
8
352
7
5
13
13
3764
Weight
0.9%
0.2%
0.1%
1.7%
1.8%
0.7%
1.3%
1.9%
0.3%
2.0%
1.0%
1.0%
0.6%
0.3%
0.1%
0.5%
0.7%
1.8%
0.2%
0.1%
0.1%
0.2%
0.9%
0.3%
0.2%
0.1%
0.3%
1.2%
1.1%
0.6%
0.9%
0.2%
0.2%
0.9%
0.1%
0.1%
0.2%
0.5%
0.5%
1.0%
0.4%
1.0%
2.3%
0.1%
0.1%
1.0%
0.4%
0.8%
1.0%
1.3%
0.4%
0.5%
0.1%
0.4%
0.8%
0.6%
0.5%
0.7%
1.5%
0.1%
0.8%
0.5%
1.1%
0.4%
1.0%
4.8%
0.0%
0.2%
1.2%
0.5%
0.1%
0.6%
3.0%
0.8%
0.5%
1.0%
2.0%
0.1%
0.1%
0.8%
0.2%
0.0%
0.6%
0.2%
0.5%
1.2%
0.0%
0.4%
0.2%
1.2%
3.3%
2.4%
1.6%
0.7%
0.7%
0.4%
1.9%
1.3%
5.2%
0.4%
0.4%
1.1%
0.3%
11.0%
0.2%
0.1%
1.2%
2.9%
100.0%
IV, Fixed, 95% CI
-0.20 [-0.43, 0.02]
-0.73 [-1.26, -0.20]
0.07 [-0.76, 0.91]
-0.06 [-0.22, 0.11]
-0.24 [-0.40, -0.08]
-0.09 [-0.35, 0.17]
-0.22 [-0.41, -0.03]
-0.30 [-0.45, -0.14]
-0.78 [-1.15, -0.40]
-0.02 [-0.17, 0.13]
-0.03 [-0.24, 0.19]
0.04 [-0.18, 0.26]
-0.20 [-0.47, 0.07]
-0.05 [-0.44, 0.34]
-0.29 [-0.86, 0.29]
0.14 [-0.17, 0.44]
-0.26 [-0.51, -0.01]
-0.14 [-0.29, 0.02]
-0.15 [-0.60, 0.30]
-0.07 [-0.67, 0.52]
-0.73 [-1.48, 0.03]
-0.42 [-0.96, 0.12]
-0.16 [-0.39, 0.07]
-0.02 [-0.40, 0.36]
-0.05 [-0.53, 0.43]
-0.26 [-0.96, 0.44]
-0.41 [-0.82, 0.01]
-0.17 [-0.37, 0.02]
-0.22 [-0.43, -0.01]
-0.05 [-0.32, 0.23]
-0.23 [-0.46, -0.01]
-0.13 [-0.64, 0.38]
-0.16 [-0.66, 0.35]
-0.26 [-0.49, -0.03]
0.08 [-0.59, 0.74]
-0.12 [-0.75, 0.51]
-0.38 [-0.81, 0.05]
-0.32 [-0.63, -0.01]
0.31 [0.02, 0.61]
-0.37 [-0.59, -0.15]
-0.30 [-0.64, 0.03]
-0.28 [-0.50, -0.07]
-0.18 [-0.32, -0.04]
-0.59 [-1.27, 0.08]
-0.20 [-0.90, 0.50]
-0.31 [-0.52, -0.10]
0.02 [-0.31, 0.35]
-0.34 [-0.58, -0.10]
0.04 [-0.17, 0.26]
0.14 [-0.05, 0.33]
-0.07 [-0.43, 0.30]
-0.57 [-0.87, -0.28]
0.04 [-0.66, 0.74]
-0.25 [-0.60, 0.10]
-0.17 [-0.40, 0.07]
-0.08 [-0.37, 0.21]
-0.15 [-0.45, 0.15]
0.17 [-0.08, 0.42]
-0.28 [-0.45, -0.10]
-1.84 [-2.41, -1.27]
-0.03 [-0.27, 0.21]
0.15 [-0.16, 0.46]
-0.19 [-0.39, 0.02]
0.14 [-0.18, 0.46]
-0.08 [-0.29, 0.13]
-0.18 [-0.28, -0.08]
-0.05 [-1.39, 1.28]
-0.34 [-0.77, 0.09]
-0.05 [-0.25, 0.15]
-0.14 [-0.44, 0.16]
0.57 [-0.12, 1.25]
-0.10 [-0.38, 0.18]
0.03 [-0.10, 0.15]
-0.12 [-0.37, 0.13]
-0.43 [-0.75, -0.12]
-0.27 [-0.48, -0.06]
-0.39 [-0.54, -0.24]
0.21 [-0.60, 1.03]
0.15 [-0.76, 1.06]
-0.53 [-0.77, -0.29]
-0.02 [-0.46, 0.42]
-0.89 [-1.96, 0.18]
-0.30 [-0.58, -0.02]
-0.28 [-0.72, 0.16]
-0.53 [-0.84, -0.21]
-0.07 [-0.27, 0.12]
0.29 [-0.91, 1.49]
0.01 [-0.32, 0.34]
-0.16 [-0.61, 0.30]
-0.14 [-0.33, 0.05]
-0.08 [-0.20, 0.04]
-0.07 [-0.21, 0.06]
-0.26 [-0.43, -0.09]
-0.04 [-0.29, 0.21]
0.04 [-0.21, 0.29]
-0.30 [-0.63, 0.03]
-0.16 [-0.32, -0.00]
-0.02 [-0.21, 0.17]
-0.03 [-0.12, 0.07]
-0.03 [-0.37, 0.31]
-0.16 [-0.52, 0.20]
-0.00 [-0.21, 0.21]
0.00 [-0.39, 0.39]
-0.06 [-0.13, 0.00]
-1.13 [-1.60, -0.66]
0.26 [-0.32, 0.85]
-0.25 [-0.45, -0.05]
-0.16 [-0.29, -0.03]
-0.14 [-0.16, -0.12]
Favours plant protein Animal Protein
Mean Difference
Mean Difference
IV, Fixed, 95% CI
-2
-1
0
1
2
Favours plant protein
Favours animal protein
Downloaded from http://ahajournals.org by on June 4, 2019
  
 
Figure S3 (Continued). LDL-C Forest Plot, fixed-effects model. HC=hypercholesterolemic; IF=isoflavones; LF=low-fat; 
N=normal; NIF=no isoflavones; Pre-MS=pre-metabolic syndrome. The pooled effect estimate (diamond) is shown. Paired 
analyses were applied to all crossover trials. The studies by Duane et al. 1999 (26), Lovati et al. 1987 (56), Sirtori et al. 2002 
(80), and Van Horn et al. 2001 (91) were missing variance data, which were imputed using the average standard of the mean 
differences across included trials based on the respective trial’s sample size. Data are expressed as MDs with 95% CIs, 
using generic inverse-variance fixed-effects models. Inter-study heterogeneity was tested using the Cochran Q statistic 
(chi-square) at a significance level of P<0.10 and quantified by I2, levels of ≥50% represented substantial heterogeneity. 
Mean Difference IV,
Fixed, 95% CI  
Ma 2005 (57)
78
81
0.8%
-0.03 [-0.27, 0.21]
Ma 2011 (58)
45
45
0.5%
0.15 [-0.16, 0.46]
Maki 2010 (59)
28
30
1.1%
-0.19 [-0.39, 0.02]
Markova 2015 (60)
18
19
0.4%
0.14 [-0.18, 0.46]
Matthan 2007 (61)
28
28
1.0%
-0.08 [-0.29, 0.13]
McVeigh 2006 (62)
35
35
4.8%
-0.18 [-0.28, -0.08]
Mercer 1987 (63)
33
33
0.0%
-0.05 [-1.39, 1.28]
Meredith 1989 (64)
10
10
0.2%
-0.34 [-0.77, 0.09]
Meyer 2004 (65)
23
23
1.2%
-0.05 [-0.25, 0.15]
Miraghajani 2013 (66)
25
25
0.5%
-0.14 [-0.44, 0.16]
Napora 2011 (67)
16
17
0.1%
0.57 [-0.12, 1.25]
Onning 1998 (68)
10
12
0.6%
-0.10 [-0.38, 0.18]
Padhi 2015 (69)
71
142
3.0%
0.03 [-0.10, 0.15]
Pipe 2009 (70)
29
29
0.8%
-0.12 [-0.37, 0.13]
Potter 1993 (71)
25
25
0.5%
-0.43 [-0.75, -0.12]
Puska 2002 (72)
28
24
1.0%
-0.27 [-0.48, -0.06]
Puska 2004 (73)
73
59
2.0%
-0.39 [-0.54, -0.24]
Roughead 2005 (74)
13
13
0.1%
0.21 [-0.60, 1.03]
Santo 2008 (75)
9
21
0.1%
0.15 [-0.76, 1.06]
Shidfar 2009 (76)
21
21
0.8%
-0.53 [-0.77, -0.29]
Shige 1998 (77)
11
11
0.2%
-0.02 [-0.46, 0.42]
Sirtori 1977 (78)
20
20
0.0%
-0.89 [-1.96, 0.18]
Sirtori 1999 (79)
21
21
0.6%
-0.30 [-0.58, -0.02]
Sirtori 2002 (80)
20
20
0.2%
-0.28 [-0.72, 0.16]
Steele 1992 (81)
32
32
0.5%
-0.53 [-0.84, -0.21]
Steinberg 2003 (82)
28
28
1.2%
-0.07 [-0.27, 0.12]
Sucher 2016 (83)
18
19
0.0%
0.29 [-0.91, 1.49]
Tabibi 2010 (84)
18
18
0.4%
0.01 [-0.32, 0.34]
Takahira 2011 (85)
24
22
0.2%
-0.16 [-0.61, 0.30]
Teede 2001 (86)
93
86
1.2%
-0.14 [-0.33, 0.05]
Teixeira 2004 (88)
14
14
3.3%
-0.08 [-0.20, 0.04]
Thorp 2008 (89)
91
91
2.4%
-0.07 [-0.21, 0.06]
Tonstad 2002 (90)
65
65
1.6%
-0.26 [-0.43, -0.09]
Van Horn 2001 (Oats) (91)
32
32
0.7%
-0.04 [-0.29, 0.21]
Van Horn 2001 (Wheat) (91)
32
31
0.7%
0.04 [-0.21, 0.29]
van Nielen 2014 (92)
15
15
0.4%
-0.30 [-0.63, 0.03]
van Raaij 1981 (93)
25
20
1.9%
-0.16 [-0.32, -0.00]
van Raaij 1982 (93)
17
40
1.3%
-0.02 [-0.21, 0.17]
Vega-Lopez 2010 (95)
30
30
5.2%
-0.03 [-0.12, 0.07]
Vigna 2000 (96)
37
40
0.4%
-0.03 [-0.37, 0.31]
Weisse 2010 (97)
21
22
0.4%
-0.16 [-0.52, 0.20]
West 2005 (98)
32
32
1.1%
-0.00 [-0.21, 0.21]
Wiebe 1984 (100)
8
8
0.3%
0.00 [-0.39, 0.39]
Wofford 2012 (101)
352
352
11.0%
-0.06 [-0.13, 0.00]
Wolfe 1981 (102)
7
7
0.2%
-1.13 [-1.60, -0.66]
Wolfe 1985 (103)
5
5
0%
0.26 [-0.32, 0.85]
Wong 1998 (HC) (104)
13
13
1.2%
-0.25 [-0.45, -0.05]
Wong 1998 (N) (104)
13
13
2.9%
-0.16 [-0.29, -0.03]
Total (95% CI)
3637
3764
100.0%
-0.14 [-0.16, -0.12]
Heterogeneity: Chi² = 233.79, df = 107 (P < 0.00001); I² = 54%
Test for overall effect: Z = 12.63 (P < 0.00001)
            -2                -1                 0                  1                 2 
          Favours plant protein         Favours animal protein
Animal 
protein N
Weight
Mean Difference (95% CI) in LDL-C, mmol/L
Study or subgroup
Plant 
protein N
Study or Subgroup
Abd-Mishani 2014
Abete 2009
Ahmed 2011
Allen 2007
Appt 2008
Ashton 2000
Azadbakht 2003
Azadbakht 2007
Azadbakht 2008
Bahr 2013
Bahr 2014
Bakhit 1994 (Cellulose)
Bakhit 1994 (Cotyledon)
Basaria 2009
Beavers 2010
Blum 2003
Bricarello 2004
Burns-Whitmore 2014
Campbell 2010
Chen 2005 (HC)
Chen 2005 (N)
Chen 2006
Crouse 1999
Cuevas 2003
Dent 2001
Duane 1999
Dunn 1986
Finley 2007 (N)
Finley 2007 (Pre-MS)
Gardner 2001
Gardner 2007
Giovanetti 1986 (LF)
Giovanetti 1986 (N)
Goldberg 1982 (HC)
Goldberg 1982 (N)
Greany 2004
Haub 2005
Hermansen 2001
Hill 2015
Hoie 2005
Hoie 2005B
Hoie 2007
Hosseinpour-Niazi 2014
Huff 1984
Jenkins 1989
Jenkins 2002
Jenkins 2010
Kestin 1989
Kjolbaek 2017
Kreijkamp-Kaspers 2004
Kurowska 1997
Laidlaw 1985
Laurin 1991
Li 2016
Liao 2007
Lichenstein 2002 (IF)
Lichenstein 2002 (NIF)
Liu 2012
Liu 2014
Lovati 1987
Ma 2005
Ma 2011
Maki 2010
Markova 2015
Matthan 2007
McVeigh 2006
Mercer 1987
Meredith 1989
Meyer 2004
Miraghajani 2013
Napora 2011
Onning 1998
Padhi 2015
Pipe 2009
Potter 1993
Puska 2002
Puska 2004
Roughead 2005
Santo 2008
Shidfar 2009
Shige 1998
Sirtori 1977
Sirtori 1999
Sirtori 2002
Steele 1992
Steinberg 2003
Sucher 2016
Tabibi 2010
Takahira 2011
Teede 2001
Teixeira 2004
Thorp 2008
Tonstad 2002
Van Horn 2001 (Oats)
Van Horn 2001 (Wheat)
van Nielen 2014
van Raaij 1981
van Raaij 1982
Vega-Lopez 2010
Vigna 2000
Weisse 2010
West 2005
Wiebe 1984
Wofford 2012
Wolfe 1981
Wolfe 1985
Wong 1998 (HC)
Wong 1998 (N)
Total (95% CI)
Heterogeneity: Chi² = 233.79, df = 107 (P < 0.00001); I² = 54%
Test for overall effect: Z = 12.63 (P < 0.00001)
Mean Difference
-0.20429
-0.73356
0.074994
-0.05922
-0.24
-0.09
-0.21722
-0.29739
-0.7758
-0.02
-0.025
0.04
-0.2
-0.05172
-0.28756
0.135248
-0.2586
-0.135
-0.14844
-0.07499
-0.72667
-0.42
-0.15687
-0.02069
-0.04967
-0.2586
-0.40514
-0.17326
-0.21981
-0.04531
-0.23274
-0.1293
-0.15516
-0.2586
0.07758
-0.12
-0.38
-0.32
0.313474
-0.37
-0.305
-0.28333
-0.17843
-0.59478
-0.2
-0.31
0.02
-0.34
0.040519
0.14
-0.065
-0.57409
0.04
-0.25
-0.1655
-0.08
-0.15
0.17
-0.275
-1.84284
-0.03164
0.15
-0.18645
0.14
-0.08333
-0.18
-0.05172
-0.33618
-0.05
-0.14171
0.566334
-0.1
0.025
-0.12
-0.43333
-0.27
-0.39
0.210063
0.147279
-0.53194
-0.02
-0.89
-0.3
-0.27951
-0.525
-0.075
0.29
0.01293
-0.15516
-0.14
-0.08
-0.075
-0.26
-0.04
0.04
-0.3
-0.16033
-0.02198
-0.02586
-0.03
-0.16
-0.0025
0
-0.06336
-1.12676
0.263772
-0.25
-0.16
SE
0.11452535
0.26987818
0.426344
0.084345
0.0813546
0.131158
0.09606812
0.079559
0.19276
0.07698878
0.109846
0.111505
0.138633
0.197426
0.292276
0.154629
0.12865
0.081302
0.22893
0.304249
0.386834
0.274633
0.117133
0.193242
0.246534
0.357197
0.211496
0.09888703
0.106026
0.138911
0.114886
0.2586
0.2586
0.116879
0.339151
0.322438
0.22115218
0.156716
0.15163
0.11067581
0.16966043
0.11072121
0.07261498
0.345693
0.355949
0.109683
0.17088
0.120044
0.10974299
0.09449112
0.183995
0.14884671
0.355949
0.177352
0.12157684
0.14597
0.152136
0.130039
0.08952853
0.29165
0.12145
0.15811388
0.10597332
0.16459601
0.106917
0.049949
0.680762
0.219582
0.1
0.152259
0.350227
0.14142136
0.06339256
0.1253
0.160601
0.10969388
0.07653061
0.41584262
0.463726
0.123114
0.222445
0.546361
0.143124
0.225911
0.16034175
0.099549
0.611153
0.16737012
0.229805
0.09899495
0.06
0.069928
0.08673469
0.12628833
0.12728667
0.169312
0.079964
0.0956362
0.047847
0.17214256
0.18182265
0.106516
0.198875
0.03291872
0.240536
0.299954
0.100839
0.064537
Total
24
18
9
98
32
42
14
42
21
33
68
21
21
46
16
24
60
20
27
9
10
13
31
18
21
8
12
20
20
30
28
12
12
4
12
71
10
20
41
38
38
28
31
5
11
41
23
18
77
87
34
19
9
17
15
42
42
120
180
12
78
45
28
18
28
35
33
10
23
25
16
10
71
29
25
28
73
13
9
21
11
20
21
20
32
28
18
18
24
93
14
91
65
32
32
15
25
17
30
37
21
32
8
352
7
5
13
13
3637
Total
24
8
18
93
32
42
14
42
20
33
68
21
21
38
16
24
60
20
35
10
8
13
115
18
48
8
12
20
20
64
28
12
12
4
12
72
11
20
21
78
78
60
31
5
11
41
23
17
36
88
34
19
9
17
15
42
42
60
90
12
81
45
30
19
28
35
33
10
23
25
17
12
142
29
25
24
59
13
21
21
11
20
21
20
32
28
19
18
22
86
14
91
65
32
31
15
20
40
30
40
22
32
8
352
7
5
13
13
3764
Weight
0.9%
0.2%
0.1%
1.7%
1.8%
0.7%
1.3%
1.9%
0.3%
2.0%
1.0%
1.0%
0.6%
0.3%
0.1%
0.5%
0.7%
1.8%
0.2%
0.1%
0.1%
0.2%
0.9%
0.3%
0.2%
0.1%
0.3%
1.2%
1.1%
0.6%
0.9%
0.2%
0.2%
0.9%
0.1%
0.1%
0.2%
0.5%
0.5%
1.0%
0.4%
1.0%
2.3%
0.1%
0.1%
1.0%
0.4%
0.8%
1.0%
1.3%
0.4%
0.5%
0.1%
0.4%
0.8%
0.6%
0.5%
0.7%
1.5%
0.1%
0.8%
0.5%
1.1%
0.4%
1.0%
4.8%
0.0%
0.2%
1.2%
0.5%
0.1%
0.6%
3.0%
0.8%
0.5%
1.0%
2.0%
0.1%
0.1%
0.8%
0.2%
0.0%
0.6%
0.2%
0.5%
1.2%
0.0%
0.4%
0.2%
1.2%
3.3%
2.4%
1.6%
0.7%
0.7%
0.4%
1.9%
1.3%
5.2%
0.4%
0.4%
1.1%
0.3%
11.0%
0.2%
0.1%
1.2%
2.9%
100.0%
IV, Fixed, 95% CI
-0.20 [-0.43, 0.02]
-0.73 [-1.26, -0.20]
0.07 [-0.76, 0.91]
-0.06 [-0.22, 0.11]
-0.24 [-0.40, -0.08]
-0.09 [-0.35, 0.17]
-0.22 [-0.41, -0.03]
-0.30 [-0.45, -0.14]
-0.78 [-1.15, -0.40]
-0.02 [-0.17, 0.13]
-0.03 [-0.24, 0.19]
0.04 [-0.18, 0.26]
-0.20 [-0.47, 0.07]
-0.05 [-0.44, 0.34]
-0.29 [-0.86, 0.29]
0.14 [-0.17, 0.44]
-0.26 [-0.51, -0.01]
-0.14 [-0.29, 0.02]
-0.15 [-0.60, 0.30]
-0.07 [-0.67, 0.52]
-0.73 [-1.48, 0.03]
-0.42 [-0.96, 0.12]
-0.16 [-0.39, 0.07]
-0.02 [-0.40, 0.36]
-0.05 [-0.53, 0.43]
-0.26 [-0.96, 0.44]
-0.41 [-0.82, 0.01]
-0.17 [-0.37, 0.02]
-0.22 [-0.43, -0.01]
-0.05 [-0.32, 0.23]
-0.23 [-0.46, -0.01]
-0.13 [-0.64, 0.38]
-0.16 [-0.66, 0.35]
-0.26 [-0.49, -0.03]
0.08 [-0.59, 0.74]
-0.12 [-0.75, 0.51]
-0.38 [-0.81, 0.05]
-0.32 [-0.63, -0.01]
0.31 [0.02, 0.61]
-0.37 [-0.59, -0.15]
-0.30 [-0.64, 0.03]
-0.28 [-0.50, -0.07]
-0.18 [-0.32, -0.04]
-0.59 [-1.27, 0.08]
-0.20 [-0.90, 0.50]
-0.31 [-0.52, -0.10]
0.02 [-0.31, 0.35]
-0.34 [-0.58, -0.10]
0.04 [-0.17, 0.26]
0.14 [-0.05, 0.33]
-0.07 [-0.43, 0.30]
-0.57 [-0.87, -0.28]
0.04 [-0.66, 0.74]
-0.25 [-0.60, 0.10]
-0.17 [-0.40, 0.07]
-0.08 [-0.37, 0.21]
-0.15 [-0.45, 0.15]
0.17 [-0.08, 0.42]
-0.28 [-0.45, -0.10]
-1.84 [-2.41, -1.27]
-0.03 [-0.27, 0.21]
0.15 [-0.16, 0.46]
-0.19 [-0.39, 0.02]
0.14 [-0.18, 0.46]
-0.08 [-0.29, 0.13]
-0.18 [-0.28, -0.08]
-0.05 [-1.39, 1.28]
-0.34 [-0.77, 0.09]
-0.05 [-0.25, 0.15]
-0.14 [-0.44, 0.16]
0.57 [-0.12, 1.25]
-0.10 [-0.38, 0.18]
0.03 [-0.10, 0.15]
-0.12 [-0.37, 0.13]
-0.43 [-0.75, -0.12]
-0.27 [-0.48, -0.06]
-0.39 [-0.54, -0.24]
0.21 [-0.60, 1.03]
0.15 [-0.76, 1.06]
-0.53 [-0.77, -0.29]
-0.02 [-0.46, 0.42]
-0.89 [-1.96, 0.18]
-0.30 [-0.58, -0.02]
-0.28 [-0.72, 0.16]
-0.53 [-0.84, -0.21]
-0.07 [-0.27, 0.12]
0.29 [-0.91, 1.49]
0.01 [-0.32, 0.34]
-0.16 [-0.61, 0.30]
-0.14 [-0.33, 0.05]
-0.08 [-0.20, 0.04]
-0.07 [-0.21, 0.06]
-0.26 [-0.43, -0.09]
-0.04 [-0.29, 0.21]
0.04 [-0.21, 0.29]
-0.30 [-0.63, 0.03]
-0.16 [-0.32, -0.00]
-0.02 [-0.21, 0.17]
-0.03 [-0.12, 0.07]
-0.03 [-0.37, 0.31]
-0.16 [-0.52, 0.20]
-0.00 [-0.21, 0.21]
0.00 [-0.39, 0.39]
-0.06 [-0.13, 0.00]
-1.13 [-1.60, -0.66]
0.26 [-0.32, 0.85]
-0.25 [-0.45, -0.05]
-0.16 [-0.29, -0.03]
-0.14 [-0.16, -0.12]
Favours plant protein Animal Protein
Mean Difference
Mean Difference
IV, Fixed, 95% CI
-2
-1
0
1
2
Favours plant protein
Favours animal protein
Downloaded from http://ahajournals.org by on June 4, 2019
  
 
Figure S4. LDL-C Visual Subgroup. Point estimates for each subgroup level (squares) are the pooled effect estimates. 
The dashed line represents the pooled effect estimate for the overall (total) analysis. The residual I2 value indicates the 
interstudy heterogeneity unexplained by the subgroup. Statistically significant pairwise subgroup effect modification by 
meta-regression analyses at P < 0.05. 
 
 
 
Subgroup
Level
Trials
Participants
Residual I2
p-value
Within subgroups
Between subgroups
Total
108
5,582
            
-0.16 [-0.20 to -0.12]
-
-
-
Design
Parallel
50
3,840
             
-0.14 [-0.20 to -0.08]
-0.03 [-0.12 to 0.05]
55.00%
0.43
Crossover
58
1,742
             
-0.17 [-0.23 to -0.12]
Follow-up
<3 months
85
3,578
             
-0.17 [-0.22 to -0.13]
0.06 [-0.04 to 0.16]
54.79%
0.26
≥3months
23
2,004
             
-0.11 [-0.20 to -0.02]
Plant protein type
Soy
92
5,024
             
-0.17 [-0.22 to -0.13]
0.06 [-0.04 to 0.17]
54.29%
0.24
Other
16
558
                
-0.11 [-0.20 to -0.02]
Animal protein type
Dairy
70
4,664
             
-0.14 [-0.19 to -0.09]
-0.06 [-0.15 to 0.03]
54.39%
0.18
Other
38
918
                
-0.2 [-0.27 to -0.13]
Dose
≤25g/d
48
2,757
             
-0.14 [-0.21 to -0.08]
-0.04 [-0.12 to 0.05]
57.20%
0.37
>25g/d
64
2,916
             
-0.18 [-0.24 to -0.13]
Baseline 
<3.5mmol/L
47
2,263
             
-0.12 [-0.18 to -0.06]
-0.07 [-0.15 to 0.02]
54.27%
0.12
LDL-C
≥3.5mmol/L
61
3,319
             
-0.19 [-0.24 to -0.13]
Favours plant protein       Favours animal protein
Mean Difference (95% CI) in LDL cholesterol, mmol/L
-0.3
-0.1
0.1
0.3
Downloaded from http://ahajournals.org by on June 4, 2019
  
 
Figure S5. Post-Hoc Subgroups. Point estimates for each subgroup level (squares) are the pooled effect estimates. The 
dashed line represents the pooled effect estimate for the overall (total) analysis. The residual I2 value indicates the 
interstudy heterogeneity unexplained by the subgroup. Statistically significant pairwise subgroup effect modification by 
meta-regression analyses at P < 0.05. 
 
 
 
 
 
Residual I
Residual I2
P-
value
value
-0.05(-0.13 to 0.04)
55.19%
0.26
-0.04(-0.13 to 0.04)
61.00%
0.33
-0.01(-0.04 to 0.03)
43.09%
0.64
Mean Difference (95% CI), 
Mean Difference (95% CI), mmol
mmol/L (LDL
/L (LDL-C, non
C, non-HDL
HDL-C) or g/L (Apo B)
C) or g/L (Apo B)
Favors plant protein                 Favors animal protein
Between Subgroups
Within Subgroups
Appendix Figure 3. 
Appendix Figure 3. Post hoc Subgroup Analyses
Total non
Total non-
HDL
HDL-C
102
5401
-0.18 (-0.22 to -0.14)
Protein 
Protein 
Form
Form
Protein Isolate
63
3672
-0.18 (-0.23 to -0.12)
Whole
40
1729
-0.22 (-0.28 to -0.15)
Total Apo B
Total Apo B
37
1506
-0.04 (-0.06 to -0.03)
Protein 
Protein 
Form
Form
Protein Isolate
28
1179
-0.05 (-0.07 to -0.03)
Whole
10
369
-0.05(-0.08 to -0.01)
Subgroup
Subgroup
Level
Level
Trials
Trials
Participants
Participants
Total LDL
Total LDL-C
108
5582
-0.16 (-0.20 to -0.12)
Protein 
Protein 
Form
Form
Protein Isolate
72
4074
-0.14 (-0.20 to -0.09)
Whole
38
1478
-0.19 (-0.26 to -0.13)
-0.1
-0.05
0
0.05
0.1
-0.5
-0.3
-0.1
0.1
0.3
-0.3
-0.1
0.1
0.3
Downloaded from http://ahajournals.org by on June 4, 2019
  
Figure S6. Non-HDL-C Forest Plot, random-effects model.  
Mean Difference IV,
 Random, 95% CI  
Abd-Mishani 2014 (1)
24
24
1.1%
-0.24 [-0.55, 0.06]
Abete 2009 (2)
18
8
0.5%
-0.64 [-1.21, -0.07]
Ahmed 2011 (3)
9
18
0.2%
0.31 [-0.65, 1.26]
Allen 2007 (4)
98
93
1.1%
-0.12 [-0.43, 0.19]
Appt 2008 (5)
32
32
0.7%
-0.24 [-0.69, 0.21]
Ashton 2000 (6)
42
42
1.1%
-0.15 [-0.46, 0.16]
Azadbakht 2003 (7)
14
14
1.5%
-0.47 [-0.71, -0.23]
Azadbakht 2007 (8)
42
42
2.6%
-0.40 [-0.45, -0.34]
Azadbakht 2008 (9)
21
20
0.2%
-0.93 [-1.99, 0.13]
Bahr 2013 (10)
33
33
1.9%
-0.04 [-0.21, 0.13]
Bahr 2014 (11)
68
68
1.4%
-0.02 [-0.26, 0.22]
Bakhit 1994 (Cellulose) (12)
21
21
1.6%
0.01 [-0.20, 0.22]
Bakhit 1994 (Cotyledon) (12)
21
21
1.3%
-0.20 [-0.46, 0.06]
Basaria 2009 (13)
46
38
0.4%
0.09 [-0.54, 0.73]
Baum 1998 (14)
22
44
1.7%
-0.27 [-0.46, -0.07]
Beavers 2010 (15)
16
16
0.2%
0.02 [-0.89, 0.92]
Blum 2003 (16)
24
24
0.8%
0.13 [-0.25, 0.51]
Borodin 2009 (17)
28
28
0.7%
-0.36 [-0.81, 0.09]
Bricarello 2004 (18)
60
60
1.5%
-0.23 [-0.46, -0.01]
Burns-Whitmore 2014 (19)
20
20
1.8%
-0.25 [-0.44, -0.06]
Campbell 2010 (20)
27
35
0.3%
-0.11 [-0.82, 0.61]
Chen 2005 (HC) (21)
9
10
0.3%
-0.11 [-0.80, 0.59]
Chen 2005 (N) (21)
10
8
0.1%
-1.16 [-2.23, -0.09]
Chen 2006 (22)
13
13
0.2%
-0.88 [-1.71, -0.05]
Crouse 1999 (23)
31
115
1.2%
-0.21 [-0.49, 0.08]
Cuevas 2003 (24)
18
18
0.7%
-0.14 [-0.59, 0.31]
Duane 1999 (26)
8
8
0.2%
-0.11 [-0.92, 0.71]
Dunn 1986 (27)
12
12
0.3%
-0.57 [-1.26, 0.12]
Finley 2007 (N) (28)
20
20
1.7%
-0.16 [-0.37, 0.04]
Finley 2007 (Pre-MS) (28)
20
20
1.0%
-0.19 [-0.53, 0.15]
Gardner 2001 (29)
30
44
1.0%
-0.15 [-0.49, 0.20]
Giovanetti 1986 (LF) (31)
12
12
0.7%
-0.03 [-0.44, 0.39]
Giovanetti 1986 (N) (31)
12
12
0.7%
-0.03 [-0.44, 0.39]
Goldberg 1982 (HC) (32)
4
4
1.0%
-0.18 [-0.52, 0.16]
Goldberg 1982 (N) (32)
12
12
0.5%
-0.03 [-0.58, 0.52]
Greany 2004 (33)
71
72
2.5%
-0.16 [-0.24, -0.08]
Haub 2005 (34)
10
11
0.6%
-0.18 [-0.64, 0.28]
Hermansen 2001 (35)
20
20
0.5%
-0.45 [-1.00, 0.10]
Hill 2015 (36)
41
21
1.0%
0.21 [-0.12, 0.55]
Hoie 2005 (37)
38
78
2.0%
-0.45 [-0.61, -0.28]
Hoie 2005B (38)
39
78
1.5%
-0.34 [-0.57, -0.12]
Hoie 2007 (39)
28
60
0.8%
-0.24 [-0.66, 0.17]
Hosseinpour-Niazi 2014 (40)
31
31
1.3%
-0.08 [-0.35, 0.19]
Huff 1984 (41)
5
5
0.2%
-0.58 [-1.43, 0.26]
Jenkins 1989 (42)
11
11
0.2%
-0.26 [-1.08, 0.56]
Jenkins 2002 (43)
41
41
1.4%
-0.40 [-0.65, -0.15]
Jenkins 2010 (44)
23
23
0.4%
0.06 [-0.52, 0.64]
Kestin 1989 (45)
18
17
0.9%
-0.37 [-0.74, -0.00]
Kjolbaek 2017 (46)
77
36
0.5%
0.05 [-0.50, 0.60]
Kreijkamp-Kaspers 2004 (47)
87
88
1.1%
0.18 [-0.13, 0.48]
Kurowska 1997 (48)
34
34
0.8%
-0.01 [-0.42, 0.39]
Laidlaw 1985 (49)
19
19
1.1%
-0.52 [-0.82, -0.21]
Laurin 1991 (50)
9
9
0.1%
-0.32 [-1.41, 0.77]
Li 2016 (51)
17
17
0.3%
0.02 [-0.75, 0.78]
Liao 2007 (52)
15
15
0.9%
-0.18 [-0.53, 0.18]
Lichenstein 2002 (IF) (53)
42
42
0.9%
-0.13 [-0.49, 0.23]
                -2              -1               0               1               2
      Favours plant protein         Favours animal protein
Study or subgroup
Plant 
protein N
Animal 
protein N
Weight
Mean Difference (95% CI) in non-HDL-C, mmol/L
Study or Subgroup
Abd-Mishani 2014
Abete 2009
Ahmed 2011
Allen 2007
Appt 2008
Ashton 2000
Azadbakht 2003
Azadbakht 2007
Azadbakht 2008
Bahr 2013
Bahr 2014
Bakhit 1994 (Cellulose)
Bakhit 1994 (Cotyledon)
Basaria 2009
Baum 1998
Beavers 2010
Blum 2003
Borodin 2009
Bricarello 2004
Burns-Whitmore 2014
Campbell 2010
Chen 2005 (HC)
Chen 2005 (N)
Chen 2006
Crouse 1999
Cuevas 2003
Duane 1999
Dunn 1986
Finley 2007 (N)
Finley 2007 (Pre-MS)
Gardner 2001
Giovanetti 1986 (LF)
Giovanetti 1986 (N)
Goldberg 1982 (HC)
Goldberg 1982 (N)
Greany 2004
Haub 2005
Hermansen 2001
Hill 2015
Hoie 2005
Hoie 2005B
Hoie 2007
Hosseinpour-Niazi 2014
Huff 1984
Jenkins 1989
Jenkins 2002
Jenkins 2010
Kestin 1989
Kjolbaek 2017
Kreijkamp-Kaspers 2004
Kurowska 1997
Laidlaw 1985
Laurin 1991
Li 2016
Liao 2007
Lichenstein 2002 (IF)
Lichenstein 2002 (NIF)
Liu 2012
Liu 2014
Ma 2005
Ma 2011
Maki 2010
Markova 2015
Matthan 2007
McVeigh 2006
Mercer 1987
Meredith 1989
Meyer 2004
Miraghajani 2013
Napora 2011
Onning 1998
Padhi 2015
Pipe 2009
Potter 1993
Puska 2002
Puska 2004
Roughead 2005
Shidfar 2009
Shige 1998
Steele 1992
Steinberg 2003
Sucher 2016
Tabibi 2010
Teede 2001
Teixeira 2000
Teixeira 2004
Thorp 2008
Tonstad 2002
van Nielen 2014
van Raaij 1981
van Raaij 1982
Vega-Lopez 2010
Vigna 2000
Weisse 2010
West 2005
Wheeler 2002
Wiebe 1984
Wofford 2012
Wolfe 1981
Wolfe 1985
Wong 1998 (HC)
Wong 1998 (N)
Total (95% CI)
Heterogeneity: Tau² = 0.02; Chi² = 209.94, df = 101 (P < 0.00001); I² = 52%
Test for overall effect: Z = 8.33 (P < 0.00001)
Mean Difference
-0.24308
-0.63791
0.307734
-0.11844
-0.24
-0.15
-0.47065
-0.39695
-0.93096
-0.04
-0.02
0.01
-0.2
0.093096
-0.26568
0.018102
0.129817
-0.36204
-0.23274
-0.25
-0.10654
-0.10603
-1.15853
-0.88
-0.20713
-0.13964
-0.10603
-0.57108
-0.16292
-0.18749
-0.14531
-0.02586
-0.02586
-0.18102
-0.02586
-0.16
-0.18
-0.45
0.213061
-0.445
-0.345
-0.24267
-0.07603
-0.58444
-0.26
-0.4
0.06
-0.37
0.050779
0.176262
-0.015
-0.5172
-0.32
0.01618
-0.17843
-0.13
-0.23
0.2
-0.2685
-0.07014
0.070982
-0.30256
0.19
-0.03333
-0.15
-0.07758
-0.28446
-0.07
-0.27618
-0.01991
0
0.015
-0.12
-0.60333
-0.26
-0.4
0.145214
-0.64185
-0.09
-0.5625
-0.04
0.19
0.31032
-0.22
-0.38877
-0.2
-0.115
-0.59169
0
-0.09051
-0.13577
-0.02586
-0.04
-0.12
-0.04375
-0.1
0.10344
-0.07629
-0.9679
-0.01552
-0.21
-0.13
SE
0.154094
0.290274
0.488027
0.157505
0.22769
0.158039
0.121752
0.027906
0.539805
0.085941
0.123668
0.109125
0.132755
0.324324
0.099251
0.462626
0.19502
0.230198
0.115649
0.095033
0.363082
0.355799
0.546417
0.424352
0.146362
0.231176
0.41533
0.352739
0.105076
0.17455
0.176467
0.213247
0.213247
0.175327
0.280837
0.040017
0.235488
0.279217
0.169372
0.081733
0.116
0.211717
0.137464
0.432303
0.420623
0.129723
0.295808
0.187602
0.27973
0.15626
0.206725
0.156068
0.557791
0.389003
0.180575
0.183974
0.183522
0.147767
0.109914
0.14122
0.196802
0.106098
0.449333
0.143026
0.049949
0.409999
0.135357
0.226264
0.389462
0.674799
0.141421
0.058499
0.135277
0.189612
0.130891
0.076531
0.780012
0.212352
0.313454
0.169424
0.168001
0.457493
0.369153
0.136748
0.266114
0.094868
0.094663
0.123688
0.278904
0.106561
0.10151
0.135617
0.321743
0.227175
0.120574
0.323396
0.182553
0.055439
0.418347
0.071572
0.275861
0.253463
Total
24
18
9
98
32
42
14
42
21
33
68
21
21
46
22
16
24
28
60
20
27
9
10
13
31
18
8
12
20
20
30
12
12
4
12
71
10
20
41
38
39
28
31
5
11
41
23
18
77
87
34
19
9
17
15
42
42
120
180
78
45
28
18
28
35
33
10
23
25
16
10
71
29
25
28
73
13
21
11
32
28
18
18
93
16
14
91
65
15
25
17
30
37
21
32
17
8
352
7
5
13
13
3502
Total
24
8
18
93
32
42
14
42
20
33
68
21
21
38
44
16
24
28
60
20
35
10
8
13
115
18
8
12
20
20
44
12
12
4
12
72
11
20
21
78
78
60
31
5
11
41
23
17
36
88
34
19
9
17
15
42
42
60
90
81
45
30
19
28
35
33
10
23
25
17
12
142
29
25
24
59
13
21
11
32
28
19
18
86
65
14
91
65
15
20
40
30
40
22
32
17
8
352
7
5
13
13
3643
Weight
1.1%
0.5%
0.2%
1.1%
0.7%
1.1%
1.5%
2.6%
0.2%
1.9%
1.4%
1.6%
1.3%
0.4%
1.7%
0.2%
0.8%
0.7%
1.5%
1.8%
0.3%
0.3%
0.1%
0.2%
1.2%
0.7%
0.2%
0.3%
1.7%
1.0%
1.0%
0.7%
0.7%
1.0%
0.5%
2.5%
0.6%
0.5%
1.0%
2.0%
1.5%
0.8%
1.3%
0.2%
0.2%
1.4%
0.4%
0.9%
0.5%
1.1%
0.8%
1.1%
0.1%
0.3%
0.9%
0.9%
0.9%
1.2%
1.6%
1.3%
0.8%
1.6%
0.2%
1.2%
2.4%
0.3%
1.3%
0.7%
0.3%
0.1%
1.3%
2.3%
1.3%
0.9%
1.4%
2.0%
0.1%
0.8%
0.4%
1.0%
1.0%
0.2%
0.3%
1.3%
0.5%
1.8%
1.8%
1.4%
0.5%
1.6%
1.7%
1.3%
0.4%
0.7%
1.5%
0.4%
0.9%
2.3%
0.2%
2.1%
0.5%
0.6%
100.0%
IV, Random, 95% CI
-0.24 [-0.55, 0.06]
-0.64 [-1.21, -0.07]
0.31 [-0.65, 1.26]
-0.12 [-0.43, 0.19]
-0.24 [-0.69, 0.21]
-0.15 [-0.46, 0.16]
-0.47 [-0.71, -0.23]
-0.40 [-0.45, -0.34]
-0.93 [-1.99, 0.13]
-0.04 [-0.21, 0.13]
-0.02 [-0.26, 0.22]
0.01 [-0.20, 0.22]
-0.20 [-0.46, 0.06]
0.09 [-0.54, 0.73]
-0.27 [-0.46, -0.07]
0.02 [-0.89, 0.92]
0.13 [-0.25, 0.51]
-0.36 [-0.81, 0.09]
-0.23 [-0.46, -0.01]
-0.25 [-0.44, -0.06]
-0.11 [-0.82, 0.61]
-0.11 [-0.80, 0.59]
-1.16 [-2.23, -0.09]
-0.88 [-1.71, -0.05]
-0.21 [-0.49, 0.08]
-0.14 [-0.59, 0.31]
-0.11 [-0.92, 0.71]
-0.57 [-1.26, 0.12]
-0.16 [-0.37, 0.04]
-0.19 [-0.53, 0.15]
-0.15 [-0.49, 0.20]
-0.03 [-0.44, 0.39]
-0.03 [-0.44, 0.39]
-0.18 [-0.52, 0.16]
-0.03 [-0.58, 0.52]
-0.16 [-0.24, -0.08]
-0.18 [-0.64, 0.28]
-0.45 [-1.00, 0.10]
0.21 [-0.12, 0.55]
-0.45 [-0.61, -0.28]
-0.34 [-0.57, -0.12]
-0.24 [-0.66, 0.17]
-0.08 [-0.35, 0.19]
-0.58 [-1.43, 0.26]
-0.26 [-1.08, 0.56]
-0.40 [-0.65, -0.15]
0.06 [-0.52, 0.64]
-0.37 [-0.74, -0.00]
0.05 [-0.50, 0.60]
0.18 [-0.13, 0.48]
-0.01 [-0.42, 0.39]
-0.52 [-0.82, -0.21]
-0.32 [-1.41, 0.77]
0.02 [-0.75, 0.78]
-0.18 [-0.53, 0.18]
-0.13 [-0.49, 0.23]
-0.23 [-0.59, 0.13]
0.20 [-0.09, 0.49]
-0.27 [-0.48, -0.05]
-0.07 [-0.35, 0.21]
0.07 [-0.31, 0.46]
-0.30 [-0.51, -0.09]
0.19 [-0.69, 1.07]
-0.03 [-0.31, 0.25]
-0.15 [-0.25, -0.05]
-0.08 [-0.88, 0.73]
-0.28 [-0.55, -0.02]
-0.07 [-0.51, 0.37]
-0.28 [-1.04, 0.49]
-0.02 [-1.34, 1.30]
0.00 [-0.28, 0.28]
0.01 [-0.10, 0.13]
-0.12 [-0.39, 0.15]
-0.60 [-0.97, -0.23]
-0.26 [-0.52, -0.00]
-0.40 [-0.55, -0.25]
0.15 [-1.38, 1.67]
-0.64 [-1.06, -0.23]
-0.09 [-0.70, 0.52]
-0.56 [-0.89, -0.23]
-0.04 [-0.37, 0.29]
0.19 [-0.71, 1.09]
0.31 [-0.41, 1.03]
-0.22 [-0.49, 0.05]
-0.39 [-0.91, 0.13]
-0.20 [-0.39, -0.01]
-0.12 [-0.30, 0.07]
-0.59 [-0.83, -0.35]
0.00 [-0.55, 0.55]
-0.09 [-0.30, 0.12]
-0.14 [-0.33, 0.06]
-0.03 [-0.29, 0.24]
-0.04 [-0.67, 0.59]
-0.12 [-0.57, 0.33]
-0.04 [-0.28, 0.19]
-0.10 [-0.73, 0.53]
0.10 [-0.25, 0.46]
-0.08 [-0.18, 0.03]
-0.97 [-1.79, -0.15]
-0.02 [-0.16, 0.12]
-0.21 [-0.75, 0.33]
-0.13 [-0.63, 0.37]
-0.18 [-0.22, -0.14]
Plant Protein Animal Protein
Mean Difference
Mean Difference
IV, Random, 95% CI
-2
-1
0
1
2
Favours plant protein
Favours animal protein
Study or Subgroup
Abd-Mishani 2014
Abete 2009
Ahmed 2011
Allen 2007
Appt 2008
Ashton 2000
Azadbakht 2003
Azadbakht 2007
Azadbakht 2008
Bahr 2013
Bahr 2014
Bakhit 1994 (Cellulose)
Bakhit 1994 (Cotyledon)
Basaria 2009
Baum 1998
Beavers 2010
Blum 2003
Borodin 2009
Bricarello 2004
Burns-Whitmore 2014
Campbell 2010
Chen 2005 (HC)
Chen 2005 (N)
Chen 2006
Crouse 1999
Cuevas 2003
Duane 1999
Dunn 1986
Finley 2007 (N)
Finley 2007 (Pre-MS)
Gardner 2001
Giovanetti 1986 (LF)
Giovanetti 1986 (N)
Goldberg 1982 (HC)
Goldberg 1982 (N)
Greany 2004
Haub 2005
Hermansen 2001
Hill 2015
Hoie 2005
Hoie 2005B
Hoie 2007
Hosseinpour-Niazi 2014
Huff 1984
Jenkins 1989
Jenkins 2002
Jenkins 2010
Kestin 1989
Kjolbaek 2017
Kreijkamp-Kaspers 2004
Kurowska 1997
Laidlaw 1985
Laurin 1991
Li 2016
Liao 2007
Lichenstein 2002 (IF)
Lichenstein 2002 (NIF)
Liu 2012
Liu 2014
Ma 2005
Ma 2011
Maki 2010
Markova 2015
Matthan 2007
McVeigh 2006
Mercer 1987
Meredith 1989
Meyer 2004
Miraghajani 2013
Napora 2011
Onning 1998
Padhi 2015
Pipe 2009
Potter 1993
Puska 2002
Puska 2004
Roughead 2005
Shidfar 2009
Shige 1998
Steele 1992
Steinberg 2003
Sucher 2016
Tabibi 2010
Teede 2001
Teixeira 2000
Teixeira 2004
Thorp 2008
Tonstad 2002
van Nielen 2014
van Raaij 1981
van Raaij 1982
Vega-Lopez 2010
Vigna 2000
Weisse 2010
West 2005
Wheeler 2002
Wiebe 1984
Wofford 2012
Wolfe 1981
Wolfe 1985
Wong 1998 (HC)
Wong 1998 (N)
Total (95% CI)
Heterogeneity: Tau² = 0.02; Chi² = 209.94, df = 101 (P < 0.00001); I² = 52%
Test for overall effect: Z = 8.33 (P < 0.00001)
Mean Difference
-0.24308
-0.63791
0.307734
-0.11844
-0.24
-0.15
-0.47065
-0.39695
-0.93096
-0.04
-0.02
0.01
-0.2
0.093096
-0.26568
0.018102
0.129817
-0.36204
-0.23274
-0.25
-0.10654
-0.10603
-1.15853
-0.88
-0.20713
-0.13964
-0.10603
-0.57108
-0.16292
-0.18749
-0.14531
-0.02586
-0.02586
-0.18102
-0.02586
-0.16
-0.18
-0.45
0.213061
-0.445
-0.345
-0.24267
-0.07603
-0.58444
-0.26
-0.4
0.06
-0.37
0.050779
0.176262
-0.015
-0.5172
-0.32
0.01618
-0.17843
-0.13
-0.23
0.2
-0.2685
-0.07014
0.070982
-0.30256
0.19
-0.03333
-0.15
-0.07758
-0.28446
-0.07
-0.27618
-0.01991
0
0.015
-0.12
-0.60333
-0.26
-0.4
0.145214
-0.64185
-0.09
-0.5625
-0.04
0.19
0.31032
-0.22
-0.38877
-0.2
-0.115
-0.59169
0
-0.09051
-0.13577
-0.02586
-0.04
-0.12
-0.04375
-0.1
0.10344
-0.07629
-0.9679
-0.01552
-0.21
-0.13
SE
0.154094
0.290274
0.488027
0.157505
0.22769
0.158039
0.121752
0.027906
0.539805
0.085941
0.123668
0.109125
0.132755
0.324324
0.099251
0.462626
0.19502
0.230198
0.115649
0.095033
0.363082
0.355799
0.546417
0.424352
0.146362
0.231176
0.41533
0.352739
0.105076
0.17455
0.176467
0.213247
0.213247
0.175327
0.280837
0.040017
0.235488
0.279217
0.169372
0.081733
0.116
0.211717
0.137464
0.432303
0.420623
0.129723
0.295808
0.187602
0.27973
0.15626
0.206725
0.156068
0.557791
0.389003
0.180575
0.183974
0.183522
0.147767
0.109914
0.14122
0.196802
0.106098
0.449333
0.143026
0.049949
0.409999
0.135357
0.226264
0.389462
0.674799
0.141421
0.058499
0.135277
0.189612
0.130891
0.076531
0.780012
0.212352
0.313454
0.169424
0.168001
0.457493
0.369153
0.136748
0.266114
0.094868
0.094663
0.123688
0.278904
0.106561
0.10151
0.135617
0.321743
0.227175
0.120574
0.323396
0.182553
0.055439
0.418347
0.071572
0.275861
0.253463
Total
24
18
9
98
32
42
14
42
21
33
68
21
21
46
22
16
24
28
60
20
27
9
10
13
31
18
8
12
20
20
30
12
12
4
12
71
10
20
41
38
39
28
31
5
11
41
23
18
77
87
34
19
9
17
15
42
42
120
180
78
45
28
18
28
35
33
10
23
25
16
10
71
29
25
28
73
13
21
11
32
28
18
18
93
16
14
91
65
15
25
17
30
37
21
32
17
8
352
7
5
13
13
3502
Total
24
8
18
93
32
42
14
42
20
33
68
21
21
38
44
16
24
28
60
20
35
10
8
13
115
18
8
12
20
20
44
12
12
4
12
72
11
20
21
78
78
60
31
5
11
41
23
17
36
88
34
19
9
17
15
42
42
60
90
81
45
30
19
28
35
33
10
23
25
17
12
142
29
25
24
59
13
21
11
32
28
19
18
86
65
14
91
65
15
20
40
30
40
22
32
17
8
352
7
5
13
13
3643
Weight
1.1%
0.5%
0.2%
1.1%
0.7%
1.1%
1.5%
2.6%
0.2%
1.9%
1.4%
1.6%
1.3%
0.4%
1.7%
0.2%
0.8%
0.7%
1.5%
1.8%
0.3%
0.3%
0.1%
0.2%
1.2%
0.7%
0.2%
0.3%
1.7%
1.0%
1.0%
0.7%
0.7%
1.0%
0.5%
2.5%
0.6%
0.5%
1.0%
2.0%
1.5%
0.8%
1.3%
0.2%
0.2%
1.4%
0.4%
0.9%
0.5%
1.1%
0.8%
1.1%
0.1%
0.3%
0.9%
0.9%
0.9%
1.2%
1.6%
1.3%
0.8%
1.6%
0.2%
1.2%
2.4%
0.3%
1.3%
0.7%
0.3%
0.1%
1.3%
2.3%
1.3%
0.9%
1.4%
2.0%
0.1%
0.8%
0.4%
1.0%
1.0%
0.2%
0.3%
1.3%
0.5%
1.8%
1.8%
1.4%
0.5%
1.6%
1.7%
1.3%
0.4%
0.7%
1.5%
0.4%
0.9%
2.3%
0.2%
2.1%
0.5%
0.6%
100.0%
IV, Random, 95% CI
-0.24 [-0.55, 0.06]
-0.64 [-1.21, -0.07]
0.31 [-0.65, 1.26]
-0.12 [-0.43, 0.19]
-0.24 [-0.69, 0.21]
-0.15 [-0.46, 0.16]
-0.47 [-0.71, -0.23]
-0.40 [-0.45, -0.34]
-0.93 [-1.99, 0.13]
-0.04 [-0.21, 0.13]
-0.02 [-0.26, 0.22]
0.01 [-0.20, 0.22]
-0.20 [-0.46, 0.06]
0.09 [-0.54, 0.73]
-0.27 [-0.46, -0.07]
0.02 [-0.89, 0.92]
0.13 [-0.25, 0.51]
-0.36 [-0.81, 0.09]
-0.23 [-0.46, -0.01]
-0.25 [-0.44, -0.06]
-0.11 [-0.82, 0.61]
-0.11 [-0.80, 0.59]
-1.16 [-2.23, -0.09]
-0.88 [-1.71, -0.05]
-0.21 [-0.49, 0.08]
-0.14 [-0.59, 0.31]
-0.11 [-0.92, 0.71]
-0.57 [-1.26, 0.12]
-0.16 [-0.37, 0.04]
-0.19 [-0.53, 0.15]
-0.15 [-0.49, 0.20]
-0.03 [-0.44, 0.39]
-0.03 [-0.44, 0.39]
-0.18 [-0.52, 0.16]
-0.03 [-0.58, 0.52]
-0.16 [-0.24, -0.08]
-0.18 [-0.64, 0.28]
-0.45 [-1.00, 0.10]
0.21 [-0.12, 0.55]
-0.45 [-0.61, -0.28]
-0.34 [-0.57, -0.12]
-0.24 [-0.66, 0.17]
-0.08 [-0.35, 0.19]
-0.58 [-1.43, 0.26]
-0.26 [-1.08, 0.56]
-0.40 [-0.65, -0.15]
0.06 [-0.52, 0.64]
-0.37 [-0.74, -0.00]
0.05 [-0.50, 0.60]
0.18 [-0.13, 0.48]
-0.01 [-0.42, 0.39]
-0.52 [-0.82, -0.21]
-0.32 [-1.41, 0.77]
0.02 [-0.75, 0.78]
-0.18 [-0.53, 0.18]
-0.13 [-0.49, 0.23]
-0.23 [-0.59, 0.13]
0.20 [-0.09, 0.49]
-0.27 [-0.48, -0.05]
-0.07 [-0.35, 0.21]
0.07 [-0.31, 0.46]
-0.30 [-0.51, -0.09]
0.19 [-0.69, 1.07]
-0.03 [-0.31, 0.25]
-0.15 [-0.25, -0.05]
-0.08 [-0.88, 0.73]
-0.28 [-0.55, -0.02]
-0.07 [-0.51, 0.37]
-0.28 [-1.04, 0.49]
-0.02 [-1.34, 1.30]
0.00 [-0.28, 0.28]
0.01 [-0.10, 0.13]
-0.12 [-0.39, 0.15]
-0.60 [-0.97, -0.23]
-0.26 [-0.52, -0.00]
-0.40 [-0.55, -0.25]
0.15 [-1.38, 1.67]
-0.64 [-1.06, -0.23]
-0.09 [-0.70, 0.52]
-0.56 [-0.89, -0.23]
-0.04 [-0.37, 0.29]
0.19 [-0.71, 1.09]
0.31 [-0.41, 1.03]
-0.22 [-0.49, 0.05]
-0.39 [-0.91, 0.13]
-0.20 [-0.39, -0.01]
-0.12 [-0.30, 0.07]
-0.59 [-0.83, -0.35]
0.00 [-0.55, 0.55]
-0.09 [-0.30, 0.12]
-0.14 [-0.33, 0.06]
-0.03 [-0.29, 0.24]
-0.04 [-0.67, 0.59]
-0.12 [-0.57, 0.33]
-0.04 [-0.28, 0.19]
-0.10 [-0.73, 0.53]
0.10 [-0.25, 0.46]
-0.08 [-0.18, 0.03]
-0.97 [-1.79, -0.15]
-0.02 [-0.16, 0.12]
-0.21 [-0.75, 0.33]
-0.13 [-0.63, 0.37]
-0.18 [-0.22, -0.14]
Plant Protein
Animal Protein
Mean Difference
Mean Difference
IV, Random, 95% CI
-2
-1
0
1
2
Favours plant protein
Favours animal protein
Downloaded from http://ahajournals.org by on June 4, 2019
  
Figure S6 (Continued). Non-HDL-C Forest Plot, random-effects model. HC=hypercholesterolemic; IF=isoflavones; 
LF=low-fat; N=normal; NIF=no isoflavones; Pre-MS=pre-metabolic syndrome. The pooled effect estimate (diamond) is 
shown. Paired analyses were applied to all crossover trials. The study by Duane et al. 1999 (26) was missing variance data, 
which was imputed using the average standard of the mean differences across included trials based on the respective 
trial’s sample size. Data are expressed as MDs with 95% CIs, using generic inverse-variance random-effects models. 
Inter-study heterogeneity was tested using the Cochran Q statistic (chi-square) at a significance level of P<0.10 and 
quantified by I2, levels of ≥50% represented substantial heterogeneity. 
Mean Difference IV,
 Random, 95% CI  
Lichenstein 2002 (NIF) (53)
42
42
0.9%
-0.23 [-0.59, 0.13]
Liu 2012 (54)
120
60
1.2%
0.20 [-0.09, 0.49]
Liu 2014 (55)
180
90
1.6%
-0.27 [-0.48, -0.05]
Ma 2005 (57)
78
81
1.3%
-0.07 [-0.35, 0.21]
Ma 2011 (58)
45
45
0.8%
0.07 [-0.31, 0.46]
Maki 2010 (59)
28
30
1.6%
-0.30 [-0.51, -0.09]
Markova 2015 (60)
18
19
0.2%
0.19 [-0.69, 1.07]
Matthan 2007 (61)
28
28
1.2%
-0.03 [-0.31, 0.25]
McVeigh 2006 (62)
35
35
2.4%
-0.15 [-0.25, -0.05]
Mercer 1987 (63)
33
33
0.3%
-0.08 [-0.88, 0.73]
Meredith 1989 (64)
10
10
1.3%
-0.28 [-0.55, -0.02]
Meyer 2004 (65)
23
23
0.7%
-0.07 [-0.51, 0.37]
Miraghajani 2013 (66)
25
25
0.3%
-0.28 [-1.04, 0.49]
Napora 2011 (67)
16
17
0.1%
-0.02 [-1.34, 1.30]
Onning 1998 (68)
10
12
1.3%
0.00 [-0.28, 0.28]
Padhi 2015 (69)
71
142
2.3%
0.01 [-0.10, 0.13]
Pipe 2009 (70)
29
29
1.3%
-0.12 [-0.39, 0.15]
Potter 1993 (71)
25
25
0.9%
-0.60 [-0.97, -0.23]
Puska 2002 (72)
28
24
1.4%
-0.26 [-0.52, -0.00]
Puska 2004 (73)
73
59
2.0%
-0.40 [-0.55, -0.25]
Roughead 2005 (74)
13
13
0.1%
0.15 [-1.38, 1.67]
Shidfar 2009 (76)
21
21
0.8%
-0.64 [-1.06, -0.23]
Shige 1998 (77)
11
11
0.4%
-0.09 [-0.70, 0.52]
Steele 1992 (81)
32
32
1.0%
-0.56 [-0.89, -0.23]
Steinberg 2003 (82)
28
28
1.0%
-0.04 [-0.37, 0.29]
Sucher 2016 (83)
18
19
0.2%
0.19 [-0.71, 1.09]
Tabibi 2010 (84)
18
18
0.3%
0.31 [-0.41, 1.03]
Teede 2001 (86)
93
86
1.3%
-0.22 [-0.49, 0.05]
Teixeira 2000 (87)
16
65
0.5%
-0.39 [-0.91, 0.13]
Teixeira 2004 (88)
14
14
1.8%
-0.20 [-0.39, -0.01]
Thorp 2008 (89)
91
91
1.8%
-0.12 [-0.30, 0.07]
Tonstad 2002 (90)
65
65
1.4%
-0.59 [-0.83, -0.35]
van Nielen 2014 (92)
15
15
0.5%
0.00 [-0.55, 0.55]
van Raaij 1981 (93)
25
20
1.6%
-0.09 [-0.30, 0.12]
van Raaij 1982 (93)
17
40
1.7%
-0.14 [-0.33, 0.06]
Vega-Lopez 2010 (95)
30
30
1.3%
-0.03 [-0.29, 0.24]
Vigna 2000 (96)
37
40
0.4%
-0.04 [-0.67, 0.59]
Weisse 2010 (97)
21
22
0.7%
-0.12 [-0.57, 0.33]
West 2005 (98)
32
32
1.5%
-0.04 [-0.28, 0.19]
Wheeler 2002 (99)
17
17
0.4%
-0.10 [-0.73, 0.53]
Wiebe 1984 (100)
8
8
0.9%
0.10 [-0.25, 0.46]
Wofford 2012 (101)
352
352
2.3%
-0.08 [-0.18, 0.03]
Wolfe 1981 (102)
7
7
0.2%
-0.97 [-1.79, -0.15]
Wolfe 1985 (103)
5
5
2.1%
-0.02 [-0.16, 0.12]
Wong 1998 (HC) (104)
13
13
0.5%
-0.21 [-0.75, 0.33]
Wong 1998 (N) (104)
13
13
0.6%
-0.13 [-0.63, 0.37]
Total (95% CI)
3502
3643
100.0%
-0.18 [-0.22, -0.14]
Heterogeneity: Tau² = 0.02; Chi² = 209.94, df = 101 (P < 0.00001); I² = 52%
Test for overall effect: Z = 8.33 (P < 0.00001)
              -2              -1                0                1                 2
      Favours plant protein         Favours animal protein
Study or subgroup
Plant 
protein N
Animal 
protein N
Weight
Mean Difference (95% CI) in non-HDL-C, mmol/L
Study or Subgroup
Abd-Mishani 2014
Abete 2009
Ahmed 2011
Allen 2007
Appt 2008
Ashton 2000
Azadbakht 2003
Azadbakht 2007
Azadbakht 2008
Bahr 2013
Bahr 2014
Bakhit 1994 (Cellulose)
Bakhit 1994 (Cotyledon)
Basaria 2009
Baum 1998
Beavers 2010
Blum 2003
Borodin 2009
Bricarello 2004
Burns-Whitmore 2014
Campbell 2010
Chen 2005 (HC)
Chen 2005 (N)
Chen 2006
Crouse 1999
Cuevas 2003
Duane 1999
Dunn 1986
Finley 2007 (N)
Finley 2007 (Pre-MS)
Gardner 2001
Giovanetti 1986 (LF)
Giovanetti 1986 (N)
Goldberg 1982 (HC)
Goldberg 1982 (N)
Greany 2004
Haub 2005
Hermansen 2001
Hill 2015
Hoie 2005
Hoie 2005B
Hoie 2007
Hosseinpour-Niazi 2014
Huff 1984
Jenkins 1989
Jenkins 2002
Jenkins 2010
Kestin 1989
Kjolbaek 2017
Kreijkamp-Kaspers 2004
Kurowska 1997
Laidlaw 1985
Laurin 1991
Li 2016
Liao 2007
Lichenstein 2002 (IF)
Lichenstein 2002 (NIF)
Liu 2012
Liu 2014
Ma 2005
Ma 2011
Maki 2010
Markova 2015
Matthan 2007
McVeigh 2006
Mercer 1987
Meredith 1989
Meyer 2004
Miraghajani 2013
Napora 2011
Onning 1998
Padhi 2015
Pipe 2009
Potter 1993
Puska 2002
Puska 2004
Roughead 2005
Shidfar 2009
Shige 1998
Steele 1992
Steinberg 2003
Sucher 2016
Tabibi 2010
Teede 2001
Teixeira 2000
Teixeira 2004
Thorp 2008
Tonstad 2002
van Nielen 2014
van Raaij 1981
van Raaij 1982
Vega-Lopez 2010
Vigna 2000
Weisse 2010
West 2005
Wheeler 2002
Wiebe 1984
Wofford 2012
Wolfe 1981
Wolfe 1985
Wong 1998 (HC)
Wong 1998 (N)
Total (95% CI)
Heterogeneity: Tau² = 0.02; Chi² = 209.94, df = 101 (P < 0.00001); I² = 52%
Test for overall effect: Z = 8.33 (P < 0.00001)
Mean Difference
-0.24308
-0.63791
0.307734
-0.11844
-0.24
-0.15
-0.47065
-0.39695
-0.93096
-0.04
-0.02
0.01
-0.2
0.093096
-0.26568
0.018102
0.129817
-0.36204
-0.23274
-0.25
-0.10654
-0.10603
-1.15853
-0.88
-0.20713
-0.13964
-0.10603
-0.57108
-0.16292
-0.18749
-0.14531
-0.02586
-0.02586
-0.18102
-0.02586
-0.16
-0.18
-0.45
0.213061
-0.445
-0.345
-0.24267
-0.07603
-0.58444
-0.26
-0.4
0.06
-0.37
0.050779
0.176262
-0.015
-0.5172
-0.32
0.01618
-0.17843
-0.13
-0.23
0.2
-0.2685
-0.07014
0.070982
-0.30256
0.19
-0.03333
-0.15
-0.07758
-0.28446
-0.07
-0.27618
-0.01991
0
0.015
-0.12
-0.60333
-0.26
-0.4
0.145214
-0.64185
-0.09
-0.5625
-0.04
0.19
0.31032
-0.22
-0.38877
-0.2
-0.115
-0.59169
0
-0.09051
-0.13577
-0.02586
-0.04
-0.12
-0.04375
-0.1
0.10344
-0.07629
-0.9679
-0.01552
-0.21
-0.13
SE
0.154094
0.290274
0.488027
0.157505
0.22769
0.158039
0.121752
0.027906
0.539805
0.085941
0.123668
0.109125
0.132755
0.324324
0.099251
0.462626
0.19502
0.230198
0.115649
0.095033
0.363082
0.355799
0.546417
0.424352
0.146362
0.231176
0.41533
0.352739
0.105076
0.17455
0.176467
0.213247
0.213247
0.175327
0.280837
0.040017
0.235488
0.279217
0.169372
0.081733
0.116
0.211717
0.137464
0.432303
0.420623
0.129723
0.295808
0.187602
0.27973
0.15626
0.206725
0.156068
0.557791
0.389003
0.180575
0.183974
0.183522
0.147767
0.109914
0.14122
0.196802
0.106098
0.449333
0.143026
0.049949
0.409999
0.135357
0.226264
0.389462
0.674799
0.141421
0.058499
0.135277
0.189612
0.130891
0.076531
0.780012
0.212352
0.313454
0.169424
0.168001
0.457493
0.369153
0.136748
0.266114
0.094868
0.094663
0.123688
0.278904
0.106561
0.10151
0.135617
0.321743
0.227175
0.120574
0.323396
0.182553
0.055439
0.418347
0.071572
0.275861
0.253463
Total
24
18
9
98
32
42
14
42
21
33
68
21
21
46
22
16
24
28
60
20
27
9
10
13
31
18
8
12
20
20
30
12
12
4
12
71
10
20
41
38
39
28
31
5
11
41
23
18
77
87
34
19
9
17
15
42
42
120
180
78
45
28
18
28
35
33
10
23
25
16
10
71
29
25
28
73
13
21
11
32
28
18
18
93
16
14
91
65
15
25
17
30
37
21
32
17
8
352
7
5
13
13
3502
Total
24
8
18
93
32
42
14
42
20
33
68
21
21
38
44
16
24
28
60
20
35
10
8
13
115
18
8
12
20
20
44
12
12
4
12
72
11
20
21
78
78
60
31
5
11
41
23
17
36
88
34
19
9
17
15
42
42
60
90
81
45
30
19
28
35
33
10
23
25
17
12
142
29
25
24
59
13
21
11
32
28
19
18
86
65
14
91
65
15
20
40
30
40
22
32
17
8
352
7
5
13
13
3643
Weight
1.1%
0.5%
0.2%
1.1%
0.7%
1.1%
1.5%
2.6%
0.2%
1.9%
1.4%
1.6%
1.3%
0.4%
1.7%
0.2%
0.8%
0.7%
1.5%
1.8%
0.3%
0.3%
0.1%
0.2%
1.2%
0.7%
0.2%
0.3%
1.7%
1.0%
1.0%
0.7%
0.7%
1.0%
0.5%
2.5%
0.6%
0.5%
1.0%
2.0%
1.5%
0.8%
1.3%
0.2%
0.2%
1.4%
0.4%
0.9%
0.5%
1.1%
0.8%
1.1%
0.1%
0.3%
0.9%
0.9%
0.9%
1.2%
1.6%
1.3%
0.8%
1.6%
0.2%
1.2%
2.4%
0.3%
1.3%
0.7%
0.3%
0.1%
1.3%
2.3%
1.3%
0.9%
1.4%
2.0%
0.1%
0.8%
0.4%
1.0%
1.0%
0.2%
0.3%
1.3%
0.5%
1.8%
1.8%
1.4%
0.5%
1.6%
1.7%
1.3%
0.4%
0.7%
1.5%
0.4%
0.9%
2.3%
0.2%
2.1%
0.5%
0.6%
100.0%
IV, Random, 95% CI
-0.24 [-0.55, 0.06]
-0.64 [-1.21, -0.07]
0.31 [-0.65, 1.26]
-0.12 [-0.43, 0.19]
-0.24 [-0.69, 0.21]
-0.15 [-0.46, 0.16]
-0.47 [-0.71, -0.23]
-0.40 [-0.45, -0.34]
-0.93 [-1.99, 0.13]
-0.04 [-0.21, 0.13]
-0.02 [-0.26, 0.22]
0.01 [-0.20, 0.22]
-0.20 [-0.46, 0.06]
0.09 [-0.54, 0.73]
-0.27 [-0.46, -0.07]
0.02 [-0.89, 0.92]
0.13 [-0.25, 0.51]
-0.36 [-0.81, 0.09]
-0.23 [-0.46, -0.01]
-0.25 [-0.44, -0.06]
-0.11 [-0.82, 0.61]
-0.11 [-0.80, 0.59]
-1.16 [-2.23, -0.09]
-0.88 [-1.71, -0.05]
-0.21 [-0.49, 0.08]
-0.14 [-0.59, 0.31]
-0.11 [-0.92, 0.71]
-0.57 [-1.26, 0.12]
-0.16 [-0.37, 0.04]
-0.19 [-0.53, 0.15]
-0.15 [-0.49, 0.20]
-0.03 [-0.44, 0.39]
-0.03 [-0.44, 0.39]
-0.18 [-0.52, 0.16]
-0.03 [-0.58, 0.52]
-0.16 [-0.24, -0.08]
-0.18 [-0.64, 0.28]
-0.45 [-1.00, 0.10]
0.21 [-0.12, 0.55]
-0.45 [-0.61, -0.28]
-0.34 [-0.57, -0.12]
-0.24 [-0.66, 0.17]
-0.08 [-0.35, 0.19]
-0.58 [-1.43, 0.26]
-0.26 [-1.08, 0.56]
-0.40 [-0.65, -0.15]
0.06 [-0.52, 0.64]
-0.37 [-0.74, -0.00]
0.05 [-0.50, 0.60]
0.18 [-0.13, 0.48]
-0.01 [-0.42, 0.39]
-0.52 [-0.82, -0.21]
-0.32 [-1.41, 0.77]
0.02 [-0.75, 0.78]
-0.18 [-0.53, 0.18]
-0.13 [-0.49, 0.23]
-0.23 [-0.59, 0.13]
0.20 [-0.09, 0.49]
-0.27 [-0.48, -0.05]
-0.07 [-0.35, 0.21]
0.07 [-0.31, 0.46]
-0.30 [-0.51, -0.09]
0.19 [-0.69, 1.07]
-0.03 [-0.31, 0.25]
-0.15 [-0.25, -0.05]
-0.08 [-0.88, 0.73]
-0.28 [-0.55, -0.02]
-0.07 [-0.51, 0.37]
-0.28 [-1.04, 0.49]
-0.02 [-1.34, 1.30]
0.00 [-0.28, 0.28]
0.01 [-0.10, 0.13]
-0.12 [-0.39, 0.15]
-0.60 [-0.97, -0.23]
-0.26 [-0.52, -0.00]
-0.40 [-0.55, -0.25]
0.15 [-1.38, 1.67]
-0.64 [-1.06, -0.23]
-0.09 [-0.70, 0.52]
-0.56 [-0.89, -0.23]
-0.04 [-0.37, 0.29]
0.19 [-0.71, 1.09]
0.31 [-0.41, 1.03]
-0.22 [-0.49, 0.05]
-0.39 [-0.91, 0.13]
-0.20 [-0.39, -0.01]
-0.12 [-0.30, 0.07]
-0.59 [-0.83, -0.35]
0.00 [-0.55, 0.55]
-0.09 [-0.30, 0.12]
-0.14 [-0.33, 0.06]
-0.03 [-0.29, 0.24]
-0.04 [-0.67, 0.59]
-0.12 [-0.57, 0.33]
-0.04 [-0.28, 0.19]
-0.10 [-0.73, 0.53]
0.10 [-0.25, 0.46]
-0.08 [-0.18, 0.03]
-0.97 [-1.79, -0.15]
-0.02 [-0.16, 0.12]
-0.21 [-0.75, 0.33]
-0.13 [-0.63, 0.37]
-0.18 [-0.22, -0.14]
Plant Protein Animal Protein
Mean Difference
Mean Difference
IV, Random, 95% CI
-2
-1
0
1
2
Favours plant protein
Favours animal protein
Downloaded from http://ahajournals.org by on June 4, 2019
  
 
Figure S7. Non-HDL-C Forest Plot, fixed-effects model.  
Mean Difference IV,
 Fixed, 95% CI  
Abd-Mishani 2014 (1)
24
24
0.6%
-0.24 [-0.55, 0.06]
Abete 2009 (2)
18
8
0.2%
-0.64 [-1.21, -0.07]
Ahmed 2011 (3)
9
18
0.1%
0.31 [-0.65, 1.26]
Allen 2007 (4)
98
93
0.6%
-0.12 [-0.43, 0.19]
Appt 2008 (5)
32
32
0.3%
-0.24 [-0.69, 0.21]
Ashton 2000 (6)
42
42
0.6%
-0.15 [-0.46, 0.16]
Azadbakht 2003 (7)
14
14
1.0%
-0.47 [-0.71, -0.23]
Azadbakht 2007 (8)
42
42
19.0%
-0.40 [-0.45, -0.34]
Azadbakht 2008 (9)
21
20
0.1%
-0.93 [-1.99, 0.13]
Bahr 2013 (10)
33
33
2.0%
-0.04 [-0.21, 0.13]
Bahr 2014 (11)
68
68
1.0%
-0.02 [-0.26, 0.22]
Bakhit 1994 (Cellulose) (12)
21
21
1.2%
0.01 [-0.20, 0.22]
Bakhit 1994 (Cotyledon) (12)
21
21
0.8%
-0.20 [-0.46, 0.06]
Basaria 2009 (13)
46
38
0.1%
0.09 [-0.54, 0.73]
Baum 1998 (14)
22
44
1.5%
-0.27 [-0.46, -0.07]
Beavers 2010 (15)
16
16
0.1%
0.02 [-0.89, 0.92]
Blum 2003 (16)
24
24
0.4%
0.13 [-0.25, 0.51]
Borodin 2009 (17)
28
28
0.3%
-0.36 [-0.81, 0.09]
Bricarello 2004 (18)
60
60
1.1%
-0.23 [-0.46, -0.01]
Burns-Whitmore 2014 (19)
20
20
1.6%
-0.25 [-0.44, -0.06]
Campbell 2010 (20)
27
35
0.1%
-0.11 [-0.82, 0.61]
Chen 2005 (HC) (21)
9
10
0.1%
-0.11 [-0.80, 0.59]
Chen 2005 (N) (21)
10
8
0.0%
-1.16 [-2.23, -0.09]
Chen 2006 (22)
13
13
0.1%
-0.88 [-1.71, -0.05]
Crouse 1999 (23)
31
115
0.7%
-0.21 [-0.49, 0.08]
Cuevas 2003 (24)
18
18
0.3%
-0.14 [-0.59, 0.31]
Duane 1999 (26)
8
8
0.1%
-0.11 [-0.92, 0.71]
Dunn 1986 (27)
12
12
0.1%
-0.57 [-1.26, 0.12]
Finley 2007 (N) (28)
20
20
1.3%
-0.16 [-0.37, 0.04]
Finley 2007 (Pre-MS) (28)
20
20
0.5%
-0.19 [-0.53, 0.15]
Gardner 2001 (29)
30
44
0.5%
-0.15 [-0.49, 0.20]
Giovanetti 1986 (LF) (31)
12
12
0.3%
-0.03 [-0.44, 0.39]
Giovanetti 1986 (N) (31)
12
12
0.3%
-0.03 [-0.44, 0.39]
Goldberg 1982 (HC) (32)
4
4
0.5%
-0.18 [-0.52, 0.16]
Goldberg 1982 (N) (32)
12
12
0.2%
-0.03 [-0.58, 0.52]
Greany 2004 (33)
71
72
9.2%
-0.16 [-0.24, -0.08]
Haub 2005 (34)
10
11
0.3%
-0.18 [-0.64, 0.28]
Hermansen 2001 (35)
20
20
0.2%
-0.45 [-1.00, 0.10]
Hill 2015 (36)
41
21
0.5%
0.21 [-0.12, 0.55]
Hoie 2005 (37)
38
78
2.2%
-0.45 [-0.61, -0.28]
Hoie 2005B (38)
39
78
1.1%
-0.34 [-0.57, -0.12]
Hoie 2007 (39)
28
60
0.3%
-0.24 [-0.66, 0.17]
Hosseinpour-Niazi 2014 (40)
31
31
0.8%
-0.08 [-0.35, 0.19]
Huff 1984 (41)
5
5
0.1%
-0.58 [-1.43, 0.26]
Jenkins 1989 (42)
11
11
0.1%
-0.26 [-1.08, 0.56]
Jenkins 2002 (43)
41
41
0.9%
-0.40 [-0.65, -0.15]
Jenkins 2010 (44)
23
23
0.2%
0.06 [-0.52, 0.64]
Kestin 1989 (45)
18
17
0.4%
-0.37 [-0.74, -0.00]
Kjolbaek 2017 (46)
77
36
0.2%
0.05 [-0.50, 0.60]
Kreijkamp-Kaspers 2004 (47)
87
88
0.6%
0.18 [-0.13, 0.48]
Kurowska 1997 (48)
34
34
0.3%
-0.01 [-0.42, 0.39]
Laidlaw 1985 (49)
19
19
0.6%
-0.52 [-0.82, -0.21]
Laurin 1991 (50)
9
9
0.0%
-0.32 [-1.41, 0.77]
Li 2016 (51)
17
17
0.1%
0.02 [-0.75, 0.78]
Liao 2007 (52)
15
15
0.5%
-0.18 [-0.53, 0.18]
Lichenstein 2002 (IF) (53)
42
42
0.4%
-0.13 [-0.49, 0.23]
                -2              -1               0               1               2
      Favours plant protein         Favours animal protein
Study or subgroup
Plant 
protein N
Animal 
protein N
Weight
Mean Difference (95% CI) in non-HDL-C, mmol/L
Study or Subgroup
Abd-Mishani 2014
Abete 2009
Ahmed 2011
Allen 2007
Appt 2008
Ashton 2000
Azadbakht 2003
Azadbakht 2007
Azadbakht 2008
Bahr 2013
Bahr 2014
Bakhit 1994 (Cellulose)
Bakhit 1994 (Cotyledon)
Basaria 2009
Baum 1998
Beavers 2010
Blum 2003
Borodin 2009
Bricarello 2004
Burns-Whitmore 2014
Campbell 2010
Chen 2005 (HC)
Chen 2005 (N)
Chen 2006
Crouse 1999
Cuevas 2003
Duane 1999
Dunn 1986
Finley 2007 (N)
Finley 2007 (Pre-MS)
Gardner 2001
Giovanetti 1986 (LF)
Giovanetti 1986 (N)
Goldberg 1982 (HC)
Goldberg 1982 (N)
Greany 2004
Haub 2005
Hermansen 2001
Hill 2015
Hoie 2005
Hoie 2005B
Hoie 2007
Hosseinpour-Niazi 2014
Huff 1984
Jenkins 1989
Jenkins 2002
Jenkins 2010
Kestin 1989
Kjolbaek 2017
Kreijkamp-Kaspers 2004
Kurowska 1997
Laidlaw 1985
Laurin 1991
Li 2016
Liao 2007
Lichenstein 2002 (IF)
Lichenstein 2002 (NIF)
Liu 2012
Liu 2014
Ma 2005
Ma 2011
Maki 2010
Markova 2015
Matthan 2007
McVeigh 2006
Mercer 1987
Meredith 1989
Meyer 2004
Miraghajani 2013
Napora 2011
Onning 1998
Padhi 2015
Pipe 2009
Potter 1993
Puska 2002
Puska 2004
Roughead 2005
Shidfar 2009
Shige 1998
Steele 1992
Steinberg 2003
Sucher 2016
Tabibi 2010
Teede 2001
Teixeira 2000
Teixeira 2004
Thorp 2008
Tonstad 2002
van Nielen 2014
van Raaij 1981
van Raaij 1982
Vega-Lopez 2010
Vigna 2000
Weisse 2010
West 2005
Wheeler 2002
Wiebe 1984
Wofford 2012
Wolfe 1981
Wolfe 1985
Wong 1998 (HC)
Wong 1998 (N)
Total (95% CI)
Heterogeneity: Tau² = 0.02; Chi² = 209.94, df = 101 (P < 0.00001); I² = 52%
Test for overall effect: Z = 8.33 (P < 0.00001)
Mean Difference
-0.24308
-0.63791
0.307734
-0.11844
-0.24
-0.15
-0.47065
-0.39695
-0.93096
-0.04
-0.02
0.01
-0.2
0.093096
-0.26568
0.018102
0.129817
-0.36204
-0.23274
-0.25
-0.10654
-0.10603
-1.15853
-0.88
-0.20713
-0.13964
-0.10603
-0.57108
-0.16292
-0.18749
-0.14531
-0.02586
-0.02586
-0.18102
-0.02586
-0.16
-0.18
-0.45
0.213061
-0.445
-0.345
-0.24267
-0.07603
-0.58444
-0.26
-0.4
0.06
-0.37
0.050779
0.176262
-0.015
-0.5172
-0.32
0.01618
-0.17843
-0.13
-0.23
0.2
-0.2685
-0.07014
0.070982
-0.30256
0.19
-0.03333
-0.15
-0.07758
-0.28446
-0.07
-0.27618
-0.01991
0
0.015
-0.12
-0.60333
-0.26
-0.4
0.145214
-0.64185
-0.09
-0.5625
-0.04
0.19
0.31032
-0.22
-0.38877
-0.2
-0.115
-0.59169
0
-0.09051
-0.13577
-0.02586
-0.04
-0.12
-0.04375
-0.1
0.10344
-0.07629
-0.9679
-0.01552
-0.21
-0.13
SE
0.154094
0.290274
0.488027
0.157505
0.22769
0.158039
0.121752
0.027906
0.539805
0.085941
0.123668
0.109125
0.132755
0.324324
0.099251
0.462626
0.19502
0.230198
0.115649
0.095033
0.363082
0.355799
0.546417
0.424352
0.146362
0.231176
0.41533
0.352739
0.105076
0.17455
0.176467
0.213247
0.213247
0.175327
0.280837
0.040017
0.235488
0.279217
0.169372
0.081733
0.116
0.211717
0.137464
0.432303
0.420623
0.129723
0.295808
0.187602
0.27973
0.15626
0.206725
0.156068
0.557791
0.389003
0.180575
0.183974
0.183522
0.147767
0.109914
0.14122
0.196802
0.106098
0.449333
0.143026
0.049949
0.409999
0.135357
0.226264
0.389462
0.674799
0.141421
0.058499
0.135277
0.189612
0.130891
0.076531
0.780012
0.212352
0.313454
0.169424
0.168001
0.457493
0.369153
0.136748
0.266114
0.094868
0.094663
0.123688
0.278904
0.106561
0.10151
0.135617
0.321743
0.227175
0.120574
0.323396
0.182553
0.055439
0.418347
0.071572
0.275861
0.253463
Total
24
18
9
98
32
42
14
42
21
33
68
21
21
46
22
16
24
28
60
20
27
9
10
13
31
18
8
12
20
20
30
12
12
4
12
71
10
20
41
38
39
28
31
5
11
41
23
18
77
87
34
19
9
17
15
42
42
120
180
78
45
28
18
28
35
33
10
23
25
16
10
71
29
25
28
73
13
21
11
32
28
18
18
93
16
14
91
65
15
25
17
30
37
21
32
17
8
352
7
5
13
13
3502
Total
24
8
18
93
32
42
14
42
20
33
68
21
21
38
44
16
24
28
60
20
35
10
8
13
115
18
8
12
20
20
44
12
12
4
12
72
11
20
21
78
78
60
31
5
11
41
23
17
36
88
34
19
9
17
15
42
42
60
90
81
45
30
19
28
35
33
10
23
25
17
12
142
29
25
24
59
13
21
11
32
28
19
18
86
65
14
91
65
15
20
40
30
40
22
32
17
8
352
7
5
13
13
3643
Weight
1.1%
0.5%
0.2%
1.1%
0.7%
1.1%
1.5%
2.6%
0.2%
1.9%
1.4%
1.6%
1.3%
0.4%
1.7%
0.2%
0.8%
0.7%
1.5%
1.8%
0.3%
0.3%
0.1%
0.2%
1.2%
0.7%
0.2%
0.3%
1.7%
1.0%
1.0%
0.7%
0.7%
1.0%
0.5%
2.5%
0.6%
0.5%
1.0%
2.0%
1.5%
0.8%
1.3%
0.2%
0.2%
1.4%
0.4%
0.9%
0.5%
1.1%
0.8%
1.1%
0.1%
0.3%
0.9%
0.9%
0.9%
1.2%
1.6%
1.3%
0.8%
1.6%
0.2%
1.2%
2.4%
0.3%
1.3%
0.7%
0.3%
0.1%
1.3%
2.3%
1.3%
0.9%
1.4%
2.0%
0.1%
0.8%
0.4%
1.0%
1.0%
0.2%
0.3%
1.3%
0.5%
1.8%
1.8%
1.4%
0.5%
1.6%
1.7%
1.3%
0.4%
0.7%
1.5%
0.4%
0.9%
2.3%
0.2%
2.1%
0.5%
0.6%
100.0%
IV, Random, 95% CI
-0.24 [-0.55, 0.06]
-0.64 [-1.21, -0.07]
0.31 [-0.65, 1.26]
-0.12 [-0.43, 0.19]
-0.24 [-0.69, 0.21]
-0.15 [-0.46, 0.16]
-0.47 [-0.71, -0.23]
-0.40 [-0.45, -0.34]
-0.93 [-1.99, 0.13]
-0.04 [-0.21, 0.13]
-0.02 [-0.26, 0.22]
0.01 [-0.20, 0.22]
-0.20 [-0.46, 0.06]
0.09 [-0.54, 0.73]
-0.27 [-0.46, -0.07]
0.02 [-0.89, 0.92]
0.13 [-0.25, 0.51]
-0.36 [-0.81, 0.09]
-0.23 [-0.46, -0.01]
-0.25 [-0.44, -0.06]
-0.11 [-0.82, 0.61]
-0.11 [-0.80, 0.59]
-1.16 [-2.23, -0.09]
-0.88 [-1.71, -0.05]
-0.21 [-0.49, 0.08]
-0.14 [-0.59, 0.31]
-0.11 [-0.92, 0.71]
-0.57 [-1.26, 0.12]
-0.16 [-0.37, 0.04]
-0.19 [-0.53, 0.15]
-0.15 [-0.49, 0.20]
-0.03 [-0.44, 0.39]
-0.03 [-0.44, 0.39]
-0.18 [-0.52, 0.16]
-0.03 [-0.58, 0.52]
-0.16 [-0.24, -0.08]
-0.18 [-0.64, 0.28]
-0.45 [-1.00, 0.10]
0.21 [-0.12, 0.55]
-0.45 [-0.61, -0.28]
-0.34 [-0.57, -0.12]
-0.24 [-0.66, 0.17]
-0.08 [-0.35, 0.19]
-0.58 [-1.43, 0.26]
-0.26 [-1.08, 0.56]
-0.40 [-0.65, -0.15]
0.06 [-0.52, 0.64]
-0.37 [-0.74, -0.00]
0.05 [-0.50, 0.60]
0.18 [-0.13, 0.48]
-0.01 [-0.42, 0.39]
-0.52 [-0.82, -0.21]
-0.32 [-1.41, 0.77]
0.02 [-0.75, 0.78]
-0.18 [-0.53, 0.18]
-0.13 [-0.49, 0.23]
-0.23 [-0.59, 0.13]
0.20 [-0.09, 0.49]
-0.27 [-0.48, -0.05]
-0.07 [-0.35, 0.21]
0.07 [-0.31, 0.46]
-0.30 [-0.51, -0.09]
0.19 [-0.69, 1.07]
-0.03 [-0.31, 0.25]
-0.15 [-0.25, -0.05]
-0.08 [-0.88, 0.73]
-0.28 [-0.55, -0.02]
-0.07 [-0.51, 0.37]
-0.28 [-1.04, 0.49]
-0.02 [-1.34, 1.30]
0.00 [-0.28, 0.28]
0.01 [-0.10, 0.13]
-0.12 [-0.39, 0.15]
-0.60 [-0.97, -0.23]
-0.26 [-0.52, -0.00]
-0.40 [-0.55, -0.25]
0.15 [-1.38, 1.67]
-0.64 [-1.06, -0.23]
-0.09 [-0.70, 0.52]
-0.56 [-0.89, -0.23]
-0.04 [-0.37, 0.29]
0.19 [-0.71, 1.09]
0.31 [-0.41, 1.03]
-0.22 [-0.49, 0.05]
-0.39 [-0.91, 0.13]
-0.20 [-0.39, -0.01]
-0.12 [-0.30, 0.07]
-0.59 [-0.83, -0.35]
0.00 [-0.55, 0.55]
-0.09 [-0.30, 0.12]
-0.14 [-0.33, 0.06]
-0.03 [-0.29, 0.24]
-0.04 [-0.67, 0.59]
-0.12 [-0.57, 0.33]
-0.04 [-0.28, 0.19]
-0.10 [-0.73, 0.53]
0.10 [-0.25, 0.46]
-0.08 [-0.18, 0.03]
-0.97 [-1.79, -0.15]
-0.02 [-0.16, 0.12]
-0.21 [-0.75, 0.33]
-0.13 [-0.63, 0.37]
-0.18 [-0.22, -0.14]
Plant Protein
Animal Protein
Mean Difference
Mean Difference
IV, Random, 95% CI
-2
-1
0
1
2
Favours plant protein
Favours animal protein
Study or Subgroup
Abd-Mishani 2014
Abete 2009
Ahmed 2011
Allen 2007
Appt 2008
Ashton 2000
Azadbakht 2003
Azadbakht 2007
Azadbakht 2008
Bahr 2013
Bahr 2014
Bakhit 1994 (Cellulose)
Bakhit 1994 (Cotyledon)
Basaria 2009
Baum 1998
Beavers 2010
Blum 2003
Borodin 2009
Bricarello 2004
Burns-Whitmore 2014
Campbell 2010
Chen 2005 (HC)
Chen 2005 (N)
Chen 2006
Crouse 1999
Cuevas 2003
Duane 1999
Dunn 1986
Finley 2007 (N)
Finley 2007 (Pre-MS)
Gardner 2001
Giovanetti 1986 (LF)
Giovanetti 1986 (N)
Goldberg 1982 (HC)
Goldberg 1982 (N)
Greany 2004
Haub 2005
Hermansen 2001
Hill 2015
Hoie 2005
Hoie 2005B
Hoie 2007
Hosseinpour-Niazi 2014
Huff 1984
Jenkins 1989
Jenkins 2002
Jenkins 2010
Kestin 1989
Kjolbaek 2017
Kreijkamp-Kaspers 2004
Kurowska 1997
Laidlaw 1985
Laurin 1991
Li 2016
Liao 2007
Lichenstein 2002 (IF)
Lichenstein 2002 (NIF)
Liu 2012
Liu 2014
Ma 2005
Ma 2011
Maki 2010
Markova 2015
Matthan 2007
McVeigh 2006
Mercer 1987
Meredith 1989
Meyer 2004
Miraghajani 2013
Napora 2011
Onning 1998
Padhi 2015
Pipe 2009
Potter 1993
Puska 2002
Puska 2004
Roughead 2005
Shidfar 2009
Shige 1998
Steele 1992
Steinberg 2003
Sucher 2016
Tabibi 2010
Teede 2001
Teixeira 2000
Teixeira 2004
Thorp 2008
Tonstad 2002
van Nielen 2014
van Raaij 1981
van Raaij 1982
Vega-Lopez 2010
Vigna 2000
Weisse 2010
West 2005
Wheeler 2002
Wiebe 1984
Wofford 2012
Wolfe 1981
Wolfe 1985
Wong 1998 (HC)
Wong 1998 (N)
Total (95% CI)
Heterogeneity: Chi² = 209.94, df = 101 (P < 0.00001); I² = 52%
Test for overall effect: Z = 17.17 (P < 0.00001)
Mean Difference
-0.24308
-0.63791
0.307734
-0.11844
-0.24
-0.15
-0.47065
-0.39695
-0.93096
-0.04
-0.02
0.01
-0.2
0.093096
-0.26568
0.018102
0.129817
-0.36204
-0.23274
-0.25
-0.10654
-0.10603
-1.15853
-0.88
-0.20713
-0.13964
-0.10603
-0.57108
-0.16292
-0.18749
-0.14531
-0.02586
-0.02586
-0.18102
-0.02586
-0.16
-0.18
-0.45
0.213061
-0.445
-0.345
-0.24267
-0.07603
-0.58444
-0.26
-0.4
0.06
-0.37
0.050779
0.176262
-0.015
-0.5172
-0.32
0.01618
-0.17843
-0.13
-0.23
0.2
-0.2685
-0.07014
0.070982
-0.30256
0.19
-0.03333
-0.15
-0.07758
-0.28446
-0.07
-0.27618
-0.01991
0
0.015
-0.12
-0.60333
-0.26
-0.4
0.145214
-0.64185
-0.09
-0.5625
-0.04
0.19
0.31032
-0.22
-0.38877
-0.2
-0.115
-0.59169
0
-0.09051
-0.13577
-0.02586
-0.04
-0.12
-0.04375
-0.1
0.10344
-0.07629
-0.9679
-0.01552
-0.21
-0.13
SE
0.154094
0.290274
0.488027
0.157505
0.22769
0.158039
0.121752
0.027906
0.539805
0.085941
0.123668
0.109125
0.132755
0.324324
0.099251
0.462626
0.19502
0.230198
0.115649
0.095033
0.363082
0.355799
0.546417
0.424352
0.146362
0.231176
0.41533
0.352739
0.105076
0.17455
0.176467
0.213247
0.213247
0.175327
0.280837
0.040017
0.235488
0.279217
0.169372
0.081733
0.116
0.211717
0.137464
0.432303
0.420623
0.129723
0.295808
0.187602
0.27973
0.15626
0.206725
0.156068
0.557791
0.389003
0.180575
0.183974
0.183522
0.147767
0.109914
0.14122
0.196802
0.106098
0.449333
0.143026
0.049949
0.409999
0.135357
0.226264
0.389462
0.674799
0.141421
0.058499
0.135277
0.189612
0.130891
0.076531
0.780012
0.212352
0.313454
0.169424
0.168001
0.457493
0.369153
0.136748
0.266114
0.094868
0.094663
0.123688
0.278904
0.106561
0.10151
0.135617
0.321743
0.227175
0.120574
0.323396
0.182553
0.055439
0.418347
0.071572
0.275861
0.253463
Total
24
18
9
98
32
42
14
42
21
33
68
21
21
46
22
16
24
28
60
20
27
9
10
13
31
18
8
12
20
20
30
12
12
4
12
71
10
20
41
38
39
28
31
5
11
41
23
18
77
87
34
19
9
17
15
42
42
120
180
78
45
28
18
28
35
33
10
23
25
16
10
71
29
25
28
73
13
21
11
32
28
18
18
93
16
14
91
65
15
25
17
30
37
21
32
17
8
352
7
5
13
13
3502
Total
24
8
18
93
32
42
14
42
20
33
68
21
21
38
44
16
24
28
60
20
35
10
8
13
115
18
8
12
20
20
44
12
12
4
12
72
11
20
21
78
78
60
31
5
11
41
23
17
36
88
34
19
9
17
15
42
42
60
90
81
45
30
19
28
35
33
10
23
25
17
12
142
29
25
24
59
13
21
11
32
28
19
18
86
65
14
91
65
15
20
40
30
40
22
32
17
8
352
7
5
13
13
3643
Weight
0.6%
0.2%
0.1%
0.6%
0.3%
0.6%
1.0%
19.0%
0.1%
2.0%
1.0%
1.2%
0.8%
0.1%
1.5%
0.1%
0.4%
0.3%
1.1%
1.6%
0.1%
0.1%
0.0%
0.1%
0.7%
0.3%
0.1%
0.1%
1.3%
0.5%
0.5%
0.3%
0.3%
0.5%
0.2%
9.2%
0.3%
0.2%
0.5%
2.2%
1.1%
0.3%
0.8%
0.1%
0.1%
0.9%
0.2%
0.4%
0.2%
0.6%
0.3%
0.6%
0.0%
0.1%
0.5%
0.4%
0.4%
0.7%
1.2%
0.7%
0.4%
1.3%
0.1%
0.7%
5.9%
0.1%
0.8%
0.3%
0.1%
0.0%
0.7%
4.3%
0.8%
0.4%
0.9%
2.5%
0.0%
0.3%
0.2%
0.5%
0.5%
0.1%
0.1%
0.8%
0.2%
1.6%
1.6%
1.0%
0.2%
1.3%
1.4%
0.8%
0.1%
0.3%
1.0%
0.1%
0.4%
4.8%
0.1%
2.9%
0.2%
0.2%
100.0%
IV, Fixed, 95% CI
-0.24 [-0.55, 0.06]
-0.64 [-1.21, -0.07]
0.31 [-0.65, 1.26]
-0.12 [-0.43, 0.19]
-0.24 [-0.69, 0.21]
-0.15 [-0.46, 0.16]
-0.47 [-0.71, -0.23]
-0.40 [-0.45, -0.34]
-0.93 [-1.99, 0.13]
-0.04 [-0.21, 0.13]
-0.02 [-0.26, 0.22]
0.01 [-0.20, 0.22]
-0.20 [-0.46, 0.06]
0.09 [-0.54, 0.73]
-0.27 [-0.46, -0.07]
0.02 [-0.89, 0.92]
0.13 [-0.25, 0.51]
-0.36 [-0.81, 0.09]
-0.23 [-0.46, -0.01]
-0.25 [-0.44, -0.06]
-0.11 [-0.82, 0.61]
-0.11 [-0.80, 0.59]
-1.16 [-2.23, -0.09]
-0.88 [-1.71, -0.05]
-0.21 [-0.49, 0.08]
-0.14 [-0.59, 0.31]
-0.11 [-0.92, 0.71]
-0.57 [-1.26, 0.12]
-0.16 [-0.37, 0.04]
-0.19 [-0.53, 0.15]
-0.15 [-0.49, 0.20]
-0.03 [-0.44, 0.39]
-0.03 [-0.44, 0.39]
-0.18 [-0.52, 0.16]
-0.03 [-0.58, 0.52]
-0.16 [-0.24, -0.08]
-0.18 [-0.64, 0.28]
-0.45 [-1.00, 0.10]
0.21 [-0.12, 0.55]
-0.45 [-0.61, -0.28]
-0.34 [-0.57, -0.12]
-0.24 [-0.66, 0.17]
-0.08 [-0.35, 0.19]
-0.58 [-1.43, 0.26]
-0.26 [-1.08, 0.56]
-0.40 [-0.65, -0.15]
0.06 [-0.52, 0.64]
-0.37 [-0.74, -0.00]
0.05 [-0.50, 0.60]
0.18 [-0.13, 0.48]
-0.01 [-0.42, 0.39]
-0.52 [-0.82, -0.21]
-0.32 [-1.41, 0.77]
0.02 [-0.75, 0.78]
-0.18 [-0.53, 0.18]
-0.13 [-0.49, 0.23]
-0.23 [-0.59, 0.13]
0.20 [-0.09, 0.49]
-0.27 [-0.48, -0.05]
-0.07 [-0.35, 0.21]
0.07 [-0.31, 0.46]
-0.30 [-0.51, -0.09]
0.19 [-0.69, 1.07]
-0.03 [-0.31, 0.25]
-0.15 [-0.25, -0.05]
-0.08 [-0.88, 0.73]
-0.28 [-0.55, -0.02]
-0.07 [-0.51, 0.37]
-0.28 [-1.04, 0.49]
-0.02 [-1.34, 1.30]
0.00 [-0.28, 0.28]
0.01 [-0.10, 0.13]
-0.12 [-0.39, 0.15]
-0.60 [-0.97, -0.23]
-0.26 [-0.52, -0.00]
-0.40 [-0.55, -0.25]
0.15 [-1.38, 1.67]
-0.64 [-1.06, -0.23]
-0.09 [-0.70, 0.52]
-0.56 [-0.89, -0.23]
-0.04 [-0.37, 0.29]
0.19 [-0.71, 1.09]
0.31 [-0.41, 1.03]
-0.22 [-0.49, 0.05]
-0.39 [-0.91, 0.13]
-0.20 [-0.39, -0.01]
-0.12 [-0.30, 0.07]
-0.59 [-0.83, -0.35]
0.00 [-0.55, 0.55]
-0.09 [-0.30, 0.12]
-0.14 [-0.33, 0.06]
-0.03 [-0.29, 0.24]
-0.04 [-0.67, 0.59]
-0.12 [-0.57, 0.33]
-0.04 [-0.28, 0.19]
-0.10 [-0.73, 0.53]
0.10 [-0.25, 0.46]
-0.08 [-0.18, 0.03]
-0.97 [-1.79, -0.15]
-0.02 [-0.16, 0.12]
-0.21 [-0.75, 0.33]
-0.13 [-0.63, 0.37]
-0.21 [-0.23, -0.18]
Plant Protein Animal Protein
Mean Difference
Mean Difference
IV, Fixed, 95% CI
-2
-1
0
1
2
Favours plant protein
Favours animal protein
Downloaded from http://ahajournals.org by on June 4, 2019
  
Figure S7 (Continued). Non-HDL-C Forest Plot, fixed-effects model. HC=hypercholesterolemic; IF=isoflavones; 
LF=low-fat; N=normal; NIF=no isoflavones; Pre-MS=pre-metabolic syndrome. The pooled effect estimate (diamond) is 
shown. Paired analyses were applied to all crossover trials. The study by Duane et al. 1999 (26) was missing variance data, 
which was imputed using the average standard of the mean differences across included trials based on the respective 
trial’s sample size. Data are expressed as MDs with 95% CIs, using generic inverse-variance fixed-effects models. Inter-
study heterogeneity was tested using the Cochran Q statistic (chi-square) at a significance level of P<0.10 and quantified 
by I2, levels of ≥50% represented substantial heterogeneity. 
 
Mean Difference IV,
 Fixed, 95% CI  
Lichenstein 2002 (NIF) (53)
42
42
0.4%
-0.23 [-0.59, 0.13]
Liu 2012 (54)
120
60
0.7%
0.20 [-0.09, 0.49]
Liu 2014 (55)
180
90
1.2%
-0.27 [-0.48, -0.05]
Ma 2005 (57)
78
81
0.7%
-0.07 [-0.35, 0.21]
Ma 2011 (58)
45
45
0.4%
0.07 [-0.31, 0.46]
Maki 2010 (59)
28
30
1.3%
-0.30 [-0.51, -0.09]
Markova 2015 (60)
18
19
0.1%
0.19 [-0.69, 1.07]
Matthan 2007 (61)
28
28
0.7%
-0.03 [-0.31, 0.25]
McVeigh 2006 (62)
35
35
5.9%
-0.15 [-0.25, -0.05]
Mercer 1987 (63)
33
33
0.1%
-0.08 [-0.88, 0.73]
Meredith 1989 (64)
10
10
0.8%
-0.28 [-0.55, -0.02]
Meyer 2004 (65)
23
23
0.3%
-0.07 [-0.51, 0.37]
Miraghajani 2013 (66)
25
25
0.1%
-0.28 [-1.04, 0.49]
Napora 2011 (67)
16
17
0.0%
-0.02 [-1.34, 1.30]
Onning 1998 (68)
10
12
0.7%
0.00 [-0.28, 0.28]
Padhi 2015 (69)
71
142
4.3%
0.01 [-0.10, 0.13]
Pipe 2009 (70)
29
29
0.8%
-0.12 [-0.39, 0.15]
Potter 1993 (71)
25
25
0.4%
-0.60 [-0.97, -0.23]
Puska 2002 (72)
28
24
0.9%
-0.26 [-0.52, -0.00]
Puska 2004 (73)
73
59
2.5%
-0.40 [-0.55, -0.25]
Roughead 2005 (74)
13
13
0.0%
0.15 [-1.38, 1.67]
Shidfar 2009 (76)
21
21
0.3%
-0.64 [-1.06, -0.23]
Shige 1998 (77)
11
11
0.2%
-0.09 [-0.70, 0.52]
Steele 1992 (81)
32
32
0.5%
-0.56 [-0.89, -0.23]
Steinberg 2003 (82)
28
28
0.5%
-0.04 [-0.37, 0.29]
Sucher 2016 (83)
18
19
0.1%
0.19 [-0.71, 1.09]
Tabibi 2010 (84)
18
18
0.1%
0.31 [-0.41, 1.03]
Teede 2001 (86)
93
86
0.8%
-0.22 [-0.49, 0.05]
Teixeira 2000 (87)
16
65
0.2%
-0.39 [-0.91, 0.13]
Teixeira 2004 (88)
14
14
1.6%
-0.20 [-0.39, -0.01]
Thorp 2008 (89)
91
91
1.6%
-0.12 [-0.30, 0.07]
Tonstad 2002 (90)
65
65
1.0%
-0.59 [-0.83, -0.35]
van Nielen 2014 (92)
15
15
0.2%
0.00 [-0.55, 0.55]
van Raaij 1981 (93)
25
20
1.3%
-0.09 [-0.30, 0.12]
van Raaij 1982 (93)
17
40
1.4%
-0.14 [-0.33, 0.06]
Vega-Lopez 2010 (95)
30
30
0.8%
-0.03 [-0.29, 0.24]
Vigna 2000 (96)
37
40
0.1%
-0.04 [-0.67, 0.59]
Weisse 2010 (97)
21
22
0.3%
-0.12 [-0.57, 0.33]
West 2005 (98)
32
32
1.0%
-0.04 [-0.28, 0.19]
Wheeler 2002 (99)
17
17
0.1%
-0.10 [-0.73, 0.53]
Wiebe 1984 (100)
8
8
0.4%
0.10 [-0.25, 0.46]
Wofford 2012 (101)
352
352
4.8%
-0.08 [-0.18, 0.03]
Wolfe 1981 (102)
7
7
0.1%
-0.97 [-1.79, -0.15]
Wolfe 1985 (103)
5
5
2.9%
-0.02 [-0.16, 0.12]
Wong 1998 (HC) (104)
13
13
0.2%
-0.21 [-0.75, 0.33]
Wong 1998 (N) (104)
13
13
0.2%
-0.13 [-0.63, 0.37]
Total (95% CI)
3502
3643
100.0%
-0.21 [-0.23, -0.18]
Heterogeneity: Chi² = 209.94, df = 101 (P < 0.00001); I² = 52%
Test for overall effect: Z = 17.17 (P < 0.00001)
                -2              -1                0                1                 2
      Favours plant protein         Favours animal protein
Animal 
protein N
Weight
Mean Difference (95% CI) in non-HDL-C, mmol/L
Study or subgroup
Plant 
protein N
Study or Subgroup
Abd-Mishani 2014
Abete 2009
Ahmed 2011
Allen 2007
Appt 2008
Ashton 2000
Azadbakht 2003
Azadbakht 2007
Azadbakht 2008
Bahr 2013
Bahr 2014
Bakhit 1994 (Cellulose)
Bakhit 1994 (Cotyledon)
Basaria 2009
Baum 1998
Beavers 2010
Blum 2003
Borodin 2009
Bricarello 2004
Burns-Whitmore 2014
Campbell 2010
Chen 2005 (HC)
Chen 2005 (N)
Chen 2006
Crouse 1999
Cuevas 2003
Duane 1999
Dunn 1986
Finley 2007 (N)
Finley 2007 (Pre-MS)
Gardner 2001
Giovanetti 1986 (LF)
Giovanetti 1986 (N)
Goldberg 1982 (HC)
Goldberg 1982 (N)
Greany 2004
Haub 2005
Hermansen 2001
Hill 2015
Hoie 2005
Hoie 2005B
Hoie 2007
Hosseinpour-Niazi 2014
Huff 1984
Jenkins 1989
Jenkins 2002
Jenkins 2010
Kestin 1989
Kjolbaek 2017
Kreijkamp-Kaspers 2004
Kurowska 1997
Laidlaw 1985
Laurin 1991
Li 2016
Liao 2007
Lichenstein 2002 (IF)
Lichenstein 2002 (NIF)
Liu 2012
Liu 2014
Ma 2005
Ma 2011
Maki 2010
Markova 2015
Matthan 2007
McVeigh 2006
Mercer 1987
Meredith 1989
Meyer 2004
Miraghajani 2013
Napora 2011
Onning 1998
Padhi 2015
Pipe 2009
Potter 1993
Puska 2002
Puska 2004
Roughead 2005
Shidfar 2009
Shige 1998
Steele 1992
Steinberg 2003
Sucher 2016
Tabibi 2010
Teede 2001
Teixeira 2000
Teixeira 2004
Thorp 2008
Tonstad 2002
van Nielen 2014
van Raaij 1981
van Raaij 1982
Vega-Lopez 2010
Vigna 2000
Weisse 2010
West 2005
Wheeler 2002
Wiebe 1984
Wofford 2012
Wolfe 1981
Wolfe 1985
Wong 1998 (HC)
Wong 1998 (N)
Total (95% CI)
Heterogeneity: Chi² = 209.94, df = 101 (P < 0.00001); I² = 52%
Test for overall effect: Z = 17.17 (P < 0.00001)
Mean Difference
-0.24308
-0.63791
0.307734
-0.11844
-0.24
-0.15
-0.47065
-0.39695
-0.93096
-0.04
-0.02
0.01
-0.2
0.093096
-0.26568
0.018102
0.129817
-0.36204
-0.23274
-0.25
-0.10654
-0.10603
-1.15853
-0.88
-0.20713
-0.13964
-0.10603
-0.57108
-0.16292
-0.18749
-0.14531
-0.02586
-0.02586
-0.18102
-0.02586
-0.16
-0.18
-0.45
0.213061
-0.445
-0.345
-0.24267
-0.07603
-0.58444
-0.26
-0.4
0.06
-0.37
0.050779
0.176262
-0.015
-0.5172
-0.32
0.01618
-0.17843
-0.13
-0.23
0.2
-0.2685
-0.07014
0.070982
-0.30256
0.19
-0.03333
-0.15
-0.07758
-0.28446
-0.07
-0.27618
-0.01991
0
0.015
-0.12
-0.60333
-0.26
-0.4
0.145214
-0.64185
-0.09
-0.5625
-0.04
0.19
0.31032
-0.22
-0.38877
-0.2
-0.115
-0.59169
0
-0.09051
-0.13577
-0.02586
-0.04
-0.12
-0.04375
-0.1
0.10344
-0.07629
-0.9679
-0.01552
-0.21
-0.13
SE
0.154094
0.290274
0.488027
0.157505
0.22769
0.158039
0.121752
0.027906
0.539805
0.085941
0.123668
0.109125
0.132755
0.324324
0.099251
0.462626
0.19502
0.230198
0.115649
0.095033
0.363082
0.355799
0.546417
0.424352
0.146362
0.231176
0.41533
0.352739
0.105076
0.17455
0.176467
0.213247
0.213247
0.175327
0.280837
0.040017
0.235488
0.279217
0.169372
0.081733
0.116
0.211717
0.137464
0.432303
0.420623
0.129723
0.295808
0.187602
0.27973
0.15626
0.206725
0.156068
0.557791
0.389003
0.180575
0.183974
0.183522
0.147767
0.109914
0.14122
0.196802
0.106098
0.449333
0.143026
0.049949
0.409999
0.135357
0.226264
0.389462
0.674799
0.141421
0.058499
0.135277
0.189612
0.130891
0.076531
0.780012
0.212352
0.313454
0.169424
0.168001
0.457493
0.369153
0.136748
0.266114
0.094868
0.094663
0.123688
0.278904
0.106561
0.10151
0.135617
0.321743
0.227175
0.120574
0.323396
0.182553
0.055439
0.418347
0.071572
0.275861
0.253463
Total
24
18
9
98
32
42
14
42
21
33
68
21
21
46
22
16
24
28
60
20
27
9
10
13
31
18
8
12
20
20
30
12
12
4
12
71
10
20
41
38
39
28
31
5
11
41
23
18
77
87
34
19
9
17
15
42
42
120
180
78
45
28
18
28
35
33
10
23
25
16
10
71
29
25
28
73
13
21
11
32
28
18
18
93
16
14
91
65
15
25
17
30
37
21
32
17
8
352
7
5
13
13
3502
Total
24
8
18
93
32
42
14
42
20
33
68
21
21
38
44
16
24
28
60
20
35
10
8
13
115
18
8
12
20
20
44
12
12
4
12
72
11
20
21
78
78
60
31
5
11
41
23
17
36
88
34
19
9
17
15
42
42
60
90
81
45
30
19
28
35
33
10
23
25
17
12
142
29
25
24
59
13
21
11
32
28
19
18
86
65
14
91
65
15
20
40
30
40
22
32
17
8
352
7
5
13
13
3643
Weight
0.6%
0.2%
0.1%
0.6%
0.3%
0.6%
1.0%
19.0%
0.1%
2.0%
1.0%
1.2%
0.8%
0.1%
1.5%
0.1%
0.4%
0.3%
1.1%
1.6%
0.1%
0.1%
0.0%
0.1%
0.7%
0.3%
0.1%
0.1%
1.3%
0.5%
0.5%
0.3%
0.3%
0.5%
0.2%
9.2%
0.3%
0.2%
0.5%
2.2%
1.1%
0.3%
0.8%
0.1%
0.1%
0.9%
0.2%
0.4%
0.2%
0.6%
0.3%
0.6%
0.0%
0.1%
0.5%
0.4%
0.4%
0.7%
1.2%
0.7%
0.4%
1.3%
0.1%
0.7%
5.9%
0.1%
0.8%
0.3%
0.1%
0.0%
0.7%
4.3%
0.8%
0.4%
0.9%
2.5%
0.0%
0.3%
0.2%
0.5%
0.5%
0.1%
0.1%
0.8%
0.2%
1.6%
1.6%
1.0%
0.2%
1.3%
1.4%
0.8%
0.1%
0.3%
1.0%
0.1%
0.4%
4.8%
0.1%
2.9%
0.2%
0.2%
100.0%
IV, Fixed, 95% CI
-0.24 [-0.55, 0.06]
-0.64 [-1.21, -0.07]
0.31 [-0.65, 1.26]
-0.12 [-0.43, 0.19]
-0.24 [-0.69, 0.21]
-0.15 [-0.46, 0.16]
-0.47 [-0.71, -0.23]
-0.40 [-0.45, -0.34]
-0.93 [-1.99, 0.13]
-0.04 [-0.21, 0.13]
-0.02 [-0.26, 0.22]
0.01 [-0.20, 0.22]
-0.20 [-0.46, 0.06]
0.09 [-0.54, 0.73]
-0.27 [-0.46, -0.07]
0.02 [-0.89, 0.92]
0.13 [-0.25, 0.51]
-0.36 [-0.81, 0.09]
-0.23 [-0.46, -0.01]
-0.25 [-0.44, -0.06]
-0.11 [-0.82, 0.61]
-0.11 [-0.80, 0.59]
-1.16 [-2.23, -0.09]
-0.88 [-1.71, -0.05]
-0.21 [-0.49, 0.08]
-0.14 [-0.59, 0.31]
-0.11 [-0.92, 0.71]
-0.57 [-1.26, 0.12]
-0.16 [-0.37, 0.04]
-0.19 [-0.53, 0.15]
-0.15 [-0.49, 0.20]
-0.03 [-0.44, 0.39]
-0.03 [-0.44, 0.39]
-0.18 [-0.52, 0.16]
-0.03 [-0.58, 0.52]
-0.16 [-0.24, -0.08]
-0.18 [-0.64, 0.28]
-0.45 [-1.00, 0.10]
0.21 [-0.12, 0.55]
-0.45 [-0.61, -0.28]
-0.34 [-0.57, -0.12]
-0.24 [-0.66, 0.17]
-0.08 [-0.35, 0.19]
-0.58 [-1.43, 0.26]
-0.26 [-1.08, 0.56]
-0.40 [-0.65, -0.15]
0.06 [-0.52, 0.64]
-0.37 [-0.74, -0.00]
0.05 [-0.50, 0.60]
0.18 [-0.13, 0.48]
-0.01 [-0.42, 0.39]
-0.52 [-0.82, -0.21]
-0.32 [-1.41, 0.77]
0.02 [-0.75, 0.78]
-0.18 [-0.53, 0.18]
-0.13 [-0.49, 0.23]
-0.23 [-0.59, 0.13]
0.20 [-0.09, 0.49]
-0.27 [-0.48, -0.05]
-0.07 [-0.35, 0.21]
0.07 [-0.31, 0.46]
-0.30 [-0.51, -0.09]
0.19 [-0.69, 1.07]
-0.03 [-0.31, 0.25]
-0.15 [-0.25, -0.05]
-0.08 [-0.88, 0.73]
-0.28 [-0.55, -0.02]
-0.07 [-0.51, 0.37]
-0.28 [-1.04, 0.49]
-0.02 [-1.34, 1.30]
0.00 [-0.28, 0.28]
0.01 [-0.10, 0.13]
-0.12 [-0.39, 0.15]
-0.60 [-0.97, -0.23]
-0.26 [-0.52, -0.00]
-0.40 [-0.55, -0.25]
0.15 [-1.38, 1.67]
-0.64 [-1.06, -0.23]
-0.09 [-0.70, 0.52]
-0.56 [-0.89, -0.23]
-0.04 [-0.37, 0.29]
0.19 [-0.71, 1.09]
0.31 [-0.41, 1.03]
-0.22 [-0.49, 0.05]
-0.39 [-0.91, 0.13]
-0.20 [-0.39, -0.01]
-0.12 [-0.30, 0.07]
-0.59 [-0.83, -0.35]
0.00 [-0.55, 0.55]
-0.09 [-0.30, 0.12]
-0.14 [-0.33, 0.06]
-0.03 [-0.29, 0.24]
-0.04 [-0.67, 0.59]
-0.12 [-0.57, 0.33]
-0.04 [-0.28, 0.19]
-0.10 [-0.73, 0.53]
0.10 [-0.25, 0.46]
-0.08 [-0.18, 0.03]
-0.97 [-1.79, -0.15]
-0.02 [-0.16, 0.12]
-0.21 [-0.75, 0.33]
-0.13 [-0.63, 0.37]
-0.21 [-0.23, -0.18]
Plant Protein Animal Protein
Mean Difference
Mean Difference
IV, Fixed, 95% CI
-2
-1
0
1
2
Favours plant protein
Favours animal protein
Downloaded from http://ahajournals.org by on June 4, 2019
  
Figure S8. Non-HDL-C Visual Subgroup. Point estimates for each subgroup level (squares) are the pooled effect 
estimates. The dashed line represents the pooled effect estimate for the overall (total) analysis. The residual I2 value 
indicates the interstudy heterogeneity unexplained by the subgroup. Statistically significant pairwise subgroup effect 
modification by meta-regression analyses at P < 0.05. 
 
 
 
 
Subgroup
Level
Trials
Participants
Residual I2
p-value
Within subgroups
Between subgroups
Total
102
5,401
            
 -0.18 [-0.22 to -0.14]
-
-
-
Design
Parallel
47
3,698
             
-0.19 [-0.26 to -0.13]
0.02 [-0.07 to 0.10]
52.23%
0.63
Crossover
55
1,703
             
-0.17 [-0.23 to -0.12]
Follow-up
<3 months
80
3,446
             
-0.19 [-0.23 to -0.14]
0.03 [-0.07 to 0.13]
52.13%
0.61
≥3months
22
1,955
             
-0.16 [-0.26 to -0.06]
Plant protein type
Soy
84
4,802
             
-0.20 [-0.24 to -0.15]
0.1 [-0.003 to 0.21]
50.27%
0.09
Other
18
599
                
-0.10 [-0.20 to 0.00]
Animal protein type
Dairy
64
4,474
             
-0.19 [-0.24 to -0.14]
0.02 [-0.07 to 0.11]
48.51%
0.62
Other
38
927
                
-0.17 [-0.24 to -0.09]
Dose
≤25g/d
40
2,537
             
-0.18 [-0.24 to -0.12]
0.00 [-0.07 to 0.08]
51.31%
0.92
>25g/d
65
2,864
             
-0.18 [-0.23 to -0.12]
Baseline 
<3.5mmol/L
52
2,625
             
-0.14 [-0.19 to -0.08]
-0.09 [-0.17 to -0.01]
43.12%
0.03
LDL-C
≥3.5mmol/L
50
2,776
             
-0.22 [-0.28 to -0.17]
Favours plant protein       Favours animal protein
Mean Difference (95% CI) in non-HDL cholesterol, mmol/L
-0.3
-0.1
0.1
0.3
Downloaded from http://ahajournals.org by on June 4, 2019
  
Figure S9. Apo-B Forest Plot, random-effects model. HC=hypercholesterolemic; IF=isoflavones; LF=low-fat; N=normal; 
NIF=no isoflavones. The pooled effect estimate (diamond) is shown. Paired analyses were applied to all crossover trials. 
Data are expressed as MDs with 95% CIs, using generic inverse-variance random-effects models. Inter-study 
heterogeneity was tested using the Cochran Q statistic (chi-square) at a significance level of P<0.10 and quantified by I2, 
levels of ≥50% represented substantial heterogeneity. 
Mean Difference IV,
 Random, 95% CI  
Azadbakht 2007 (8)
42
42
3.1%
-0.13 [-0.19, -0.07]
Bakhit 1994 (Cellulose) (12)
21
21
2.9%
0.02 [-0.05, 0.09]
Bakhit 1994 (Cotyledon) (12)
21
21
2.5%
-0.03 [-0.11, 0.04]
Burns-Whitmore 2014 (19)
20
20
5.7%
-0.06 [-0.09, -0.02]
Campbell 2010 (20)
27
35
0.7%
-0.08 [-0.24, 0.08]
Chen 2005 (HC) (21)
10
8
0.5%
-0.20 [-0.38, -0.02]
Chen 2005 (N) (21)
9
10
0.7%
-0.00 [-0.16, 0.15]
Chen 2006 (22)
13
13
0.7%
-0.16 [-0.31, -0.01]
Goldberg 1982 (HC) (32)
4
4
4.1%
-0.06 [-0.11, -0.01]
Goldberg 1982 (N) (32)
12
12
2.0%
-0.10 [-0.19, -0.01]
Hermansen 2001 (35)
20
20
1.6%
-0.12 [-0.22, -0.02]
Hoie 2005 (37)
38
78
2.2%
-0.11 [-0.19, -0.03]
Hoie 2005B (38)
39
78
3.4%
-0.10 [-0.16, -0.04]
Jenkins 2002 (43)
41
41
3.6%
-0.09 [-0.14, -0.03]
Kurowska 1997 (48)
34
34
1.2%
0.00 [-0.11, 0.11]
Laurin 1991 (50)
9
9
1.5%
0.00 [-0.10, 0.10]
Li 2016 (51)
17
17
1.7%
-0.08 [-0.18, 0.02]
Lichenstein 2002 (IF) (53)
42
42
3.3%
-0.03 [-0.09, 0.03]
Lichenstein 2002 (NIF) (53)
42
42
5.9%
-0.04 [-0.08, -0.00]
Ma 2011 (58)
45
45
3.9%
0.00 [-0.06, 0.06]
Maki 2010 (59)
28
30
3.9%
-0.08 [-0.14, -0.03]
Matthan 2007 (61)
28
28
5.4%
-0.01 [-0.05, 0.03]
McVeigh 2006 (62)
35
35
9.3%
-0.04 [-0.06, -0.03]
Pipe 2009 (70)
29
29
2.3%
-0.02 [-0.10, 0.06]
Potter 1993 (71)
15
15
1.5%
-0.06 [-0.16, 0.04]
Puska 2002 (72)
28
24
1.9%
0.00 [-0.09, 0.09]
Santo 2008 (75)
9
21
0.8%
0.04 [-0.11, 0.19]
Shige 1998 (77)
11
11
1.7%
-0.02 [-0.11, 0.07]
Tabibi 2010 (84)
18
18
0.6%
0.12 [-0.05, 0.29]
Takahira 2011 (85)
24
22
1.0%
-0.06 [-0.18, 0.07]
Teixeira 2000 (87)
16
65
0.4%
-0.15 [-0.36, 0.06]
Tonstad 2002 (90)
65
65
5.0%
-0.04 [-0.08, 0.00]
Vega-Lopez 2010 (95)
30
30
8.0%
-0.01 [-0.04, 0.01]
Vigna 2000 (96)
37
40
1.6%
-0.06 [-0.16, 0.04]
West 2005 (98)
32
32
3.6%
-0.00 [-0.06, 0.06]
Wong 1998 (HC) (104)
13
13
0.5%
-0.11 [-0.29, 0.07]
Wong 1998 (N) (104)
13
13
1.2%
-0.01 [-0.12, 0.10]
Total (95% CI)
937
1083
100.0%
-0.05 [-0.06, -0.03]
Heterogeneity: Tau² = 0.00; Chi² = 51.36, df = 36 (P = 0.05); I² = 30%
Test for overall effect: Z = 6.64 (P < 0.00001)
                             -0.2    -0.1       0      0.1     0.2
      Favours plant protein         Favours animal protein
Study or subgroup
Plant 
protein N
Animal 
protein N
Weight
Mean Difference (95% CI) in Apo-B, g/L
Study or Subgroup
Azadbakht 2007
Bakhit 1994 (Cellulose)
Bakhit 1994 (Cotyledon)
Burns-Whitmore 2014
Campbell 2010
Chen 2005 (HC)
Chen 2005 (N)
Chen 2006
Goldberg 1982 (HC)
Goldberg 1982 (N)
Hermansen 2001
Hoie 2005
Hoie 2005B
Jenkins 2002
Kurowska 1997
Laurin 1991
Li 2016
Lichenstein 2002 (IF)
Lichenstein 2002 (NIF)
Ma 2011
Maki 2010
Matthan 2007
McVeigh 2006
Pipe 2009
Potter 1993
Puska 2002
Santo 2008
Shige 1998
Tabibi 2010
Takahira 2011
Teixeira 2000
Tonstad 2002
Vega-Lopez 2010
Vigna 2000
West 2005
Wong 1998 (HC)
Wong 1998 (N)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 51.36, df = 36 (P = 0.05); I² = 30%
Test for overall effect: Z = 6.64 (P < 0.00001)
Mean Difference
-0.13
0.018
-0.033
-0.055
-0.08373
-0.199
-0.004
-0.16
-0.06
-0.1
-0.12
-0.11
-0.1005
-0.085
0
0
-0.08
-0.03
-0.04
0
-0.0849
-0.01263
-0.045
-0.02
-0.06
0
0.039381
-0.02
0.12
-0.059
-0.15
-0.04
-0.015
-0.06
-0.00381
-0.11
-0.01
SE
0.033063
0.035141
0.037859
0.020278
0.081676
0.093858
0.0798
0.077155
0.027118
0.043589
0.050547
0.04141
0.031048
0.029913
0.058142
0.052915
0.049037
0.03166
0.019715
0.028284
0.027987
0.021569
0.009982
0.04
0.051732
0.045918
0.075821
0.047863
0.086538
0.06382
0.105457
0.022959
0.013253
0.050564
0.030194
0.092943
0.058441
Total
42
21
21
20
27
10
9
13
4
12
20
38
39
41
34
9
17
42
42
45
28
28
35
29
15
28
9
11
18
24
16
65
30
37
32
13
13
937
Total
42
21
21
20
35
8
10
13
4
12
20
78
78
41
34
9
17
42
42
45
30
28
35
29
15
24
21
11
18
22
65
65
30
40
32
13
13
1083
Weight
3.1%
2.9%
2.5%
5.7%
0.7%
0.5%
0.7%
0.7%
4.1%
2.0%
1.6%
2.2%
3.4%
3.6%
1.2%
1.5%
1.7%
3.3%
5.9%
3.9%
3.9%
5.4%
9.3%
2.3%
1.5%
1.9%
0.8%
1.7%
0.6%
1.0%
0.4%
5.0%
8.0%
1.6%
3.6%
0.5%
1.2%
100.0%
IV, Random, 95% CI
-0.13 [-0.19, -0.07]
0.02 [-0.05, 0.09]
-0.03 [-0.11, 0.04]
-0.06 [-0.09, -0.02]
-0.08 [-0.24, 0.08]
-0.20 [-0.38, -0.02]
-0.00 [-0.16, 0.15]
-0.16 [-0.31, -0.01]
-0.06 [-0.11, -0.01]
-0.10 [-0.19, -0.01]
-0.12 [-0.22, -0.02]
-0.11 [-0.19, -0.03]
-0.10 [-0.16, -0.04]
-0.09 [-0.14, -0.03]
0.00 [-0.11, 0.11]
0.00 [-0.10, 0.10]
-0.08 [-0.18, 0.02]
-0.03 [-0.09, 0.03]
-0.04 [-0.08, -0.00]
0.00 [-0.06, 0.06]
-0.08 [-0.14, -0.03]
-0.01 [-0.05, 0.03]
-0.04 [-0.06, -0.03]
-0.02 [-0.10, 0.06]
-0.06 [-0.16, 0.04]
0.00 [-0.09, 0.09]
0.04 [-0.11, 0.19]
-0.02 [-0.11, 0.07]
0.12 [-0.05, 0.29]
-0.06 [-0.18, 0.07]
-0.15 [-0.36, 0.06]
-0.04 [-0.08, 0.00]
-0.01 [-0.04, 0.01]
-0.06 [-0.16, 0.04]
-0.00 [-0.06, 0.06]
-0.11 [-0.29, 0.07]
-0.01 [-0.12, 0.10]
-0.05 [-0.06, -0.03]
Plant Protein Animal Protein
Mean Difference
Mean Difference
IV, Random, 95% CI
-0.2
-0.1
0
0.1
0.2
Favours plant protein
Favours animal protein
Downloaded from http://ahajournals.org by on June 4, 2019
  
 
Figure S10. Apo-B Forest Plot, fixed-effects model. HC=hypercholesterolemic; IF=isoflavones; LF=low-fat; N=normal; 
NIF=no isoflavones. The pooled effect estimate (diamond) is shown. Paired analyses were applied to all crossover trials. 
Data are expressed as MDs with 95% CIs, using generic inverse-variance fixed-effects models. Inter-study heterogeneity 
was tested using the Cochran Q statistic (chi-square) at a significance level of P<0.10 and quantified by I2, levels of ≥50% 
represented substantial heterogeneity. 
Mean Difference IV,
 Fixed, 95% CI  
Azadbakht 2007 (8)
42
42
2.2%
-0.13 [-0.19, -0.07]
Bakhit 1994 (Cellulose) (12)
21
21
1.9%
0.02 [-0.05, 0.09]
Bakhit 1994 (Cotyledon) (12)
21
21
1.7%
-0.03 [-0.11, 0.04]
Burns-Whitmore 2014 (19)
20
20
5.8%
-0.06 [-0.09, -0.02]
Campbell 2010 (20)
27
35
0.4%
-0.08 [-0.24, 0.08]
Chen 2005 (HC) (21)
10
8
0.3%
-0.20 [-0.38, -0.02]
Chen 2005 (N) (21)
9
10
0.4%
-0.00 [-0.16, 0.15]
Chen 2006 (22)
13
13
0.4%
-0.16 [-0.31, -0.01]
Goldberg 1982 (HC) (32)
4
4
3.2%
-0.06 [-0.11, -0.01]
Goldberg 1982 (N) (32)
12
12
1.3%
-0.10 [-0.19, -0.01]
Hermansen 2001 (35)
20
20
0.9%
-0.12 [-0.22, -0.02]
Hoie 2005 (37)
38
78
1.4%
-0.11 [-0.19, -0.03]
Hoie 2005B (38)
39
78
2.5%
-0.10 [-0.16, -0.04]
Jenkins 2002 (43)
41
41
2.7%
-0.09 [-0.14, -0.03]
Kurowska 1997 (48)
34
34
0.7%
0.00 [-0.11, 0.11]
Laurin 1991 (50)
9
9
0.9%
0.00 [-0.10, 0.10]
Li 2016 (51)
17
17
1.0%
-0.08 [-0.18, 0.02]
Lichenstein 2002 (IF) (53)
42
42
2.4%
-0.03 [-0.09, 0.03]
Lichenstein 2002 (NIF) (53)
42
42
6.1%
-0.04 [-0.08, -0.00]
Ma 2011 (58)
45
45
3.0%
0.00 [-0.06, 0.06]
Maki 2010 (59)
28
30
3.1%
-0.08 [-0.14, -0.03]
Matthan 2007 (61)
28
28
5.1%
-0.01 [-0.05, 0.03]
McVeigh 2006 (62)
35
35
24.0%
-0.04 [-0.06, -0.03]
Pipe 2009 (70)
29
29
1.5%
-0.02 [-0.10, 0.06]
Potter 1993 (71)
15
15
0.9%
-0.06 [-0.16, 0.04]
Puska 2002 (72)
28
24
1.1%
0.00 [-0.09, 0.09]
Santo 2008 (75)
9
21
0.4%
0.04 [-0.11, 0.19]
Shige 1998 (77)
11
11
1.0%
-0.02 [-0.11, 0.07]
Tabibi 2010 (84)
18
18
0.3%
0.12 [-0.05, 0.29]
Takahira 2011 (85)
24
22
0.6%
-0.06 [-0.18, 0.07]
Teixeira 2000 (87)
16
65
0.2%
-0.15 [-0.36, 0.06]
Tonstad 2002 (90)
65
65
4.5%
-0.04 [-0.08, 0.00]
Vega-Lopez 2010 (95)
30
30
13.6%
-0.01 [-0.04, 0.01]
Vigna 2000 (96)
37
40
0.9%
-0.06 [-0.16, 0.04]
West 2005 (98)
32
32
2.6%
-0.00 [-0.06, 0.06]
Wong 1998 (HC) (104)
13
13
0.3%
-0.11 [-0.29, 0.07]
Wong 1998 (N) (104)
13
13
0.7%
-0.01 [-0.12, 0.10]
Total (95% CI)
937
1083
100.0%
-0.04 [-0.05, -0.03]
Heterogeneity: Chi² = 51.36, df = 36 (P = 0.05); I² = 30%
Test for overall effect: Z = 8.68 (P < 0.00001)
                        -0.2    -0.1       0      0.1      0.2
      Favours plant protein         Favours animal protein
Study or subgroup
Plant 
protein N
Animal 
protein N
Weight
Mean Difference (95% CI) in Apo-B, g/L
Study or Subgroup
Azadbakht 2007
Bakhit 1994 (Cellulose)
Bakhit 1994 (Cotyledon)
Burns-Whitmore 2014
Campbell 2010
Chen 2005 (HC)
Chen 2005 (N)
Chen 2006
Goldberg 1982 (HC)
Goldberg 1982 (N)
Hermansen 2001
Hoie 2005
Hoie 2005B
Jenkins 2002
Kurowska 1997
Laurin 1991
Li 2016
Lichenstein 2002 (IF)
Lichenstein 2002 (NIF)
Ma 2011
Maki 2010
Matthan 2007
McVeigh 2006
Pipe 2009
Potter 1993
Puska 2002
Santo 2008
Shige 1998
Tabibi 2010
Takahira 2011
Teixeira 2000
Tonstad 2002
Vega-Lopez 2010
Vigna 2000
West 2005
Wong 1998 (HC)
Wong 1998 (N)
Total (95% CI)
Heterogeneity: Chi² = 51.36, df = 36 (P = 0.05); I² = 30%
Test for overall effect: Z = 8.68 (P < 0.00001)
Mean Difference
-0.13
0.018
-0.033
-0.055
-0.08373
-0.199
-0.004
-0.16
-0.06
-0.1
-0.12
-0.11
-0.1005
-0.085
0
0
-0.08
-0.03
-0.04
0
-0.0849
-0.01263
-0.045
-0.02
-0.06
0
0.039381
-0.02
0.12
-0.059
-0.15
-0.04
-0.015
-0.06
-0.00381
-0.11
-0.01
SE
0.033063
0.035141
0.037859
0.020278
0.081676
0.093858
0.0798
0.077155
0.027118
0.043589
0.050547
0.04141
0.031048
0.029913
0.058142
0.052915
0.049037
0.03166
0.019715
0.028284
0.027987
0.021569
0.009982
0.04
0.051732
0.045918
0.075821
0.047863
0.086538
0.06382
0.105457
0.022959
0.013253
0.050564
0.030194
0.092943
0.058441
Total
42
21
21
20
27
10
9
13
4
12
20
38
39
41
34
9
17
42
42
45
28
28
35
29
15
28
9
11
18
24
16
65
30
37
32
13
13
937
Total
42
21
21
20
35
8
10
13
4
12
20
78
78
41
34
9
17
42
42
45
30
28
35
29
15
24
21
11
18
22
65
65
30
40
32
13
13
1083
Weight
2.2%
1.9%
1.7%
5.8%
0.4%
0.3%
0.4%
0.4%
3.2%
1.3%
0.9%
1.4%
2.5%
2.7%
0.7%
0.9%
1.0%
2.4%
6.1%
3.0%
3.1%
5.1%
24.0%
1.5%
0.9%
1.1%
0.4%
1.0%
0.3%
0.6%
0.2%
4.5%
13.6%
0.9%
2.6%
0.3%
0.7%
100.0%
IV, Fixed, 95% CI
-0.13 [-0.19, -0.07]
0.02 [-0.05, 0.09]
-0.03 [-0.11, 0.04]
-0.06 [-0.09, -0.02]
-0.08 [-0.24, 0.08]
-0.20 [-0.38, -0.02]
-0.00 [-0.16, 0.15]
-0.16 [-0.31, -0.01]
-0.06 [-0.11, -0.01]
-0.10 [-0.19, -0.01]
-0.12 [-0.22, -0.02]
-0.11 [-0.19, -0.03]
-0.10 [-0.16, -0.04]
-0.09 [-0.14, -0.03]
0.00 [-0.11, 0.11]
0.00 [-0.10, 0.10]
-0.08 [-0.18, 0.02]
-0.03 [-0.09, 0.03]
-0.04 [-0.08, -0.00]
0.00 [-0.06, 0.06]
-0.08 [-0.14, -0.03]
-0.01 [-0.05, 0.03]
-0.04 [-0.06, -0.03]
-0.02 [-0.10, 0.06]
-0.06 [-0.16, 0.04]
0.00 [-0.09, 0.09]
0.04 [-0.11, 0.19]
-0.02 [-0.11, 0.07]
0.12 [-0.05, 0.29]
-0.06 [-0.18, 0.07]
-0.15 [-0.36, 0.06]
-0.04 [-0.08, 0.00]
-0.01 [-0.04, 0.01]
-0.06 [-0.16, 0.04]
-0.00 [-0.06, 0.06]
-0.11 [-0.29, 0.07]
-0.01 [-0.12, 0.10]
-0.04 [-0.05, -0.03]
Plant Protein Animal Protein
Mean Difference
Mean Difference
IV, Fixed, 95% CI
-0.2
-0.1
0
0.1
0.2
Favours plant protein
Favours animal protein
Downloaded from http://ahajournals.org by on June 4, 2019
  
Figure S11. Apo-B Visual Subgroup. Point estimates for each subgroup level (squares) are the pooled effect estimates. 
The dashed line represents the pooled effect estimate for the overall (total) analysis. The residual I2 value indicates the 
interstudy heterogeneity unexplained by the subgroup. Statistically significant pairwise subgroup effect modification by 
meta-regression analyses at P < 0.05. 
 
 
 
 
Subgroup
Level
Trials
Participants
Residual I2
p-value
Within subgroups
Between subgroups
Total
37
1,506
            
-0.05 [-0.06 to -0.03]
-
-
-
Design
Parallel
16
992
                
-0.06 [-0.08 to -0.03]
0.02 [-0.02 to 0.05]
29.21%
0.30
Crossover
21
514
                
-0.04 [-0.06 to -0.02]
Follow-up
<3 months
29
1,094
             
-0.04 [-0.06 to -0.03]
-0.02 [-0.07 to 0.02]
30.36%
0.32
≥3months
8
412
                
-0.06 [-0.11 to -0.02]
Plant protein type
Soy
34
1,422
             
-0.05 [-0.06 to -0.03]
0.01 [-0.03 to 0.05]
29.42%
0.62
Other
3
84
                   
-0.04 [-0.07 to 0.00]
Animal protein type
Dairy
25
1,190
             
-0.05 [-0.07 to -0.03]
0.00 [-0.03 to 0.03]
32.86%
0.86
Other
12
316
                
-0.04 [-0.07 to -0.02]
Dose
≤25g/d
17
755
                
-0.05 [-0.08 to -0.03]
0.00 [-0.03 to 0.03]
37.86%
0.88
>25g/d
25
751
                
-0.05 [-0.07 to -0.03]
Baseline 
<3.5mmol/L
20
594
                
-0.04 [-0.06 to -0.02]
0.00 [-0.03 to 0.03]
31.37%
0.82
LDL-C
≥3.5mmol/L
17
912
                
-0.05 [-0.07 to -0.03]
Favours plant protein       Favours animal protein
Mean Difference (95% CI) in apolipoprotein B, g/L
-0.10
-0.05
0.00
0.05
0.10
Downloaded from http://ahajournals.org by on June 4, 2019
  
 
Figure S12. Funnel Plots. Publication bias funnel plots for LDL (A), non-HDL (B), and apolipoprotein B (C). The solid 
line represents the pooled effect estimate expressed as the weighted mean difference (MD) of each analysis, and dashed 
lines represent pseudo-95% confidence limits. Circles represent effect estimates of included trials. p-values of Egger and 
Begg tests for publication bias are shown at top right for each analysis. *Statistically significant (p < 0.05). 
 
Downloaded from http://ahajournals.org by on June 4, 2019
  
Figure S13. LDL-C Trim-And-Fill Funnel Plot. The horizontal line represents the pooled effect estimate expressed as a 
mean difference. The diagonal lines represent the pseudo 95% CIs of the mean difference. The clear circles represent 
effect estimates for each included study. 
 
 
 
Downloaded from http://ahajournals.org by on June 4, 2019
 Supplemental References 
 
1. 
Abd-Mishani M, Hosseinpour-Niazi S, Delshad H, Bahadori-Monfared A, Mirmiran P, Azizi f. Effect of Modified 
Diet on Lipid Profiles in Type 2 Diabetic Patients. Iranian Journal of Endocrinology and Metabolism 2014;16:103-
110. 
2. 
Abete I, Parra D, Martinez JA. Legume-, fish-, or high-protein-based hypocaloric diets: effects on weight loss and 
mitochondrial oxidation in obese men. J Med Food 2009;12:100-8. 
3. 
Ahmed MS, Calabria AC, Kirsztajn GM. Short-term effects of soy protein diet in patients with proteinuric 
glomerulopathies. Jornal brasileiro de nefrologia : [MODIFIER LETTER PRIME]orgao oficial de Sociedades 
Brasileira e Latino-Americana de Nefrologia 2011;33:150-9. 
4. 
Allen JK, Becker DM, Kwiterovich PO, Lindenstruth KA, Curtis C. Effect of soy protein-containing isoflavones on 
lipoproteins in postmenopausal women. Menopause (New York, NY) 2007;14:106-14. 
5. 
Appt SE, Tormala R, Franke AA, Mikkola TS, Tikkanen MJ, Ylikorkala O, Clarkson TB. Soy-tibolone combination - 
effect on lipids in postmenopausal monkeys and women. Maturitas 2008;60:216-22. 
6. 
Ashton E, Ball M. Effects of soy as tofu vs meat on lipoprotein concentrations. European journal of clinical 
nutrition 2000;54:14-9. 
7. 
Azadbakht L, Shakerhosseini R, Atabak S, Jamshidian M, Mehrabi Y, Esmaill-Zadeh A. Beneficiary effect of dietary 
soy protein on lowering plasma levels of lipid and improving kidney function in type II diabetes with 
nephropathy. European journal of clinical nutrition 2003;57:1292-4. 
8. 
Azadbakht L, Kimiagar M, Mehrabi Y, Esmaillzadeh A, Padyab M, Hu FB, Willett WC. Soy inclusion in the diet 
improves features of the metabolic syndrome: a randomized crossover study in postmenopausal women. The 
American Journal of Clinical Nutrition 2007;85:735-741. 
9. 
Azadbakht L, Atabak S, Esmaillzadeh A. Soy protein intake, cardiorenal indices, and C-reactive protein in type 2 
diabetes with nephropathy. Diabetes Care 2008;31:648-54. 
10. 
Bähr M, Fechner A, Krämer J, Kiehntopf M, Jahreis G. Lupin protein positively affects plasma LDL cholesterol and 
LDL:HDL cholesterol ratio in hypercholesterolemic adults after four weeks of supplementation: a randomized, 
controlled crossover study. Nutrition Journal 2013;12:1-10. 
11. 
Bähr M, Fechner A, Kiehntopf M, Jahreis G. Consuming a mixed diet enriched with lupin protein beneficially 
affects plasma lipids in hypercholesterolemic subjects: A randomized controlled trial. Clinical Nutrition 
2014;34:7-14. 
12. 
Bakhit RM, Klein BP, Essex-Sorlie D, Ham JO, Erdman JW, Jr., Potter SM. Intake of 25 g of soybean protein with or 
without soybean fiber alters plasma lipids in men with elevated cholesterol concentrations. Journal of Nutrition 
1994;124:213-22. 
13. 
Basaria S, Wisniewski A, Dupree K, Bruno T, Song MY, Yao F, Ojumu A, John M, Dobs AS. Effect of high-dose 
isoflavones on cognition, quality of life, androgens, and lipoprotein in post-menopausal women. Journal of 
endocrinological investigation 2009;32:150-5. 
14. 
Baum JA, Teng H, Erdman JW, Weigel RM, Klein BP, Persky VW, Freels S, Surya P, Bakhit RM, Ramos E, Shay NF, 
Potter SM. Long-term intake of soy protein improves blood lipid profiles and increases mononuclear cell low-
density-lipoprotein receptor messenger RNA in hypercholesterolemic, postmenopausal women. The American 
Journal of Clinical Nutrition 1998;68:545-51. 
15. 
Beavers KM, Serra MC, Beavers DP, Hudson GM, Willoughby DS. The lipid-lowering effects of 4 weeks of daily 
soymilk or dairy milk ingestion in a postmenopausal female population. Journal of medicinal food 2010;13:650-
6. 
16. 
Blum A, Lang N, Peleg A, Vigder F, Israeli P, Gumanovsky M, Lupovitz S, Elgazi A, Ben-Ami M. Effects of oral soy 
protein on markers of inflammation in postmenopausal women with mild hypercholesterolemia. American heart 
journal 2003;145:e7. 
17. 
Borodin EA, Menshikova IG, Dorovskikh VA, Feoktistova NA, Shtarberg MA, Yamamoto T, Takamatsu K, Mori H, 
Yamamoto S. Effects of two-month consumption of 30 g a day of soy protein isolate or skimmed curd protein on 
blood lipid concentration in Russian adults with hyperlipidemia. Journal of nutritional science and vitaminology 
2009;55:492-7. 
Downloaded from http://ahajournals.org by on June 4, 2019
 18. 
Bricarello LP, Kasinski N, Bertolami MC, Faludi A, Pinto LA, Relvas WG, Izar MC, Ihara SS, Tufik S, Fonseca FA. 
Comparison between the effects of soy milk and non-fat cow milk on lipid profile and lipid peroxidation in 
patients with primary hypercholesterolemia. Nutrition (Burbank, Los Angeles County, Calif) 2004;20:200-4. 
19. 
Burns-Whitmore B, Haddad E, Sabaté J, Rajaram S. Effects of supplementing n-3 fatty acid enriched eggs and 
walnuts on cardiovascular disease risk markers in healthy free-living lacto-ovo-vegetarians: a randomized, 
crossover, free-living intervention study. Nutrition Journal 2014;13:1-9. 
20. 
Campbell SC, Khalil DA, Payton ME, Arjmandi BH. One-year soy protein supplementation does not improve lipid 
profile in postmenopausal women. Menopause 2010;17:587-93. 
21. 
Chen ST, Ferng SH, Yang CS, Peng SJ, Lee HR, Chen JR. Variable effects of soy protein on plasma lipids in 
hyperlipidemic and normolipidemic hemodialysis patients. American journal of kidney diseases : the official 
journal of the National Kidney Foundation 2005;46:1099-106. 
22. 
Chen ST, Chen JR, Yang CS, Peng SJ, Ferng SH. Effect of soya protein on serum lipid profile and lipoprotein 
concentrations in patients undergoing hypercholesterolaemic haemodialysis. The British journal of nutrition 
2006;95:366-71. 
23. 
Crouse JR, 3rd, Morgan T, Terry JG, Ellis J, Vitolins M, Burke GL. A randomized trial comparing the effect of casein 
with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and 
lipoproteins. Archives of Internal Medicine 1999;159:2070-6. 
24. 
Cuevas AM, Irribarra VL, Castillo OA, Yanez MD, Germain AM. Isolated soy protein improves endothelial function 
in postmenopausal hypercholesterolemic women. European journal of clinical nutrition 2003;57:889-94. 
25. 
Dent SB, Peterson CT, Brace LD, Swain JH, Reddy MB, Hanson KB, Robinson JG, Alekel DL. Soy Protein Intake by 
Perimenopausal Women Does Not Affect Circulating Lipids and Lipoproteins or Coagulation and Fibrinolytic 
Factors. The Journal of Nutrition 2001;131:2280-2287. 
26. 
Duane WC. Effects of soybean protein and very low dietary cholesterol on serum lipids, biliary lipids, and fecal 
sterols in humans. Metabolism: Clinical & Experimental 1999;48:489-94. 
27. 
Dunn C, Liebman M. Plasma lipid alterations in vegetarian males resulting from the substitution of tofu for 
cheese. Nutrition Research 1986;6:1343-1352. 
28. 
Finley JW, Burrell JB, Reeves PG. Pinto bean consumption changes SCFA profiles in fecal fermentations, bacterial 
populations of the lower bowel, and lipid profiles in blood of humans. J Nutr 2007;137:2391-8. 
29. 
Gardner CD, Newell KA, Cherin R, Haskell WL. The effect of soy protein with or without isoflavones relative to 
milk protein on plasma lipids in hypercholesterolemic postmenopausal women. The American journal of clinical 
nutrition 2001;73:728-35. 
30. 
Gardner CD, Messina M, Kiazand A, Morris JL, Franke AA. Effect of two types of soy milk and dairy milk on 
plasma lipids in hypercholesterolemic adults: a randomized trial. Journal of the American College of Nutrition 
2007;26:669-77. 
31. 
Giovannetti PM, Carroll KK, Wolfe BM. Constancy of fasting serum cholesterol of healthy young women upon 
substitution of soy protein isolate for meat and dairy protein in medium and low fat diets. Nutrition Research 
1986;6:609-618. 
32. 
Goldberg AP, Lim A, Kolar JB, Grundhauser JJ, Steinke FH, Schonfeld G. Soybean protein independently lowers 
plasma cholesterol levels in primary hypercholesterolemia. Atherosclerosis 1982;43:355-368. 
33. 
Greany KA, Nettleton JA, Wangen KE, Thomas W, Kurzer MS. Probiotic Consumption Does Not Enhance the 
Cholesterol-Lowering Effect of Soy in Postmenopausal Women. The Journal of Nutrition 2004;134:3277-3283. 
34. 
Haub MD, Wells AM, Campbell WW. Beef and soy-based food supplements differentially affect serum 
lipoprotein-lipid profiles because of changes in carbohydrate intake and novel nutrient intake ratios in older 
men who resistive-train. Metabolism: clinical and experimental 2005;54:769-74. 
35. 
Hermansen K, Søndergaard M, Høie L, Carstensen M, Brock B. Beneficial Effects of a Soy-Based Dietary 
Supplement on Lipid Levels and Cardiovascular Risk Markers in Type 2 Diabetic Subjects. Diabetes Care 
2001;24:228-233. 
36. 
Hill AM, Harris Jackson KA, Roussell MA, West SG, Kris-Etherton PM. Type and amount of dietary protein in the 
treatment of metabolic syndrome: a randomized controlled trial. Am J Clin Nutr 2015;102:757-70. 
37. 
Hoie LH, Morgenstern EC, Gruenwald J, Graubaum HJ, Busch R, Luder W, Zunft HJ. A double-blind placebo-
controlled clinical trial compares the cholesterol-lowering effects of two different soy protein preparations in 
hypercholesterolemic subjects. European journal of nutrition 2005;44:65-71. 
Downloaded from http://ahajournals.org by on June 4, 2019
 38. 
Høie LH, Graubaum H-J, Harde A, Gruenwald J, Wernecke K-D. Lipid-lowering effect of 2 dosages of a soy protein 
supplement in Hypercholesterolemia. Advances in Therapy 2005;22:175-186. 
39. 
Hoie LH, Guldstrand M, Sjoholm A, Graubaum HJ, Gruenwald J, Zunft HJ, Lueder W. Cholesterol-lowering effects 
of a new isolated soy protein with high levels of nondenaturated protein in hypercholesterolemic patients. 
Advances in therapy 2007;24:439-47. 
40. 
Hosseinpour-Niazi S, Mirmiran P, Hedayati M, Azizi F. Substitution of red meat with legumes in the therapeutic 
lifestyle change diet based on dietary advice improves cardiometabolic risk factors in overweight type 2 diabetes 
patients: a cross-over randomized clinical trial. Eur J Clin Nutr 2015;69:592-597. 
41. 
Huff MW, Giovannetti PM, Wolfe BM. Turnover of very low-density lipoprotein-apoprotein B is increased by 
substitution of soybean protein for meat and dairy protein in the diets of hypercholesterolemic men. The 
American journal of clinical nutrition 1984;39:888-97. 
42. 
Jenkins DJA, Wolever TMS, Spiller G, Buckley G, Lam Y, Jenkins AL, Josse RG. Hypocholesterolemic effect of 
vegetable protein in a hypocaloric diet. Atherosclerosis 1989;78:99-107. 
43. 
Jenkins DJ, Kendall CW, Jackson CJ, Connelly PW, Parker T, Faulkner D, Vidgen E, Cunnane SC, Leiter LA, Josse RG. 
Effects of high- and low-isoflavone soyfoods on blood lipids, oxidized LDL, homocysteine, and blood pressure in 
hyperlipidemic men and women. The American journal of clinical nutrition 2002;76:365-72. 
44. 
Jenkins DJ, Srichaikul K, Wong JM, Kendall CW, Bashyam B, Vidgen E, Lamarche B, Rao AV, Jones PJ, Josse RG, 
Jackson CJ, Ng V, Leong T, Leiter LA. Supplemental barley protein and casein similarly affect serum lipids in 
hypercholesterolemic women and men. The Journal of nutrition 2010;140:1633-7. 
45. 
Kestin M, Rouse IL, Correll RA, Nestel PJ. Cardiovascular disease risk factors in free-living men: comparison of 
two prudent diets, one based on lactoovovegetarianism and the other allowing lean meat. Am J Clin Nutr 
1989;50:280-7. 
46. 
Kjolbaek L, Sorensen LB, Sondertoft NB, Rasmussen CK, Lorenzen JK, Serena A, Astrup A, Larsen LH. Protein 
supplements after weight loss do not improve weight maintenance compared with recommended dietary 
protein intake despite beneficial effects on appetite sensation and energy expenditure: a randomized, 
controlled, double-blinded trial. Am J Clin Nutr 2017;106:684-697. 
47. 
Kreijkamp-Kaspers S, Kok L, Grobbee DE, de Haan EH, Aleman A, Lampe JW, van der Schouw YT. Effect of soy 
protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal 
women: a randomized controlled trial. JAMA : the journal of the American Medical Association 2004;292:65-74. 
48. 
Kurowska EM, Jordan J, Spence JD, Wetmore S, Piche LA, Radzikowski M, Dandona P, Carroll KK. Effects of 
substituting dietary soybean protein and oil for milk protein and fat in subjects with hypercholesterolemia. 
Clinical & Investigative Medicine - Medecine Clinique et Experimentale 1997;20:162-70. 
49. 
Laidlaw M, Mercer NJH. Serum cholesterol, triglyceride and lipoprotein response in hypercholesterolemic males 
to replacement of cow's milk with a soy beverage. Federation Proceedings, 1985:6360. 
50. 
Laurin D, Jacques H, Moorjani S, Steinke FH, Gagne C, Brun D, Lupien PJ. Effects of a soy-protein beverage on 
plasma lipoproteins in children with familial hypercholesterolemia. The American journal of clinical nutrition 
1991;54:98-103. 
51. 
Li J, Armstrong CL, Campbell WW. Effects of Dietary Protein Source and Quantity during Weight Loss on 
Appetite, Energy Expenditure, and Cardio-Metabolic Responses. Nutrients 2016;8:63. 
52. 
Liao FH, Shieh MJ, Yang SC, Lin SH, Chien YW. Effectiveness of a soy-based compared with a traditional low-
calorie diet on weight loss and lipid levels in overweight adults. Nutrition (Burbank, Los Angeles County, Calif) 
2007;23:551-6. 
53. 
Lichtenstein AH, Jalbert SM, Adlercreutz H, Goldin BR, Rasmussen H, Schaefer EJ, Ausman LM. Lipoprotein 
response to diets high in soy or animal protein with and without isoflavones in moderately hypercholesterolemic 
subjects. Arteriosclerosis, Thrombosis & Vascular Biology 2002;22:1852-8. 
54. 
Liu ZM, Ho SC, Chen YM, Ho YP. The effects of isoflavones combined with soy protein on lipid profiles, C-reactive 
protein and cardiovascular risk among postmenopausal Chinese women. Nutrition Metabolism & Cardiovascular 
Diseases 2012;22:712-9. 
55. 
Liu Z-m, Ho SC, Chen Y-m, Ho S, To K, Tomlinson B, Woo J. Whole soy, but not purified daidzein, had a favorable 
effect on improvement of cardiovascular risks: A 6-month randomized, double-blind, and placebo-controlled 
trial in equol-producing postmenopausal women. Molecular Nutrition & Food Research 2014;58:709-717. 
Downloaded from http://ahajournals.org by on June 4, 2019
 56. 
Lovati MR, Manzoni C, Canavesi A, Sirtori M, Vaccarino V, Marchi M, Gaddi G, Sirtori CR. Soybean protein diet 
increases low density lipoprotein receptor activity in mononuclear cells from hypercholesterolemic patients. J 
Clin Invest 1987;80:1498-502. 
57. 
Ma Y, Chiriboga D, Olendzki BC, Nicolosi R, Merriam PA, Ockene IS. Effect of soy protein containing isoflavones 
on blood lipids in moderately hypercholesterolemic adults: a randomized controlled trial. Journal of the 
American College of Nutrition 2005;24:275-85. 
58. 
Ma L, Grann K, Li M, Jiang Z. A pilot study to evaluate the effect of soy isolate protein on the serum lipid profile 
and other potential cardiovascular risk markers in moderately hypercholesterolemic Chinese adults. Ecology of 
Food & Nutrition 2011;50:473-85. 
59. 
Maki KC, Butteiger DN, Rains TM, Lawless A, Reeves MS, Schasteen C, Krul ES. Effects of soy protein on 
lipoprotein lipids and fecal bile acid excretion in men and women with moderate hypercholesterolemia. Journal 
of clinical lipidology 2010;4:531-42. 
60. 
Markova MHS, Sucher S, Pivovarova O, Pfeiffer A. Metabolic and molecular effects of a high-protein diet in 
subjects with type 2 diabetes. Diabetologia 2015;58:S335. 
61. 
Matthan NR, Jalbert SM, Ausman LM, Kuvin JT, Karas RH, Lichtenstein AH. Effect of soy protein from differently 
processed products on cardiovascular disease risk factors and vascular endothelial function in 
hypercholesterolemic subjects Am J Clin Nutr. 2007 Aug;86(2):525. The American journal of clinical nutrition 
2007;85:960-6. 
62. 
McVeigh BL, Dillingham BL, Lampe JW, Duncan AM. Effect of soy protein varying in isoflavone content on serum 
lipids in healthy young men. The American journal of clinical nutrition 2006;83:244-51. 
63. 
Mercer NJH, Carroll KK, Giovannetti PM. Effects on human plasma lipids of substituting soybean protein isolate 
for milk protein in the diet. Nutrition Reports International 1987;35:279-287. 
64. 
Meredith L, Liebman M, Graves K. Alterations in plasma lipid levels resulting from tofu and cheese consumption 
in adult women. Journal of the American College of Nutrition 1989;8:573-579. 
65. 
Meyer BJ, Larkin TA, Owen AJ, Astheimer LB, Tapsell LC, Howe PR. Limited lipid-lowering effects of regular 
consumption of whole soybean foods. Annals of nutrition & metabolism 2004;48:67-78. 
66. 
Miraghajani MS, Esmaillzadeh A, Najafabadi MM, Mirlohi M, Azadbakht L. Soy Milk Consumption, Inflammation, 
Coagulation, and Oxidative Stress Among Type 2 Diabetic Patients With Nephropathy. Diabetes Care 
2012;35:1981-1985. 
67. 
Napora JK, Short RG, Muller DC, Carlson OD, Odetunde JO, Xu X, Carducci M, Travison TG, Maggio M, Egan JM, 
Basaria S. High Dose Isoflavones do not improve Metabolic and Inflammatory Parameters in Androgen Deprived 
Men with Prostate Cancer. Journal of andrology 2011;32:40-48. 
68. 
Onning G, Akesson B, Oste R, Lundquist I. Effects of consumption of oat milk, soya milk, or cow's milk on plasma 
lipids and antioxidative capacity in healthy subjects. Annals of nutrition & metabolism 1998;42:211-20. 
69. 
Padhi EM, Blewett HJ, Duncan AM, Guzman RP, Hawke A, Seetharaman K, Tsao R, Wolever TM, Ramdath DD. 
Whole Soy Flour Incorporated into a Muffin and Consumed at 2 Doses of Soy Protein Does Not Lower LDL 
Cholesterol in a Randomized, Double-Blind Controlled Trial of Hypercholesterolemic Adults. The Journal of 
Nutrition 2015;145:2665-2674. 
70. 
Pipe EA, Gobert CP, Capes SE, Darlington GA, Lampe JW, Duncan AM. Soy protein reduces serum LDL cholesterol 
and the LDL cholesterol:HDL cholesterol and apolipoprotein B:apolipoprotein A-I ratios in adults with type 2 
diabetes. The Journal of nutrition 2009;139:1700-6. 
71. 
Potter SM, Bakhit RM, Essex-Sorlie DL, Weingartner KE, Chapman KM, Nelson RA, Prabhudesai M, Savage WD, 
Nelson AI, Winter LW. Depression of plasma cholesterol in men by consumption of baked products containing 
soy protein. The American Journal of Clinical Nutrition 1993;58:501-6. 
72. 
Puska P, Korpelainen V, Hoie LH, Skovlund E, Lahti T, Smerud KT. Soy in hypercholesterolaemia: a double-blind, 
placebo-controlled trial. European journal of clinical nutrition 2002;56:352-7. 
73. 
Puska P, Korpelainen V, Hoie LH, Skovlund E, Smerud KT. Isolated soya protein with standardised levels of 
isoflavones, cotyledon soya fibres and soya phospholipids improves plasma lipids in hypercholesterolaemia: a 
double-blind, placebo-controlled trial of a yoghurt formulation. The British journal of nutrition 2004;91:393-401. 
74. 
Roughead ZK, Hunt JR, Johnson LK, Badger TM, Lykken GI. Controlled substitution of soy protein for meat 
protein: effects on calcium retention, bone, and cardiovascular health indices in postmenopausal women. 
Journal of Clinical Endocrinology & Metabolism 2005;90:181-9. 
Downloaded from http://ahajournals.org by on June 4, 2019
 75. 
Santo AS, Cunningham AM, Alhassan S, Browne RW, Burton H, Leddy JJ, Grandjean PW, Horvath SM, Horvath PJ. 
NMR analysis of lipoprotein particle size does not increase sensitivity to the effect of soy protein on CVD risk 
when compared with the traditional lipid profile. Appl Physiol Nutr Metab 2008;33:489-500. 
76. 
Shidfar F, Ehramphosh E, Heydari I, Haghighi L, Hosseini S, Shidfar S. Effects of soy bean on serum paraoxonase 1 
activity and lipoproteins in hyperlipidemic postmenopausal women. International Journal of Food Sciences and 
Nutrition 2009;60:195-205. 
77. 
Shige H, Ishikawa T, Higashi K, Yamashita T, Tomiyasu K, Yoshida H, Hosoai H, Ito T, Nakajima K, Ayaori M, 
Yonemura A, Suzukawa M, Nakamura H. Effects of soy protein isolate (SPI) and casein on the postprandial 
lipemia in normolipidemic men. Journal of Nutritional Science & Vitaminology 1998;44:113-27. 
78. 
Sirtori CR, Agradi E, Conti F. Soybean protein diet in the treatment of type II hyperlipoproteinaemia. Lancet 
1977;1:275-277. 
79. 
Sirtori CR, Pazzucconi F, Colombo L, Battistin P, Bondioli A, Descheemaeker K. Double-blind study of the addition 
of high-protein soya milk v. cows' milk to the diet of patients with severe hypercholesterolaemia and resistance 
to or intolerance of statins. The British journal of nutrition 1999;82:91-6. 
80. 
Sirtori CR, Bosisio R, Pazzucconi F, Bondioli A, Gatti E, Lovati MR, Murphy P. Soy Milk with a High Glycitein 
Content Does Not Reduce Low-Density Lipoprotein Cholesterolemia in Type II Hypercholesterolemic Patients. 
Annals of Nutrition and Metabolism 2002;46:88-92. 
81. 
Steele MG. The effect on serum cholesterol levels of substituting milk with a soya beverage. Australian Journal 
of Nutrition and Dietetics 1992;49:24-8. 
82. 
Steinberg FM, Guthrie NL, Villablanca AC, Kumar K, Murray MJ. Soy protein with isoflavones has favorable 
effects on endothelial function that are independent of lipid and antioxidant effects in healthy postmenopausal 
women. The American journal of clinical nutrition 2003;78:123-30. 
83. 
Sucher S, Markova M, Hornemann S, Pivovarova O, Rudovich N, Thomann R, Schneeweiss R, Rohn S, Pfeiffer 
AFH. Comparison of the effects of diets high in animal or plant protein on metabolic and cardiovascular markers 
in type 2 diabetes: A randomized clinical trial. Diabetes, obesity & metabolism 2017;19:944-952. 
84. 
Tabibi H, Imani H, Hedayati M, Atabak S, Rahmani L. EFFECTS OF SOY CONSUMPTION ON SERUM LIPIDS AND 
APOPROTEINS IN PERITONEAL DIALYSIS PATIENTS: A RANDOMIZED CONTROLLED TRIAL. Peritoneal Dialysis 
International 2010;30:611-618. 
85. 
Takahira M, Noda K, Fukushima M, Zhang B, Mitsutake R, Uehara Y, Ogawa M, Kakuma T, Saku K. Randomized, 
Double-Blind, Controlled, Comparative Trial of Formula Food Containing Soy Protein vs. Milk Protein in Visceral 
Fat Obesity; FLAVO Study Circulation Journal 2011;75:2235-2243. 
86. 
Teede HJ, Dalais FS, Kotsopoulos D, Liang YL, Davis S, McGrath BP. Dietary soy has both beneficial and potentially 
adverse cardiovascular effects: a placebo-controlled study in men and postmenopausal women. Journal of 
Clinical Endocrinology & Metabolism 2001;86:3053-60. 
87. 
Teixeira SR, Potter SM, Weigel R, Hannum S, Erdman JW, Hasler CM. Effects of feeding 4 levels of soy protein for 
3 and 6 wk on blood lipids and apolipoproteins in moderately hypercholesterolemic men. The American journal 
of clinical nutrition 2000;71:1077-84. 
88. 
Teixeira SR, Tappenden KA, Carson L, Jones R, Prabhudesai M, Marshall WP, Erdman JW. Isolated soy protein 
consumption reduces urinary albumin excretion and improves the serum lipid profile in men with type 2 
diabetes mellitus and nephropathy. The Journal of nutrition 2004;134:1874-80. 
89. 
Thorp AA, Howe PR, Mori TA, Coates AM, Buckley JD, Hodgson J, Mansour J, Meyer BJ. Soy food consumption 
does not lower LDL cholesterol in either equol or nonequol producers. The American journal of clinical nutrition 
2008;88:298-304. 
90. 
Tonstad S, Smerud K, Hoie L. A comparison of the effects of 2 doses of soy protein or casein on serum lipids, 
serum lipoproteins, and plasma total homocysteine in hypercholesterolemic subjects. American Journal of 
Clinical Nutrition 2002;76:78-84. 
91. 
Van Horn L, Liu K, Gerber J, Garside D, Schiffer L, Gernhofer N, Greenland P. Oats and soy in lipid-lowering diets 
for women with hypercholesterolemia: is there synergy? Journal of the American Dietetic Association 
2001;101:1319-25. 
92. 
van Nielen M, Feskens EJM, Rietman A, Siebelink E, Mensink M. Partly Replacing Meat Protein with Soy Protein 
Alters Insulin Resistance and Blood Lipids in Postmenopausal Women with Abdominal Obesity. The Journal of 
Nutrition 2014;144:1423-1429. 
Downloaded from http://ahajournals.org by on June 4, 2019
 93. 
van Raaij JM, Katan MB, Hautvast JG, Hermus RJ. Effects of casein versus soy protein diets on serum cholesterol 
and lipoproteins in young healthy volunteers. The American journal of clinical nutrition 1981;34:1261-71. 
94. 
van Raaij JM, Katan MB, West CE, Hautvast JG. Influence of diets containing casein, soy isolate, and soy 
concentrate on serum cholesterol and lipoproteins in middle-aged volunteers. The American Journal of Clinical 
Nutrition 1982;35:925-34. 
95. 
Vega-Lopez S, Matthan NR, Ausman LM, Harding SV, Rideout TC, Ai M, Otokozawa S, Freed A, Kuvin JT, Jones PJ, 
Schaefer EJ, Lichtenstein AH. Altering dietary lysine:arginine ratio has little effect on cardiovascular risk factors 
and vascular reactivity in moderately hypercholesterolemic adults. Atherosclerosis 2010;210:555-62. 
96. 
Vigna GB, Pansini F, Bonaccorsi G, Albertazzi P, Donega P, Zanotti L, De Aloysio D, Mollica G, Fellin R. Plasma 
lipoproteins in soy-treated postmenopausal women: a double-blind, placebo-controlled trial. Nutrition 
Metabolism & Cardiovascular Diseases 2000;10:315-22. 
97. 
Weisse K, Brandsch C, Zernsdorf B, Nkengfack Nembongwe GS, Hofmann K, Eder K, Stangl GI. Lupin protein 
compared to casein lowers the LDL cholesterol:HDL cholesterol-ratio of hypercholesterolemic adults. European 
journal of nutrition 2010;49:65-71. 
98. 
West SG, Hilpert KF, Juturu V, Bordi PL, Lampe JW, Mousa SA, Kris-Etherton PM. Effects of including soy protein 
in a blood cholesterol-lowering diet on markers of cardiac risk in men and in postmenopausal women with and 
without hormone replacement therapy. Journal of Women's Health 2005;14:253-262. 
99. 
Wheeler ML, Fineberg SE, Fineberg NS, Gibson RG, Hackward LL. Animal versus plant protein meals in individuals 
with type 2 diabetes and microalbuminuria: effects on renal, glycemic, and lipid parameters. Diabetes Care 
2002;25:1277-1282. 
100. 
Wiebe SL, Bruce VM, McDonald BE. A comparison of the effect of diets containing beef protein and plant 
proteins on blood lipids of healthy young men. The American journal of clinical nutrition 1984;40:982-9. 
101. 
Wofford MR, Rebholz CM, Reynolds K, Chen J, Chen CS, Myers L, Xu J, Jones DW, Whelton PK, He J. Effect of soy 
and milk protein supplementation on serum lipid levels: A randomized controlled trial. European Journal of 
Clinical Nutrition 2012;66:419-425. 
102. 
Wolfe BM, Giovannetti PM, Cheng DCH. Hypolipidemic effect of substituting soybean protein isolate for all meat 
and dairy protein in the diets of hypercholesterolemic men. Nutrition Reports International 1981;24:1187-1198. 
103. 
Wolfe BM, Giovannetti PM. Elevation of VLDL-cholesterol during substitution of soy protein for animal protein in 
diets of hypercholesterolemic Canadians. Nutrition Reports International 1985;32:1057-1065. 
104. 
Wong WW, Smith EO, Stuff JE, Hachey DL, Heird WC, Pownell HJ. Cholesterol-lowering effect of soy protein in 
normocholesterolemic and hypercholesterolemic men. American Journal of Clinical Nutrition 1998;68:1385S-
1389S. 
 
Downloaded from http://ahajournals.org by on June 4, 2019
